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Abstrad
11is retrospedive study on breast cancer investigated the inter.raation of the
apoplotic: facton, Bd-2, Bax, Illd pro~feration factors Ki-67, PCNA, logether wi"'!heir
potential u predictorsof1oca1 recurrenceoftumour. Tumour specimensofpatientswith local
recumnc;:c (defined u recumncc oftumour within a period ofS years foUowing diagnosis,
at the site oforiginal surgery or adjacent axillary region) were expected to show inc:reucd
proIifention and decreased apoplotic behavior thereby SUbstantially increasing the risk of
local recumnce. In addition. loss of function of the tumour suppressor gent, pS3, which
normally functions as the inIIibitor oCtile proliferation and an activator of tile apoptosis, wu
expected to play 1ft integral part in promoting tumour growth.
Immunohistochemical analysis of the apoptotic and proliferative markers showed
several significanl associations between the biological parameters. AnalysiJ ofthe association
between pS3 and Bcl-2 expression indicated no statistical significance. Further analysis of
the raw data revealed I general trend towards an inverse association between the two
markers. Thus, suggesting that pS3 in its mutant fonn behaves in a similar manner IS the wild
type pS3 which functions to inhitXt the expression ofBcl-2. Loss of pS3 function we also
associated with an increase in the proliferative rate u measured by the expression of Ki-67
IlldPCNA.
The Bcl-2 protein, known to inhibit apoptosis, failed lodisplay 1ft invmeassociation
with the rate of apoplosis (as measured by the TUNEL method) and the pro--apoplotic
ii
protein, Bax. '" oddilioo, 8<1-2, also known to promote tho retention ofcells in tho GOIGI
phue of tho cell cyde did IIOl exhibk an inverse relatiooship with expmoion of 8<1-2
expmoion and tho proliferative markers, Ki-67 and PCNA
Amonl tho dinicopalholosical _en suc:h u tumour grade and lymph node
IWUS •only tumour size showed asignificant associationwith local recurrence where tumour
size grater than 2em indicated an increased likelihood oflacal recurrence. In an analysis of
the inter-relltion between the biological parameters and clinicopathological features, tumour
snde and not tumour size exhibited significant positive associations with &1·2 and pS3
expression. As expected, Bd·2 positive tumours were associated with low tumour arade
while loss ofpSJ function was associated with high tumour grade. The presence of lymph
node stltus indicated a positive association with the proliferative mark.er, PCNA
Contrary to our expectations., the expression ofBcl-2 and p53 failed to prediCllocai
rec:urrence ofbreast cancer. 'The results obtained from the study confirm the need for f'wthcr
analysis of the intcr-relations oCthe biological markers using more quantitative laboratory
techniques namely, quantitative RT·peR and Row cytomeuy.
iii
Acluaowledemcau
AI this lime, Iwould like to express my ll"1itude to thoJewho have helped me durina
Ihe """'" of............ req.ar-u for my Masten. Dr. Robb, thank-you for Ihe IllIIly
IeIcllina seuions both ill Puhology and ill Life. You always laid, 'Iif. i. hard, Syble' You
have chaUenged me to become a stronger and more persistent individual.
To the supervisory committee memben, Dr. George. Dr. Khalifa, Or. Larsen. Dr.
Haegert, andDr. Gadag. thank-you foryour insight and support espec::ially in thedevdopment:
oft!li. llIIllUsaipt.
Cathy Searle, thank-you for helping me finish this projc;:t..and for all the misty stories!
To myfamity, you have always been there for me..Mom, your sacrifice and unconditional love
and Rlpport has been my foundation. Anna (big brother), thank-you for the years of
tiiendship, guidaoc:e, and love. To Marc, you have been my partner throughout chis Iorlaand
sometimes tiresome joomey. Tbank·you!
Finally (would like to say a special thank-you to Shyam KonilU. Shyam, .hank-you









1.0 EpidemioloBY.. . .1
1.1 R.isltFactOf$..... . .2
1.1.1 In<rasintI Ase .. .. .2
1.1.2 M-.uaI and Reproductive History. .. .2
1.1.3 EJwsellous Esttoseo SlimllWion.... . J
1.1.4 FWIy History (Genclic Influences) J
l.I.l DietIlldc.w.ryofBinh... . 4
1.1.6 Fibrocysti< Cqe ofBreast l
1.2 Prognosis in Breast Cancer . 5
1.2.1 Screening.. . l
1.2.2 T_.... .. 6
1.2.3 Proposti<F"""" 7
1.2.3. AxiUuy lymph Node Metastases 7
l.2.3b Local Re<:umnce . ..........................•
1.2.3e Tumour Size .. . .....
1.2.3d TlIll1OIIrllistologi<alGrade 9
1.2.3. DNA Ploidy and CeU Proliferation .. ......9
1.2.3f Abnormalities in Tumour·Suppressor
GeneExpression ... ...... .10
1.2.31 Eotrogen Rc<ep.... S.......... ........... 10
1.3 BioIogi<aI Choro<1eristics, Inter-relationship ond Prognostic Sianifieonce of
Parameters Investigated in this Study 10
1.3.1 Apoplosis 11












2.0 Apoptosis.... . 15
2.1 Quanti1ation ofApoplO$i•......................................................................16
2.2 The Bd·2 FIlIliIy 16
2.2.1 Iltalb Agonist. and Antagonists of1he Bcl-2 \7
2.2.2 BcI-2 and Box... . . . 17
2.2.2& Bcl-2IBcl-2 Homodimerization 19
2.2.2b Bcl-2IBax Heterodimerization 20
2.2.2c BaxlBax Homodimerization 20
2.3 Bd-2 SIld ea- 21
2.4 Clinical Significance ofBcl-2 Expression in Breast Cancer 24
Chapter 3
Cellular prolirentioa
3.0 The Cell Cycle 27
3.1 Cell cycle SIldCancer.. . 27
3.2 Proliferating Cell nuclear Antigen (PCNA) 28
3.2.\ PCNAand Cell Cycle 29
3.2.2 PCNA SIld Breast Cancer 30
3.3 Ki-67.. . 31
vii
3.3.1 Ki-67 and Cd! Cydc... .. 32
3.3.2 Ki-67 and Breast Cancer . 32
3.4 Ki-67 and PCNA 33
3.S Bcl-2 and Proliferation 34
Chap.er4
m:1be Tumor Suppressor Gene
4.0 pSl.. 36
4.1 Arrest or Apoplosis 31
4.1.1 pS3 and Apoptosis... . 38
4.l.Ia pS3 and B<~2... . ...39
4.1.2 pS3 and proUferatioR.... .. 40
4.2 pS3 and Tumourigenesis... . 40
4.3 pS3 Expression and Breast Cancer... ...41
H Immunohistodlemi<alAoalysisofpS3 .41
Chapter S











7.0 Subjects.............. .. . 48
7.1 Pro<edure 48
7.2 Pretreaunentofslides.... . ll
7.3 Terminli Deoxynuc:leolidyl Transferase Mediated Nick End Labelins
(TUNEL) ll
7.4 1mmunobistochemistry... . l4
7.4.1 Application ofPrimary Antibodies for pSJ, Bcl-2, Sax. Ki-67 and
PCNA ll
7.4.2 Application ofBiotin Labeled Secondary Anubody .ll
1.4.3 Measurement of Antigen Expression 57




8.0 CeIIuIor Expraoion ofllax. Bd-2, p53, PCNA, Ki-67 .59
8.1 otio and Anti-opoplOtio Fl<to~ 68
8.1.1 Bd-2 68
8.1.2 B..... . 68
8.1.3 p53... . 68
1.3 RelaIion Between Proliferative and Apoptolic Factors 68
1.4 Apoptotic: and Proliferative Factors Related to Tumour




8.5 1nIc:r.relation between Clinicopathological Features
and Local Recurrence _._ _, 73
8.6 Summary ofSignificant Associations found in the Study 73
Chap,er9
Discualoa
9.0 Assessment of Laboratory Methods... . . 75
9.0.1 FiutionandEmbedment... . 75
9.0.2 UmitalionsoftbelliCMethod 77
9.0.3 The TUNEL McIhod 71
9.\ 1ldalion_Proopoptotic ondAllli-Apoptotio F....... . 79
9.1.1 Bd·2ondlllx 79
9.1.2 Bd·2 ond Apoplotio Rate 81
9.\.3 Bd-2ond p53 83
9.1.4 lIIxondp53 85
9.1.5 IIIx ond Apoptotic Rate.... .. 86
9.1.6 p53 ond Apoptotic Rate 87
9.2 bl.tion Between ApoptQtic Factors and Proliferative 89
9.2.1 PCNA ond Ki-67 89
9.2.2 Bcl·2 ond PCNA. Ki-67. . .. 90
9.2.3 p53 ond PCNA, Ki-67.... . 91
9.3 Apoptotic and Proliferative Factors related tumoun PatholoBY
Chanc:terisUcs and Local Recurrence..... . 92
9.3.1 Bd-2 92
9.3.2 p53 94
9.3.3 PCNAondKi-67.... .. 97
9.4 Inter·Re1aIion Between Clinical Parameters and Local Recurrence 106
Chlpter 10
10.1 Cc>ncMions.... . 104
10.2 BibIiosnPhy 109
10.3 Appendix 130
Table 10.1: Nonparametricanalysis oftheassociation between Bc1·2
Cytoplasmic expression as detected by the immunohistochemical
stainingand the rateofapoptosis ,_, 131
Table 10.2: NonparunetricanalysisoftheassociationbetweenBcI-2
Cytoplasmic and Sax Cytoplasmic expression as detected by the
immunohisto<hemicai staining.... .... 132
Table 10.3: Nonparametricanalysisoftheassociation betweenBcI-2
Cytoplasmic: and pSJ Nuclear expmsion as detected by the
iJnrnunohistothernical staining 13)
TablelO.4: Nonpararnetric analysis ofthe association between Sax
Cytoplasmic expression and pSJ Nuclear Expression as detected by
the immunohistochemicalstaining. 134
Table1O.S: Nonparametric analysis ofthe association between Sax
Cytoplasmic: expression as detected by the immunohistochemical
staininsond fapoptosis... . . 135
TablelO.6: Nonpuametric analysis ofthe association between pSJ
Nuclear Expression as detected by the inununohistochemical
xii
ltIininaand.-eofapoptosis. 136
TIbleIO.7: Nonparametric: analysis ofthe association betMen two
pr<JIilentM nwken, Ki-67 IJld PCNA u detec:ted by I!le
immunoIlistocllCIIstaininS 137
Table10.1: Nonparametncanalysisofthe associationbetween &1·2
Cytoplasmic Expression and the nuclear expression ofKi-67
as detected by the immunohistochemical staining 138
TableI0.9: Nonpu-amdricanaJysisoftbeassociation bei.weenBCI-2
Cytoplasmic expression and PCNA Nuclear Expression as detected
by the imnwnohistochemical staining 139
Table10.10: Nonparametric analysis ofthe association between pS3
Nuclear Expression and Ki-67 Nuclear Expression as detected by
the immunohisIochemic:al staining 140
Tab!eIO.II: Nonparamctric analysis ofthe association between pS3
Nuclear Expression and PCNA Nuclear Expression as detected by
l!le_ochemicaIsuining. 141
Table I0.12: Nonparamctricanalysisof1M association betweenBel-
2 Cytoplasmic: expression and local recurrence of breast
c:oncer 142




2Cytoplumic:cxpra1ion ond Tumour Size 144
TobIeIO. IS: Noapvametric lIlI1ysis oftheassociation between p53
NuclarExp ond Lo<aI Recurrence 145
TablelO.16: Nonparametric analysis oCtile association between pS3
Nuclear Expression IS detected by the immunohistochemical
staining and Tumour Size 146
TlblelO.17: Nonparametric analysis oflhe association pS3 Nuclear
.Expression IS detected by the immunohistochemical staining and
TumourGnde 147
TablelO.18: Nonparamecric analysis of the association between
PCNA Nuclear Expression expression as detected by the
immunohistochemical staining and Local Recurrence 148
1"10.19: Nonparametric analysis oCtile usociation between Kj.
67 Nuclear Expression IS detected by the immunohistochemical
stainingand Local Recurrence. .. . 149
TablelO.20: Nonparametric analysis ofthe association between Ki-
67 Nuclear Expression as detected by the immunohistochemical
stainingandTumourSize 150
Table10.21: Nonparametric analysis ofthe association between Kj-
67 Nuclear Expression as detected by the immunohistochemical
xiv
....... ondTlIl1I(lUfGnd.... . ISI
TableIO.12: Nonparametri<: analysis of the association between
PCNANudear Expression III detected by the immunohistochemical
....... ondTUllIOUtSizc IS2
TIhlcI0.23: Nonparamcuic 1IlIIysi. of the association _
PCNANuclarExpression uddcctcd by the immunohistodlemi<ll
staining and TumourGrade 1S3
TablelO.24: Nonparametric analysis of the association between
PCNA Nuclear Expression III detected by the immunohistoc::hemicaI
staininsond Lymphnode S........ . 1S4
TablelO.2S: Nonparametric analysis of the association between
Tumour Size and Local Recurrence... . 155
TablelO.26: Nonparame1ric analysis of the association between
TumourGnde and l.o<al RCCUfTCIICC 1S6
TablelO.27: Nonparamelric analysis of the association between
Tumour Size and Lymph Node Status 157
10.4 Raw Dala... . IS8
xv
FIGURES
UST OF FIGURES .I: CHART
PAGEII
Chon7.!
Contributions oCIndividuals invo)...ed in the progress afthis Study
.........50
Figure 8.1a
Expression ofBtI-2 in Breast Carcinoma. . . 62
Fillllre8.lb
Expression ofBax in Breast Carcinoma. 63
Flame a.le
Expressionofmutant pSJ inBreast Carcinoma. 64
flJlll<e8.!d
Expression ofPCNA in Breast Carcinoma 65
Figure I.le
Expression ofKi.(i7 in Breast Carcinoma... . 66
FiJlllreI.lf
A Cell underaoina Apoptosis as dete<ted by the TUNEL Method 67
FiJlllreI.l.I
Positive Association ofBax and Bcl~2 Expression... . 69
xvi
F........4.1
Inverse Association ofBd-2 expression and Tumour Grade 71
F........4.2
0Yerexpmsi0n oCpS) wocilled with Increased Tumour Grade 72
Fipte '.5
Tumou"izewocilled withLocal Recurrence 74
Fipe 10.1

































--tamina! deoK)'RUcleotidyl transferase (TdT} mediated






Breast cancer is a serious clinical problem in Canada, occurring at I frequency of I :9
with the 0IlpeclIli0n ..... OM in 25 women will die or the di...... All the provinces have
tbownlllRnued incidence rate in breast cancer since 1987. During 1987, 12396 cues of
breu: cancer were reeorded by Statistics Canada; in 1997, this figure had risen to 18 400.
In 1995, breast cancer was the most prevalent type of cancer in Newfoundland
women, and was • major cause ofdeath. There has been a steady increase in the inciden<:e of
breut c:onc:er in the province sin« 1985. A lo-year study by the Dr. R. H. Bliss Mlllphy
Cenm showed that in 1985, 167 women were diagnosed with breast cancer. In 1995, 290
women were diaposed with the disease. This increase may partty be due to such factors u
the recent introduction of regular mammographic screening, self awareness and media
1lleIllion.
I.II1iH.l1dm
Identifyins women with the risk of developing the disease allows planning of
preventive and diapostic strategies. The relative risk of development of breasa cancer is
aaeued by comparing the incidence rate ofwomen having a particular cJwacteristic: to the
1'Ilc of individuals in whom that characteristic is not present (Greenfield & Mu11hoI1and,
1991). Many risk. facton have been identified for breast cancer. These include increasing...
_ reproGoctiv<biolory,__1limuIolioa, limiIybiolory,diol ....
--.." Iibro<y1li< cbonpa (GreadieId.t MuIIhoIIIIld, 1997; RosIi, 1996).
1.1,1--,,,,"
Iawomeo lea thin 25 yeanof..__ofbrastc:anceris_ The
incidcace incteues IteIdiIy after the age of25 until menopause., (oUowed by. slower rise in
lheremaioder oflife (Greenfield.t MuUhoillld, 1997). For instance, swistics &om Ihe 1995
incidenl:e ofbr_ c:ancer re<a<ded by Ihe Bliss Murphy Centre showed 1!IIl143 or'he 290
women diqnoted were 50 yean orap or older (BUss Murphy Centre, 1995).
1.1.2 M_ud 1lopnId.dive Hill..,.
U...erNPI<d .......1lla1 cycles (IS .... in ...niparou.< women~ corIy menarche
(be{ore lheap o(12) or iIIe _ (ofterlhe 'Ile of55~ pIacos. woman at hiIher risk
for cIeveIol>in8 brast~ (GreadieId.t MuIIhoIand, 1997). Also, women who Bive binh
before Ihe ... olJO have. lower risk ofcIeveIoPn& brast~ c:ompared '0 women who
Bive binh 10 1heir lint dliId ofter 30 yean of'lle or never bear children (Rosai, 1996). TIQ
apreIated effee:t i, further demollSUl1ed by Ihe r... 1!IIl women who llive bUth before ap
0(20 yean and have their second child before 2S yean of lac have an even lower risk of
developing _ c:ancer (Rolli, 1996).
1.1.3 Eaaaa- Esmpo SlIaolati..
It is now arsued thIt the blsiccommon denominator in~opmcnt of bRut cancer
is__ 1limuIalion operating 011 • gcocticaIIy swceptibIc bacqround (Mooro ..
a1., 1913). Studies hm: shown I!IIl WOllletI who lISe exoscnous _ 10 comboI
sympl<lmI01_have an inaeued risk (2.5 fold) ofdevdopina breast cancer (Roa
0111., 1914; Kasey.t: Gammon, 1991). 80_, some IIUdies have _ thal this risk
~ oaIy Iipificant in polielIIJ wbo have had I previous diagnosis oflibrocysUc chanp (Hoover
0111., 1976). Furthermore, various IIUdies havellso shown thal oral con_bve _ do
lIOl c:onstitute I risk for breul cancer (Rolli, 1996).
I.U Family Hlslol)' (Geaetic lan....es)
A history of one or more family members (sister, daughter, mother. maternal
pndmother or maternal aunt) having breast cancer is strongly associated with. risk of
developina breul cancer (Greenfield .t: Mullholland, 1997). Th. risk becomes more
pronouoced if the relative developed bilateral breast cancer or wu initially diagnosed while
pre-1DOIlOpIUIII (Greenfield.t: Mullholland, 1997). Women with I fsmily hillolY ofb......
cancer have an absolute lifetime breast c:ancer incidence of SO% or greater (Greenfield k
MuIIhoIIand, 1997).
It is now clear that two thirdsof familial breast cancer cases. which account for about
12·lS% or all eases of breast cancer, have a weU defined senetic basis associated with
molllioaalcventscx:aurinsin Ihe BRCAI (Futralet aI., 1994) and BRCA2 (WooIIerOl 11.,
1994) pnes. BReAI,located on chromosome 17, appears to function normallyu. tumour
suppressor sene; k»sI of heterozygosity in I gennline mutation carrier results in the
deve!oplllClllofbreulcarcinoma(Futrealetl1.• 1994). BRCAI g<rmIine mutations .... abo
_cdwitbl~gnifi<antriskforlhedeve1opmclUofovari.. carcinoma(Mikietll.• 1994).
A> yet, reIaIiveIy HnIe ~ known about Ihe normal biological timclion of BRCA2 (Rolli,
1996). GennIine......,noI ...... in BRCA2 "" associated with 110_ riIk than BRCAI
for ovarian c:an:iooma but ""linked with 1 small but signilic:ant riIk ofproswic wa.-
in maIea (Roaai, 1996).
1.1.5 Diet ad Couatry or Birtb
The incidences of breast cancer are high iR Nonh America and Nonhem Europe,
inlennedWe in Southern ~rope and Latin America and very low in most Asian and A1iican
<CURlriea(Soodik, 1994). Various SlUdieshavedemoll5lraled.hat individual.emigraringfrom
Low incidence c:ountries acquire the risk ofincidence oftheir c;:ountry ofadoption (Greenfield
It MuIIIloIIand, 1997). Thi. suggest. that cliff...... cultural customs, dietary factors and other
environmental conditions may be linked with the de...elopment ofbreast cancer (Greenfield
It MuIIhoIIand, 1997). Greenfidd It MullhoUIRd (1997~ indicale that diet. high in saturated
&tty acids and obesity increase the risk for breast cancer in women.
1.1.6 FIbrocy.1lc CUIlle orB.....
Many studies have been carried out in an effort to aKertain the role of fibroeystic
chansc in breast cancer tumorigenesis (Rosai, 1996). There Ippears '0 be 1 delinitelink
between breast cancer and some elements of proliferative epithetial lesions (Rosai, 1996).
Individuals with simple ductal hyperplasia have 1 twofold risk over the general population
while tho.. with atypi<aI ductal hyperplasil IPpear to have 1 five fold risk (Poge, 1986;
Duponc et aI., 1993). It is now a general clinical policy to carefuUy follow-up patients
diogDoJed with atypical ductal hyperplasia OR 1 yearly basi. (Rolli, 1996).
1.2 Pqposit tf'rgst Capeer
Tbe clinical outcome ofbreut canc:er is ac:omplex issue which appears to be linked
to (Chlodruoma" Taylor, 1995):
1) Elfec:tive early lCJeenins
2)Typeof~
3) Various prognostic indicators
1.2.1_..,
5<reeoinamethodsfordetcctina tumours.. averyearly sugeofdevelopment u.....
JIWIIInCl8rUIlS and selforphysician examinations have been in progress for some time (It.ubins
"Fuller, 1994). A review of results from randomiz<d studies in Canada, U.S. and SW<den
have shown that the routine use ofmammosrams in women from .he age range 50.69 yean
reduces "'- cancer moruJily by obout 30% (Love" Park.., 1996).
1.2.2 Tratlaellt
Surgery hu been Ihe principal fonn of Irealment in breast canCel (Greenfield "
MuUhoIland, 1997). There are two types ofsurgery that are effective in removing tumours.
I) Mo4iJktlI'flllktllIlltDt«tDIfIY includes removal of the breast but preservation of the
pectoraIi.lII,Isdewith dissectionofthe axilla. 2) l.IIlIfII«Io,"" irIvolves the compIece excision
or tumour wilh c1eIr marains and oxiUary 1ympb node dissection foUowed by ndiation
(Gteenfield" MulIhonand, 1997).
Breast canc:cr is amoderately radiosensitive tumour (Chandrasoma &. taylor, 1995).
Iladioth<npy is ISSigned to patients following breast-consetVing SUJIlety (e.g. Iwnpectomy)
lAd ill patients who adI'cr • local recurrence in the chest will. Studies indicate I reduced
_ ofrecurr.... followins nodialio.~ oflumpectomy ..... (Ruhins &: Fullers,
1994; Chandrasoma &: Taylor, 1991).
FoDowing surzery, chemotherapy ~ administered in III but wdI diJfemllialed oxillary
lymph node negative cancers with no advcnc prognostic indicaton (Chandruoma &: TIYIor,
1995). This fonn of treatment targets microscopic foci of tumour cells in the distant
metutIIic sites. In this situation, chemotherapy has increased disease free survival but is not
CUtllive (Chmdrunma &: Taylor, 1991).
Since SO% ofbreast cancers exhibit nuclear estrogen receptor protein, antHstrosen
hormonal therapy hal also been effe<:tive in proIo'sins di..... free suMval (Rosai, 1996).
The eftec:t of estrogen in promoting tumour growth can be suppressed by either anti·
estrogen drugs such u Tamoxifen, or surgical removal ofthe ovaries or adrenal glands. Anti·
esarosen therapy has been successfu1 (60-80%) in women with estrogen or progesterone
receptor positive br.... wcionma (Greenfield &: MuIIhoIIand, 1997). However it sbouId be
stressed that the general clinical outcomes ofbreast cancer, both in regard to disease free
suMval and overall survival, appear to be related more to the actual biological chancterista
oftile IUIIlOUr than to tile type ofUIII"'" employed (Chmdrasoma &: Taylor, 1991).
1.2.3 Propostic ladiuton
The search for prognostic: indicators which win predict clinical outcome and serve u
I means of selecting patients for proper adjuvant therapy is ongoing (Greenfieid "
MuIIhoUand, 1997). A reliable independettt prosnoSlic: faaortllWt satisfy two criteria: I) it
..... diJcriminlle independendy ofother known l3cton _ groups ofpatienl. _ a
aood or poor prognosi~ 2) it ..... be demonslTated throop cliIIicallrial. lhal _
__on in the poor prognosia group improva dinicaI out"""", (Greenfield "
MuIIboIland, 1997). MultMrille IIlaIyses have shown 1ha1,. far only a smoII"'-ofthete
parameIen have reIalivcly independent sianificuce (Greenfield "Mullholland, 1997). These
indude axillary lymph node metastasis. local recurrence, tullKlUr size, tumour grade. tell
proIifcntion, abnormalities in tumour suppressor gcne expression. and estrogen reteptor
51.....
1.2.30 AUla., Ly.p. Node M....tuis
Axillary Lymph node metastasis is one of the most important known proanostic
parameters (Alderson ct aI., 1911). There is a sharp difference in survival rates between
patients who are lymph node positive and those who are lymph node negative. Patients with
rndIIt&Sis have a reduced survival rate compared to those without metastasis. In the case of
lymph node me1asIasis, the survival rale also dqlends on the level ofaxillary node "",oIved
(low, medium or high) (Berg" Robbins, 1966), the absobe number (fewer !han four venus
four or more) (Fisher et aI., 1976; FiSher et aI., 1983), the amount ofmewtllic lumout
(lluvos etll., 1911; Rosen etll., 1981),lhe presence ofextranodal spread and lhe pr ce
of_cdIs in the.- vessels (Clemente etll., 1992). II appears lhal pali _
axillary lymph node micrometutatic deposits have the same prognosis u patients without
melISWis(Picl<ml, 1961; FlSheret II., 1918). Overall three prognome groups oflymph node
.........i_in b..... eaneer: (I) negative nodes (2) I·] positive nodes (]) 4 or more
pooilive nodes (Roui. 1996).
1.1.311 LotaI Rec.rrtoce
Local recurrence. defined u the recurrence oftumour in the region of the ipsilateral
chest wall, ~ an odvene prognoS1i<: fictot (Rolli, 1996). The vast majority ofpati.... who
ha.. 1ocaI recurrence evemuaIIy die ofmetastasi. (Gilliland et 01., 19113).
1.2.3c TUIIIHrSize
Recent studies have demonstrated that the size of the primary tumour is a very
important prognoS1i<: _er(Cuter et 01., 1978; Russo et 11., 1987; Row, 1996). The
inl:icIenl:eofnodal metastasis and rate ofrelapse show • sarona correlabon with the maximum
dimension oCtbe' primary tumour (Carteret aI., 1978; Russo et aI., 1987). II is now asrecd
that tumour size, potentially quick and easy to measure, represents one of the strongest
predidors ofdissemination and rate ofrelapse in node negative breast cancer (Greenfield &:
MuIIhoUand. 1997). A tumour size of less lhao I em. defioed IS minimal breast carcinoma,
i. woc:iated willi. 75% <hance of iQ-year diJeue.free survivol (SaiIlO &: Rosen, 19110).
However, prKticaI dif&uJties in obtaining an exact measurement oftumour size can recb::e
ill value IS an important pro8JlOSli< indicator (Greenfield &: MullhoUand. 1997).
1.2..3d T••our Bistolocical Grade
Tumour grade IS _ted by the NottioBham Modification of the Bloom
Ridlanbon (Ebloa &: EIIit, 1991; Frimon et 01., 1995) syst.... ~ • strong independent
prosnosti< fictor predicting eli..... free survivol and overall survivol fot pari....willi breast
<ut:inoma. The grade~derived by odding the numericol scores for tubule f..-ioo, nuclear
pIoomorphiIm IIld milolic ...... ad> ofwllichwlSlilned a..... ofl, 2, or 3 poinls(Elalon
I< EIIia, 1991; Frienon .. 01., 1995). Grade I (sood prognosis) tumoun have 3·5 PO""
Grade ntumours have ~7 points and Grade m(aggressive) tumoun have 8or 9 points. All
pIthokJsy reports of breast carcinoma include an assessment of mitrOStOpic grade (E)_on
I<EIIia, 1991; Frienoaet aI., 1995).
t.2.3e DNA Ploidy .ad Cell ProIitentioa
DNA ploidy status has not been shown to be a significant prognostic factor in breast
caneer (Rubins& Farbers. 1994). However, tumour cell proliferation rate measured by 10-67
cxpraaion (immunohistochemistry)(Sallill et aI" 1991; M""; et aI., 1994), mitolie eount
(IlieoIerfieId et aI., 1995), or S-plwe cra"i.. (ftow <y1ometry) (Witzig et aI., 1994) has
proved to be a arona independ... prognostic factor for di..... rr.o swvival. n...,
proliferation rate ranks with microscopic arade as a powerful prognostic factor and has the
added advantage over microscopic grade, that its measurement is more objective (Rosai.
1996).
t.Ut Ab.....utiel ia T.aaou...supprasor GeDe [ ..pressio.
Ac:cumulation of pS3 protein (which normally restricts entry ofcells into the 5-phue
ofthe cell cycle), whether as a result ofsene mutation or abnormalities in the processes of
transcription or uanslation, is thought to correlate with reduced patient survival (Barnes et
aI., 1993; IIurIimann, 1993).
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Several studies have indicated that estrogen receptOr positive breast tumours ue
uoociIled with a longer eli..... he ourvivallhan esuogen receptor neptive lUJ1IOOrS (IIiIf
et aI., 1980; AamdaI et aI., 1984; Butler et aI., 1985). However, the differenc:e between the
two types oftumoun in terms ofovenll survival seems to be minimal and not statistically
Iipi1icIIlt (Rosai, 1996).
1.J BjoInkJI Q'nc'cristig. [gIft·m'liA.'hip .nd ProcnOltic Si,.intl_" pr
Plnmctm hYaljp'" jp Ihit: Slydy
During the pasl few years. • number of studies have been carried out to tese the
Iipili<an<e or various poI...ia1 prosnostic _era in breast canur (Mc:Guit<, 1987;
W_, 1993). Many orthe _era ue rellled '0 various aspe<U or tumour bioiosy
such u morphologyI proIifcnIion characteristics, oncolene status, invasive Of metISlIti<:
poteIlIiaI and hormone receptors statu. (Rosai, 1996; Rubino It farbera, 1994;GreenJield It
MuIIholIand, 1997). A potential biologic:al parameter sIIould COlTIIate with other kIloWll
prosnostic factors su<:h u twnour size, tumour srade,lympb node ...... and independendy
predict the clinical outcome.
In the present study of breast cancer, potential prognostic parameters relating 10
IpOptosis. proIifaation and morphology and their association to tumour size. tumour grade.
lymph node status. and IocaJ recurrence have been examined. Local recutreI1ce is defined u
the rec:unenee oflUmOW' wilhin. period ors years following diagnosis., II the site oforiginal
""saY or in the adjocall axillary region. The rollowing is a briefdescription orthe curnnt
\I
.... ofknowled.. ond clinical ~pifiClllCe ofthe bioIosical puamelCn invetlipted in this
!lUdy.
1.3.1 Apop••"
1.3.1. TIlt 1Id-2 F...iIl'
The role played by the Bd.2 family ofopoptotio lKton ond the twnclUTlU_
I-pS3 bas been. subject ofparticular inl...... with..,d to tumour biolOBical_viour
and clinical outcome. Bcl-2 is • prOlo-oncogene with the ability to inhibit apoptosis. It
encodes I 26 kd protein which can be found on mitochondrial membranes., the nudeIr
envelope ond endopla.lmio reticulum (Kroemer, \991). Expression ofBoI·2 in breast cancer
is related to I high degree ofhistologicaJ differentiation (van Siooten et aI., 1998) and
positive estrogeWprogesterOne status(Diaz-eano et at., 1997), boch markers for I ravourab&e
prognosis. In the cue ofnode positive breast carc:inomas, 8cl-2 is an independent indicator
of...... di..... tree lWVivai (Berardo .. 01., 1998).
Sax, another imponant member of the &1-2 family of proteins commits. cell to
_osis ond lIlIqOnizes the anti·apoplotio activity of BoI·2 (Reed, \996). All of the
memben in the 801·2 family oonlain three similar JlN<l1IR\ motif. in the protein sequence
daiBJllled BHI, BH2 ond BID rqions (Reed, \996). An 0_ representation of the Bel-
2IBIx heterodimers leads to decreased apoptosis whereas an overrepresentation of BaxIBax
homodimcrs lad. to opoplosi. (Reed, \996).
12
1.11~ p5J
Wild type pSI is 1 protein that .... U 1 DNA-binclina tnnse:ripeiooalrqulalor that
eonIrib.... to tumour suppression by inducin& cell death or apoptosis and by Iimitin. the
enIry of tumour cells into the S-p/lue of the cell <)'tIc (1(0 & Privn, 1996). Wild type pSI
tnnscriptionaIlysuppresses B<~2 expression while inducin.expression ofIlax (1(0 &Prives,
1996). Loss ofpSI function by mutation frequently occun in b...... c:ancer (Ilamcs, 1991,
Ko & Prives, 1996). This loss ofwild type pSI function directly cormltes to poor clinical
0UIC0me P'obIbly u. result of increased ceUulu proliferation and • reduttion in the rate of
apoptosis (1I<Jlatny, \996; Ko& Prives, \996).\n 1 study ofl04 b............. cucs with
.7 yarfollow-up, RUant p51 expression wu assoc:iated with shortened diseueftee survival
(poner-Jordon , Lippn1lll, 1994). Patienls who were lymph node .....ve but pSI
immunopolitive(lJldicalinamutant pSI expression)showedan 80'10 Syeat survival COIr4'I'ed
with 93% for lymph node r.egative and pSJ negative tumours.
1.3.2 ProIj(cn'iYe C"rJlc.njsti"
1.121 Ki-67
Expressionofcell proliferation markers U 1 potential P"'ll"Olti< tool hubeen SlUdied
illllllWlOllillodlemically ulina monoclonal antibodies (Bouzabar et a1., 1989; Brown et a1.,
1990; Davan et aI., 1992). Two markers of interest in this present study arc Ki-67, and
l'tnIifintin& Cell Nuclear Anti... (PeNA). Ki-67 is 1 nonhistone nuclear protein found in
all phucs of the cell c:yde except the GO p/lue (Yu et a1., 1992). The percen.... ofnuclei
IIIiaina for Ki-67 is • sc:rni-quantita measure ofthe proliferltive fraction ofceDs (Yu et
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II., 1992). Sludies have indic:aIed thal high expressionofKi-67 iJI the nudci com:Ia1os with
poor IUmOUr pode. (Pierpelll., 1996)...odcilion, high I..... 000-67 lie UIOciaIed with
Ihorleaed diJeue rre..nd ovenll survivIl (Poner·Jorcion a: Uppman, 1994). Expression of
Ki-67 iJI breast """"1jlpeaI11O be independent of .... nodI1 1IalUJ, or hormone llIlUS
(Porter·Jordon a: Uppmlll, 1994).
J.3.2bPOVA
PCNA is • 36 kd nonhistone nuclear protein that functions u an ICeessoty protein to
DNApolymerue delta (Dietri,h, 1993). The level ofpro.eiD expression ~ usooialed willl the
dearee ofcellular proliferation. spec:ifically DNA synthesis. The level ofPCNA rises durins
the late GI phase, jwt prior '0 ,he S·phase DNA syn.heoi. of.he "U 'l"1e. Level. peak
durina the S·phase IIld de<line during the G211ld Mphases ofthe <eU <y<:le (Dielri,h, 1993).
PCNA appears to _ by licilillting the entty of_ iJllO lIle S-phase ofthe <eU <y<:Ie.
InbRut taneer, cxprasion alPCNA has been associated with increased mitotic: activity and
IUmOUr pode (porter·Jordon • Uppman, 1994).
1.4 _1 ... Pmlifmtipp
Bcl·2 ~ I signifi<ant inhibitor of<ellulac proliferation presumably by <aUsina c:dls to
remain iJI the GOIGI phase ofthe <eU 'l"le. It promotes <ell ,;u,j(jty witllout promoting <ell
proIiferaIion (Craig, 1991). The first iJldi<ation of the effect ofBcl-2 on <ell ,;u,j(jty c:ame
&om studies ofhcmatopoietic: cell lines (Craig.I99S). These cells die by apoptosU upon
removal ofvarious growth factors required for their survival. However the process ofdeath
by apoptosis c:an be prevented if the <ells ace previously 'ransfected wiIh Bcl-2 willl the
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transr....... remaininB in the quiesc:alt _proliferating GO phase ofthe ceU cyde (Cni&
1995). Some Iludies have indicated tIIIl Bd-2 negative _ cancer i. usocilled with hiBb
protifention rates whereasscron.expressioaofBc:1-2 is related to krN proliferationrata (van
SiooIellelll., 1998). Thus, ~ seems tIIIl inc:reued 8,1·2 expression in _ cancer indiClles
• fa_ prosnosi' (van Sloot.. et 11., 1998).
1.5 baIua
RelaUveIy few studies have concentrated on the interrelation ofprtHpOptatic. anti-
apopcotic: and prolifentive factors and their effect on lhe c.linical outcome oebrasl CIftUf.
Tumour arowth is determined by lhc rate ofcdl proliferation and cdI death. In this study, we
examined apoplosls and proliferation in breast cancer and their potential role as predictors of
local recurrent disease. We hypothesize that local recurrence ofbreast cane« is predicted by
low expression ofBd-2 in association with a high rate ofboth prolifention and apoptOSis.





ApopI<uis, III ....... Gr<eIt word for the 'faUing 011' ol peuIs tioat IIowen wu
-...byKerr" 01.(1972) to desaibe ._c:eIldeaIh IIw occumd ill diff.....
tissues under various conditions, Through the electron mieroscope, Kerr and his usociates
(1972) detO<led apoptosis ill umreated mali8J1llll neop~ ill regression of nunoun
folIow"'a therapy, and ia bahhy ........
Apoptosis typically _. sinBIe cdb or IIIlIi1graups ofcoils ia III uyn<hrOllOUl
_ (Wylie, 1993). SlnIct\InI changes ia c:eIl. undergoing _osis are clwacterized by
two discreet stiles: 1) fOl'ml1ion ofapoplolic bodies and 2) phagocytosis and degradation by
other cdb (wylie, 1993).
Ac:eIl undergoing apoptosis illvDlves marlted _ olboch the nudeus and
the <yloplasm (Areocb ol Wylie, 1991). Conuaaion of the <ylOplasm due to Iosa ill
ioIrIcelIuIar lIuid and ions results in the encIoplasmi< reticulum dill1ina and formilla vesides
!hal fide with the plasma membrane (Arends ol Wylie, 1991). Consequently, the c:eIl o.u&t:e
exhibits • pronounced convoluted outline wIlich fiqments to provide the membrane
1lIrIOIlOlIioB~ bodies. The nudeusisbroken idol numberof&acr-solt:CCldeosed
_ (Areocb ol Wylie, 1991). The apopto<ic bodies ""'I ia number, size, and
e<npOtiIioo; ..... COllIIin one or more nuclear fnamems u wdI u t:CCldeosed <yloplasm
whereas others coRlain materiallOleIy derived from the <yloplasm (Wylie, 1993). The
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IpOpIAICic: bodies ... enauJ1'ed by members of the mononudar-pha&<Jcyte sy...... On<e
inpIIed, the _otic bodies ...."110 rapid degndation villy1olOmaI enzymes produced
by the pbqocyle (Wylie, 1993).
The potenlillexisls for the__ of the ...... ofapoplOtis in tiuue. by the
Jemi-quantitative orquantitativemeasuremedofpro- and anb-apoplotic proteinfadon using
Bow eytomecric, immunohistochcmital and molecular techniques. Apoptosis may also be
deteeced by microscopic examination but the method is generally thousht to be unreliable
(KnuPllol: Nedecky, 1995). In the present study&pop.otic rile wu ........ed byche.........
cIeoxynudeotidyll1lllSferase(TcIT)mediated deoxyuridine triphosphale (dUTPH>iotinnidc·
.... 1II>eIIinI (TUNEL) in lilU hybridization method (thi. method i. discussed in chapter 5).
U Dc Bct-2 Family
There are three phases in the processof'POplosis: initiation, cff'caor and dqradatior,.
The iniliation pIwe CUI be Iriqered by I variety of stimuli wheras che effector and che
desrIdoIion phues ... common to most edt "lloins an apoptotic process (Lewin,
1997). The._ produet. ofche BcI-2 family influential _lllolS of.he effector phue
in che apoptotic process (Kroemer. 1997).
The BcI-2 gene wu identified adjacent '0 the brealcpoint of I chromolOme
...........- conunonIy foUDd in follicular S edt lymphoma (Tsujimolo 01: Croce, 1916).
The...........- involvathe translOCIlion ofScl-2 from d1romosome 18q21 to the long
um of chromolOme l4ql2, the immunoglobulin heavy chain 10<11. (Craig,I995). The
ltIl1IIocalion RSU1ts in an increued expression ofBcl-2 (Craig, 1995). This increue in BcI-2
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--. is \houahI1O be due to the _ ofenhIn«n in the imnunosJobuIin heavy
chIin _ (ClIi& 1995).
UI Deadl AllUiou loll Ao......iou .rdle 1Jd.2 FlJDlIy
Since the discovery ofBd-2, several othergenes which share ahomology to the Bcl-2
_ IIld whose products limction u reguIotors or lpOp<osis hove been odoptcd into the
1Jd.2 fomily. The members of.he BeI-2 _ family are divided into two group.; (I) dearh
qoaisU: Bax, BoI<, Bod, Bid, Bile, BeI-Xs (2) deoth ....soniots: BeI-2, Mel-I, 1Jd...., IIld
Al (Yans & Konmeyer, 1996). Studies to date indicate that there ue four well conserved
cIomoinsinthe members ofthe 8<1-2 fsmilyealled BHI,BH2,BH3 and BH4 (BH denotes the
Bcl-2 Homology Domain)(R.eed et aI., 1996). With the exception ofBik and Bad, most
members share a homology in It least 2 ofthe 4 domains. These domains imeract with each
other, forming homodlmef's or helerodimers that commit a cell to death or survival (Reed et
.... 1996).
U21Jd.2 .... SU
Two members or the BeI-2 fsmily are ofinterest in tlU.llUdy: .he death IAlIgonisl
BeI-211ld the dearh osonill Box. The 8<1-2 sene eneodes ror I 25-26 KD protein which
contains • stretchofbydrophobicamino acids at the C-terminaJ end required for insertion into
celluIor membranes (Brown, 1991). lnsenion into the """"'ran<;. closely usocioted ..... the
lIilitily or8<l-2 10 rquIote lpoP<osi. (Brown, 1991). Subcellular loeaIizotion experimenu
irIdicIte that ti2 is present on the mitochondrial outer membrane, the nuclear membrane.
IIld the endoplasmic r<tieulum (Kromer, 1991).
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Box, adalh ........ encode.. 21 KD protein that ......homoIotlYwilh Bd-2 IlI1le
BHI, BH2 ond I1le BID domoins (Brown, 1997). Bax wu identified in immunoprecipiwion
-.. IX a Bol-2 bindina protein. II has • 45% homology 10 Bd-2 ond IIlIqOl1izes I1le
inhibitory _ ofJlcl.2 (Brown, 1997).
Current studies supeslthat Bd-2 ond Bax arc required to localize to mitochondria
in order 10 regulate apoptosis (Kroemcr, 1997). Bel-2ex, I predominant splice variant oflkJ.
2, contains • 21 amino acid carboxy-tenninal signal anchor sequence that targets the protein
to the intracellular membranes. Deletion orlhi. transmembrane (TM) region, resuhs in: (I)
inabiIily to suPp<es5 cell death, and (2) prevention oftargetiJ18 oCother &1-2 family protei..
like au 10 I1le mitochondria (Zha et aI., 1996). Addina I1le TM region &om )'CUt outer
milocbondrial membrane protein Mas-p70 which has I similar sequence, restored the
inhibitory effect of 8<:1-2 (Zba ec aI., 1996). Similar effects, such IS failure to tqet:
mitochondria and loss ofdeath promoting effect, have been observed in the Sax protein upon
rernova1 .fits TM region (Zhu et aI., 1996). FusinSI1le TM domain ofMu-p40 10 I1le
truneIkd SIx protein restores its ability to target mitochondria and perform its eytotoxic
elfecl (Zhu et aI., 1996).
Bcl·2 is also active when specifically targeted to the endoplasmic retieulum. This
__that JIcl.2 exeru some etfect on orpneIIes other than mitochondria to _ pro-
apopIOIic proteina &om tarsetins Ihe mitochondria (Kromer, 1997). For instance, Bcl-2 has
beett JIlown to interact with Box (which itselfmust target mitochoncIria 10 promote cell death)
in I1le endoplasmic reticulum 10 prevent cell death (Zba et aI., 1996).
19
nemioofcleolhqoni.(Bax)lOcIeoIhllll...... (Bd-2)delmnineswhelheracell
will respond to an apoptOtic: signal. Initiation of cell death depends Oft the competitive
m-izaIOn of"0"" and anlajonin Thoup amino ICid sequences .... simiIIr in the 4
domaina ofthe Bd-2 family. the Ilnl<tUrI1 f....... required for homo or beterodimerizatioo
.... dilferent(Reedetol.• I996).
Bd-2 homodimers (onn an antiparallel head -to -tall association where the BH4
domain ofone peptide inlen<t. with the BHI. BH2. and BIlJ domain of the otbet peptide
(Sato et 01.• 1994). Deletion of the BHI. BH2. and BH4 domains prevent. the
bomodimerization ofthe resullam mutant (Hanada et al.• 1995). The rnutanl. are unable to
inhibit cell death sullll'S'in8 that inla<t 1lt1-2 hornodimerization, dependent on BHI. BH2and
BID. is imporwu in this l\mction (IIanada et 01.• 1995). The wild type Bd-2 CIll dimerize
with the mutant but has no abmty to enhance cell death. Furthermore, dlmerization between
a sinaIe deletion of BH4 in a Bcl-2 protein and wild type Bcl-2 .iU renders the dimen
dysfimctionoI (Hunler'" Parslow. 1996). Adeletion ofBHIand BH2 CIll still result in the
IlIUWll bindina 10 the wild type (via the BR4 domain t,;nding to the BRIand BH2 domain
of the RIitInt) but the lnhibitory eJfect on lpoptosis is still absent Single deletions in
tqpnents other than the BHI· BH4 domains olIO suppress the inlubitory effect of the 1lt1-2
gene produ<t (Hunter et 01.• 1996).
Ilax, a dealh qonist, does not eomain the BH4 domain thus suggesting that this
domain is expeodable in interactins with the Bcl-2 protein. At.. result the stNeturaI features
by wllidt Bd-2 intew:ts with Bax .... diff.....; BHI. BH2 and the BIlJ domains ....
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->'filrJld.2IIIax_(Y.....L.I994).lolymphoidcells,_OC
I .......... acid io the BHI 0< the BH2,...... ofBd·2 have beat _to impair
__SaxandiollibitiUlllIi-apoptoticliln<tioo(Y II.• I994).Consequendy.
diI_the necaaily oCBHl, BH2, and BID ofSax 10 int with Bd-21O_
coli dadl.lIowever,the IIIIdilIt thai the BH4 domain oCthe Jld.2 proeein is_'0_
cell deIth but not for dimerization with 8Ix SUUestl that 8c1·2IBax interaction alone is not
IUmcieDt to suppress tell death (Reed et aI., 1996). Current research indiwes that in
mammalian~ a mutant ad·2 protein lacking in the BH4 domain is unable to~ cell
dalh despite bindins to Sax (Sato .. II.• 1994). An~ion fo< diI <:oUId be that the
BII4 domaia may _ericaIIy interfere with the binclins oC Sax to some other dalh _
proteios. _ ~<:oUId be thai the BH4 domain may ....... UI df...o<domaia
thai biods the Bd-2 pnlCein to other proeeins 10 inlobit coli dalh whereas dimerizing '0 the
BHI and BH2 domaia serws to WS" Bd·2 to Sax (Ileed .. II.• 1996).
Sludies indicaI. thai Sax ....... ddetions in the BHI and the BH2 domain do IlOl
hinder bomocIimerizIli with wild type Sax, 0< with other Sax .....- (Zha .. II.• 1996).
BIlIiIIax homodimerizatio occurs in I tail '0 tail inIeraction (Zha .. II.• 1996). The BID
domain however is essential for homodimerizjng with Sax and heterodimcrizing with Bd·2.
Sax IllUUIlIS Iackin& in BID domain WI '0 homodimerize with wild type Sax and are
iacapabIe of-"'tI coli dalh (Ileed .. II.• 1996).
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To IlIllllllIrize Iiom the llUdia:
I) Bax-Bax _ promote cell death.
2) Bd-2 functions u an inhibitor ofBax: by binding to Sax and forming an heterodimeric
complex. For Ibis to happen, the BHl, BH2 and BID sequences must be intact. FoUowing
Bd-2IBax dimerizIlion, BH4 may play.~aI role in inhibiting the liInc:tion ofBax
3) Bd-2JBcl-2 homodimers inhibit cdl death, wilb Ilax worlting '0 prevent B,~2
hornodimerization.
Formation ofdimers. BaxlBax, Bd·2IBc:1·2 or BeI-2IBax results in • ratio ofdeath
aaoniR 10 antaaoniJt which determines whether a cell wiD respond to an apoptotic signal.
Ahboup dimerizIliOll ofllax and 8<1-2 bas ... been directly cxamir.ed in lbe present Rudy,
an iDcreue in deIdt aaonisl (Sax) or death antaaonist (8cl.2) and theirinfJuence in apoptosis
wu eumined. The intcNclation of Sax and Bcl·2 and their IpOptotic influence in the
primary tumour wu also investigated.
1.3 '*2 Ind Capcer
Immunohistochemicaltecluliques indicate the expression of lbe Bcl-2 family g....
ift • wide variety of tissues. both in terms of specific: cell types and stage of cellular
diIf<rcnIiIlion (Reed. 1995). Expression ofB,I-2 bas been reponed in hormonal or growth
faclor reguIaled tiIsues (thyroid, br..... prost..e), long-lived stem.;.u. (skinor inIestine) and
.... lived poslJIlitoo, cells such IS neurons (Reed, 1995). CoOs ofmesodermal origin do not
express the Bd-2 gene (Diaz-eano .. aI., 1997). The widespread _ession ofmany Bd-2
f4miIy genes means that many types of celts simultaneously contain sevtral Bcl-2 family
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proleioa. Tbae proIeinI, ....... _ IIllllUIIts vary_. to cell type ond dearee of
... difI'erentiaIio OR avoibblo Cor pllyoi<:a1 ond filnclional intero<tioos ond therefore
provide the uoiq.._eristi<:s ofacll cell type in terms oflifespon rqulationond_
....mwy or raislance to apoptolic stimuli (Reed, 1995).
IIiab Ieveb ond aberrant polt....ofBd-2 expression have been observed in a number
ofi>lman carcinomas; proSlIle,llIJ18, pstric, rellll, and colorecul (Reed, 1995).1Iiab level.
ofBd-2 have also been found in other cancers such as acute and chronic ieubemia, non-
1IocIakin'.1ymphoma ond neuroblastoma (Reed, 1995). Abnormalities inBd-2expressioncan
be observed in early or tale Slages oftumour progression (Bronner et aI., 1995). The causes
for the dysregulation ofBcl-2 expression in neoplasms are varied. One explanation for the
IberrInI Bd--2 expression is that alterattons occur in the transcriptional ac:bvalors and
.......... thIl reauJIle the &1·2 .... (Miyoshits" ~., 1994). One lUCh repressor, the p53
sene. will be described in the following chapters.
N discussed earlier, immunohistochemical analysis 0£&1-2 has been performed in
many typeS ofhuman canc:ers. including breast carcinoma. The prtlcise role 0(&1·2 in breast
taneer is still unelear. The ratio of anti-.poptotic 10 the ~ptotic: proteins plays an.
imponaol role in determinina the letlIitivny 10 apoptotic stimuli (Reed, 1995). EIevoted
expression ofBcl·2 protein and reduced expression ofpro-apopcotic Su: protein have been
observed in women with metastatic breast canc:er (Reed, 1995), therby suggesting that •
decrease in apoptosis leads to increase in the survival oftumour cells which predisposes to
............ mCOIlttUt to this rcsuI~ Bsrgou et ~.(1995) found no ~anificant inmase in the
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IlIpI1IIioo olBd-2 ill ...... an:inomL_, the IlIpI1IIioo ol the Ilu prolein _
IipificaIy~ ill _ cortiaoma _ c:ompored 10 the exprasioo ofllu io oonnoI
_ ...... This liDdinI_..... perhaps it is the ratio oflaw Ilu exprasioo 10 the
~ Bd-2 protein in _ corcinoma dill hinders the process or_otis and
__the IWvivoi of ......... c:eII. (8...... '"1.,1995). Similarly, Knjew1IQ et 11.(1995)
abo observed that the reduction ofSax expression in women with metastatic breast cancer
wu uaoc:iIIed wid! diminished IJlOptosis.
A...... study by Musto"", (1997) sI>owed • dea.... in the Bcl·2 exprasioo in the
lite suaes ofinvasive breast carcinoma. This dcaase wu associated with an increase in the
lIle ohPDl"osis. A_ in the exprasioo orBd-2 and Ilu in the wer...,. or_
_ his ..... dernonstnled in.1IlJIlber ofIIUdies (Reed .. 11., 1996). The ..... lOr tIlis
dec:reue ill Bd-2 and Bax exprasioo in the later stages of tumour progression remains
......... Knjew1IQ ..11.(1995) _ ..... 1W1loUn, l1Ier.eenain poiDl in theit I>iclIotIicoI
prosrasion, may be less dependent on Bd·2 (or survival and that one reason for this non-
cleperldencycould be the diminished expression orBu In_'0MUJlOnen'. studywhidl
showed. suons inwne correlation between rate ofapoptosis and Bc:1·2 expression. Berardo
..11.(1998) round no uaoc:iIIion between Bd·2 expression and lJlOP'otic tal. in Iympil node
positive _ CIJCinoIlll. The ditference in the two resuIu can probIbly be expIoined by
COIlSiderilltl the l'act ..... otIler pnlIeins in the 1k1-21'ami1y "" known 10 rquIItc _otis.
Neither study anaIy1ed the exprasioo of 'PDI"Oti< pnlIeins sudllSllu and Bd-x. 0< anD-
--"<prooeins sudllS Bd-Xe.0< Md· I. The inlenctions orthe Bd-21'ami1y are complex
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IIld inlerdependenlllld 1heref... lIlIIyois of mul.iple componenu may be needed (Ileed,
1995).
Knowledge of the ItI1UJ of Sax and Bd-2 expression In breast CIBCef and its
..-iIlioo with opopIOJis IIld cli11iCll parameters such IS Iympll node .......
estrogen!proleslerone receptor ....... disease free swvival, ond tumour grade could
determine the cliniCll signili_e of&I-2.
2.4 CUgiql _lrq,'R gf BcH Elprmiog ie 'WIll Clge"
Studies have examined the association ofBcl-2 expreuion to. lUmber ofweU known
ctinicopathological parameters. As described in the previolls chapter. only tumour size,
axillary lymph node swus. presence ofmctastati<: disease and ERIPR status have so far met
the riPi specifications required ofa good independent prognostic parameter. Bharpva et
11.(1994) reported strong positive correlation between Bd-2 and estrogenlproaesterone
receptorexpression, -.agestingthe possibilityofestrogenlprosesteronerqulaIion oClhe&J.
2 protein expression in b..... carcinoma. Similarly, Berardo et 11. (1991), in. study of979
cues with invasive breast carcinoma showed a strong positive correlation between ERlPR
....epIOI swus IIld Bd·2 expression. Sierra .. 11. (1995), in their study of 124 primary
_ from pIIients with orwithou'lympb node meIISWis, shoW<:d 1ft invene corre1llion
between expression ofBd-2 ond hiSlologiCll grade ofrumour. In "'''rut to hip Bd·2
expression in Grades I and U tumours. Bcl·2 wu significantly reduced or absent in the
lDIjority aCthe cases ofGrade mcarcinoma. Sierra's results also indicated that Bcl·2 wu




Siena conduded thai Bcl-2 is ..... hquemly expressed in Tl (tumours leu than lem) with
Iympb node meIUlISis. Similar reIlIIt. have been demonstrated by l);azoCano e< aI. (1997).
He Ibowed IItron8 positive correlation between expression ofScI.2, ERIPR status., and low
grade tumours. This IUggesls that Bc&.2 expression is • probable mechanism by which
neoplastic: ceUs reaclIlongtenn growth in I weU differentiated ER positive breast carcinoma
(DiazoCano e< aI.• 1997). Ahiah grade ERJPR negative tumour which lack. BcI-2 expression
docs not rely on suclt mechanisms possibly because a selective advantage for growth has
already been acquired by othe< mechanisms (Diaz-Cano e< aI.• 1997).
A hiah expression of Bcl-2 is associated with prognostic facton known to predict
_lite llINival andoveraJlllltVival ofbreast c:ancerpatients (Koboyubi e< aI .• 1997;
Joensuu et aI., 1994). lfthis is the case, then it is logical to uc:enain ifBcI-2 by itself is an
independent favourable prognostic factor. Josenuu et aI., (1994) showed no independent
propmic value of BcI-2 expression in node negative and node positive tumours. On the
_ hind, HelImans e< aI. (1995) SUl!8esl'hat the absence ofBc~2 wu an independent
marker ofpoor proposis in axillary node positive breast carcinoma but not in node negative
tumours. Allolherstudybyvan Sloot.., e<aI.(I996), however. showed thai even thoupBcl-2
wu lSIOCiated with various other prognostic factors. Bcl-2 by itself is not an independent
_ofprognosis.
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N iIldicIIed obove, _ cIeterminins the prognostic vaIuo otBcl-2 hav. yielded dilf.....
-. To inYesti.... the effectiveness or Bcl·2 u • proflllOstic indicator, the _
~..JIlUIyexaminedtheilller-telalionorBc~2IlldBaxlotheclinic:llpanmel...1lld
the ability ofBcl-2 10 p<edi<llocal recurrence.
Chapler 3
CELLULAR PROLIFERAnON
Cell proIiferaIion isabiological processIhaI playsalUnclamenll1 role inpby1iologyand
pathoIoay. Cell growth occurs in I series ofconsecutive stases where GO (G z: gap) is the
initial phaae whenl synIhesis ofDNA does IlOl occur. As a result, cdh in lhe GO phase are IlOl
strictly COIlSidcred to be part of t!Ie cell cy<le. When """,lated, the cell. in the GO phase
_ to t!Ie G1 phase where _geeRNAs and proleins are synthesized. The GI stl8e
is__ by t!Ie Sl'hase (S • synthesis orONA) phase in whi,h DNA i. beinS repIieated.
Durirlg this 1tISt. the tOlal content of DNA increases from the diploid value of 2n to the
repliclsed value of4n. The S phase is foUawed by G2 phase where the cell has two complete
diploid sets ofchromosomes and is ready for mitosis (Lewin, 1997; Yu et aI., 1992).
10 Cd Cydc ••d CaPUt
The ceIJ~ is a hishiy regulated event where dysfilnetions in t!Ie regulatory proteins
represent potential origins for tumourigcnesis. Studies have indicated that cellcydealterations
Ire I eonunon feature of neoplasia. Indeed, cell cycle defects seem necessary for cancer
development (Nielsen eI aI., 1997).
Various tedmiques have been used in determining cell proliferation in tumour ceI1s.
COUIIIin& mitoses in ...... ",""ns is an old but well <"ablished method (Hall k~
1990). Thoup fiirIy c:rude, t!Ie teehnique ,an be rigidly _dized and has been ahewn to
be quite reliable (Hall & Levinson, 1990). A more recent and reliable method to determine
proliferation is the use ofBow cytomctry which measures proliferation as the percentage of
28
ceIIa..- in the 5-pIwe of the c:eII c:ycle (Yu .. aI., 1992). Thouah reproducible IIllI
pnc:ioe, flow C)'IOllleIric: IIIIlyois requires expenoive equipment and 'echnicallalowledae (Yu
et 01., 1992). In Jeneral, the-...-ofprolifemion by histocllemi<al methods has the
IdVIIlIaJtof~ the ljl&tial orienwion ofprolifentins cell. within tissues (Yu .. aI.,
1992). ADtibodies to proIif....ion usocialed markers such u Prolif....... Cell Nudar
Antipn(PCNA) and Ki-67 ontiB'" can be .....sed immunohistochemically(Brown8<Goner,
1990). This method, even with. number oelimitations. is. useful proc:edw-e with reprds to
the preservation of the cellular tissue arclUteaure, relative simplicity ofthe method, and the
IbWlyIO meuure proliferation reliably in panffin embedded ti...... (Brown 8< Goltcr, 1990).
The preseal study incIuda the investigation of the expression of two proliferative
markers, JCi.67 and PCNA immunohistochemically in panIIin embedded ti..... -mos. The
foUowins is I discussion ofthe markers and their involvement in the cell cycle.
U PrpIKmtigl CtII Npdqr Anti",· PeNA
PCNA, des<ribed by Miyachi .. aI. (197B) U I nuc:l.... ontigen, wu dete<ted in
proIiferaling c:eII. by autoantibodies tom patients with systemic lupu. etythemalosus (SLE).
The sen of these petients reacted with proliferating ceUs in • variety of tissues includina
mouse. rabbit and human (Yu et aI., 1992). Further investigations indicated that PCNA like
proteins and homologous genes occur in mammals. birds, and some viruses suggesting that
PCNAisonevolldionaryonnaervednudarprotein(Dietric:h, 1993). ThePCNAgeneproduc:t
is • 36 to IUClar nonbisIone protein which functions u an aeteSSOI')' protein for DNA
poIymerue deha synthesis (Dietrich, 1993)
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Study of PCNA synthesis in .... cell cycle uJins ftow cytometly and
__maximum PCNAproductioo during"" S·phoseand ......oC
....... repli<l1ioa (IlioIricIl, 1993). Reports show that .... concentration ofPCNAmer-
durins Ibe 111. 01 pltue. radios a maximum I.... in Ibe S1Jhue (approximllely 7 times Ibe
level found in Ibe quiescent cell) and gnduaI1y declines during Ibe 02 phose and mitoais
(Die<ric:h, 1993).
Similar results were observed in molecular studies. PCNA mRNA wu undetectable
in quiescent ceUs. Increased expression of PCNA maNA wu detected 8·10 hrs after
llimuII1ion oCIbe quiescent cell. by growth factors and reaclled a maximum .. 18-20 In
whidI c:ortapOflds to Ibe peak oroNA synlbesis (Jaskulski It II., 1988). There are two types
ofPCNA present in the S-plwe; a soluble form not involved in replication and an insoluble
Corm, uaociated with onsoins DNA synthesis (Bravo.t McDonald-Bravo, 1987).
MonocIonIIantibodies to PCNA have been used to assess the degree ofproliferation
of tumour cells. The mouse monoclonal antibody, PeIO, recognizes an epilope ofhunw1
PCNA in ....... fixed in Cormalin and emIledded in paraffin (Yu It II., 1992). The
meuurcmcnt ofprolifcration using immunohistochemistry Iw been shown to correlale well
with the s.phue measurement using flow cytometry (Visscher et aI., 1992). A number of





olpolioolU with__. TIle rauIu iDdic:ated no dar__PCNA
pooitiviIyllld 1lIrVivoI 0ven11, PCNAopparcd 10havolildc prosnosbc: voIue in poIiaIlI
___. C (1993) IIso sbowed no comIaIion _PCNA positivity
ond IUnlOUI gnde oe lymph node involvement. In eon""'. Tahan et 01. (1993) show<d .....
PCNA bid I potential value u • prognostic:: indicator in breast cancer; patients with • hip
PCNAsc:ore had shon"eli..... tift survival. AS1udyby Sheen-Chens" 01.(1997) wocioIed
PCNA positivity 10 IU1OIotlicoI arode. primary tumour SlaIUS ond S-pIwe _ mouured
by _ cytOmetry. S-.chens" 01. (1997) concludes thaI in ....ltiVlriato 1IlIly1i, hi'"
PCNA expressioo in brast canca' eeIls can be used u. u.seNl adverse prosnosbc: UIdieator
ill lymphnode posiIivetumours. HorigudU et 01. (1998) round ..... patients with_...-
whose tumours had • high PCNA expression showed poor survival ntcs. Abo. u Sheen-
CIIeoc's rauIu indicated. PCNA was, in • multivanalo anoIysis, an independent propostie
_.
TIle variIbiIity in these SlUdies show thaI PCNA u an individual mark" ~ not
complecely retiab&e in predict"'l survival or rate of recurrence. No doubt some of these
diIa'epancies may be related to the use of different antibodies and tecluUcaJ variations in
llIinina. However. it does seem ..... PCNA, combined with o!her marken moy prove more
_ illpredietinadioieII OUlCOllle. TIle llfellIlh ond woci&lionoltwooemoreprotifenIiClo
-...moy prov;de more vaiuallIe rauIu in lenos orvalidity ond rdiabiIily. Foe eumpIe,
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........ ol die pooIifonliw _1CJ-67 Ippat1IO comIole MIl db thai ofPCNA
(IlaOcv" 01.. 1996). The ... oldie _1CJ-67. has IlJo brouaht ..... iMipl iaIo
__ proiireratioo ond has provided ..... useful c1inicol inr..-ioa.
3.3~
In 1983. Ki-67... laG....... OIOllOcIoaII.n1..bodywuobWned .. stuefiesdirecled
.. prod\lc:qll.i>odi."oHodsJcinsdi..... (Gerdesetal.• 1983). They observed tha.1CJ-67
antibody racted only with the nuclear antigen aCcells undergoing proliferation. To validate
this obJervalion, Gerdes lIimu1a1ed Iympbo<yteswi'h phytohefnasglu.ininA(pHA) ond found
die antiaen recopUed by Ki-67~ only ...he nuete; ofprolif""tilIa <dis wberas IIle
.......~ when proIiferaIina eeIIs were induced.o 1Ile...una_. He concluded
Illat this nudear ........ de!eded by Ki-67 wu present in proIiferaIina <dis. The fi>IIowilttl
_. Gerdes .. a1.(19I4) _Baled wbethenhe presen<e ofthisanliaen is exprased" all
proIiferalioa<dis~ all pIwes ofeell cycle or ifils oc:aurence is limiled 10 certain pIwes
ollllecel1 cycle. H. UJed IWO metIlods. I) An iDdirect met1lod wIidI relaled RNA ond DNA
prockIcUon to .he expression of Ki-67 in PHA lIimulaled periphenI mononuclear bIoocI
I<ucocytes. 2) A direct met1lod w1lich Slplfaled ceUs accordina '0 .... pIwes ofcell cycle
usinla 8uorescenI-lCtivaled ceU sorter (FACS) followed by immunostaining ofthele cells
wiIJl1CJ-67.1lotIl metIlods illdicaled that Ki-67 is present .. all phases ofllle eeII cycle except
IIle GO phase. Gerdes .. a1. (1984) concluded that irnnwnolllinin8 witlllCJ-67 would prov;de
• _ by _ die powt1lhdioa ofoormal ond neopIasbc <dis <OUId be assessed. Since
IIle iaiIiaI ....... 1IIIIl)' ....... stuefies hi", confirmed IIlese observaIions. For example, Sc:ott
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.01. (1990)lbowed.aood<OtT<lalionbelweenthe_otproliferalionral......
• _ milotia llldhod aDd the _chemical detection oCKi-67 e>cprmioo in •
00- xenosroft 1IIOdeI.
ADaly1ia oCIbe structure oCKi-67...,ws no signi/k:lDt homoiosy to any other known
_(ScNdter.tll., 1993). The-.reotthecDNA-.ina'1arse6,84S-bpexonwith
16l1Ddem1y repeated 366-bp elements called Ki-67 repe.ts (Schulter.. at, 1993). Each Ki-67
repaI tontains • 66 bp hishJy conserved region known as the Ki-67 moti( known to encode
the epitope recognized by the antibody (Schulter et aI., 1993).
1.> des<ribed above, the Ki-67 anti8en is expr<ssed in all Slag" oCthe cell cycle except
the GO pIlIIe (Gerdes.. aI., 1983). Cells in the restin8 phase enterin8 the cell cya.1ack Ki-67
in the asly part oCthe 01 phase (Gerdes .. aI., 1983). One study Cound that in proIiCeraling
cells. the KtuaI amount of Ki.ti7 antigens varies with the different stases of the cell cycle
(Suaki .. aI., 1987). They observed that Ki-67 expression increases with cell progression,
riaing during the latter part oC the S-phase and reachin8 • peak in the 02\M phase. The
siJNl1taneous increueoflG-67 expression with cell cycle progression is found in both normal
and neoplastic cdls (Vcrheijen et aI., 1989).
111 Ki-6111ld Brad Callerr
The proliferativeactivity ofatumour is detennined by the growth fraction which is the
proportion ofceUs within the active part ofthe cycle (VeroN et aI., 1988). Growth fractions
-.wed by Bow cytOllletIy and Ki-67 immunohistoch.mical staining have ""wn good
cornIaIion, c:onllrming that """nohistochemical staining is u reliable. llldhod u tlow
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cylOllIIlry (V.......,1.. 1981; KomeI et ~.• 1919). Positive comIIIions have been reported
_ Ki-67 immunolIist_ staiDina and mitolie COWIl, histolotli<ll and<. IymplI
node invcIvemelll, and tumour dilJlleter(Brown& Gatter. 1990). A 1996 study byPierplbo
<:oafinned that Ki-67 expres;.&on wu positively correlated to prognostic variables sudI u
miIoIic index, tlIlllour _ receptor status, histological sndins and lymph node .......
Vuious I&Udies from the late 19801 and early 1990s indicate Xj.(j1 to be an independent
prognostic tool for weuing the dinical outcome of individual patients. For inscance.
Bouzabar et ~.(1919). Wuuzer et ~.(I99I) and Pieri' et ~. (1996) showed sipilic:ant
correlation between increased Ki-67 staining, and decreased disease free and overall survival.
JCi.67 stainina and flow cytometry are now thought to be reliable techniques for measuring
tumourprolif_(Veroniet~.,1911;KameI" 11.,1919). Furthermore, Ki-67illhougllt
to be I vaJjd propostic tool in assessing clinicaJ. outcome, independent ofnodal status.. tumour
size and and< (poner-/ordan & Lippman 1994).
3.4 Kl-67 ..d PCNA
Thoush Ki-67 can perfonn u an independent prognostic indicator it has certain
Iimitalions. For example, Ki-67 antigen expreasion is inIluenced by ...ritional supply of"'"
cell and u • resu1t tissue taken from the central area of. targe tumour may display lower
expression of the antigen (Brown &; Ganer, 1990). Also, most tumours contain i
beteropnous c;eU population within which there are different proliferation rates (Brown Ie
Gauer, 1990). Thus. combination of two markers may prove more reliab&e in assessing the
.... ofprolifention.
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A IIllDIber of IIUdies have examined the joint usoc:iIlion or PCNA and Ki-67 to
dinicII outcome in _ c:ancer. Dawson" 01.(1990) and Baaenby ot: Andenoo (1990)
_ a posi'" corrdation between PCNA and Ki-67.1IaenIev" 01. (1996), investipled
the 0lqlRSSi0n orPCNA and Ki-67 in 487 breast cancer patients. They round thaI hish PCNA
and Ki-61 scores correlated with clinicopathological features such u luge tumour size, hi&h
histological snde, and absence of estrogen and progesterone receptors. In I univariate
anoIysia Ofsllrvivol dala, Ki-67 and PCNA emerged as parllllC!ers predictive ora poor overall
survival in both lymph node positive and negative patients. However in a multivariate study,
both PCNA and Ki-67 tailed to be paramcten or independent prognoSli<: sipific:ance.
However, in another study that examined the two markers, PCNA expression did not correlate
with that ofKi-67. PCNA was not l55Oc:iated with any ofthe clinical markers such u grade,
size. and mitotic index whereas Ki-67 showed a positive correlation to these clinical
parameters (Leonardi et aI., 1992). The differences in the results suggest dw more slUdics are
needed to examine the reliability ohlle proliferative markers.
3.! Jd..2 ••d ProIireratio.
A number of studies have documented a strong inverse correlation between Bd·2
expression and proliferation ntt. In a study of441 premenopausal women with breast cancer,
van SJootcn ct al. (1998) showed • strong relationship between low BcI-2 expression and &
hishproliferative rate u measuredby J(i.67 immunohistochemicalstaining. Other repons have
obIcrved similar results where Bel-2 positive tumours are characterized by low proliferation
fIleS wbea compared to Bd-2 negative tumours (Gorczyca et at, 1995; van Siooten eI:
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11.,1996).
TUl1lOUl1 with high BcI-2 expression have been usocialed with low proliferative
aclMly IlId, u a rauk, aood olinical out<ome. This associalion has been c:onlirmed by a
...... of studies which show Itrona usocialion between lncreued Bd-2 expression and
aood <IinicaI proposis (Joensuu ,ul., 1994; Knjewski at aI.,199S; Kobayashi at aI., 1997).
Also, tumoun that Iacl< 8<1-2 expression are usually rugh grad, ond have in<nosed ..... of
protiferatjon consistent with a poorprognosis (Sierra et aI., 1995). 8cl·2 over expressingcells
IeIld to lOOlIlftI1at, in the GOIGl phase, oonfinning Craig's (I99S) observltion that 8<1·2
promot..<eII vial>ilily but no' cell proliferation (Bomer at aI., 1996). The meohaniJm bywlidl
Bcl·2 is involved in the proliferation of cells is not fully understood. Some researchers
propose that deregulation in the growth regulatory pathway may result in one oftwo evenu:
inIbiIity 10 conItOI cell growth or apoptosis (lCo &: Prives, 1996).
IntJisstudy expression ofthe proliferative markers., Ki-67 and PCNAwere associated
with the expression of tumour suppressor gene, 1'53, the apoptotic; antagonist BcI-2, and
various prognostic: factors. The tumour suppressor gene pS3 and its association with
prolifention and apoptosis will be discussed in the next chapter.
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Chapter 4
p!3: De Tumour Supprasor Ge.t
4.119
p53,' tumour suppressorsene. named for its molecular size, wu diseovered by Linzer
Illd Levine (1979) Illd L... 1lld Crawford (1979) U ISl kd protein Iha1 bound in hiP
quIIllity 10 the Iarse T antigen oCthe DNA tumour virus, SV40, ;n SV40 transformed rodent
cells. Since the discovery ofpS3, inferences regarding its function and role have undergone
• number ofchansn. In 1989, p53 was correctly classified as I tumour suppressor gene. I
view which has been confirmed frequently by subsequent studies (Finlay et at.• 1989). DNA
tc:reenlnS in patients suffering from various types ofmalignancies showed aligh frequency of
mutations in the p53 gene (BeUamy, 1997). In fact, carriers ofLi-Fraumeni Syndrome, I rare
fonn. ofheredituy cancer, possess a II'IJtated p53 gennline allele; mutation abo ofthe normal
aUeIe (oec:ond hit) brings about the developmenl oCmaHgnanq because oCthe c:omplete lack
DC tumour suppression. The imponance of p53 as a tumour suppressor is funher' sugested
by -.. which show Iha1 nuU;.ygous mice, wilh bolh gennlinc pSl aUeIes inl<:tiv..~
develop IIOnlII1Iybut are highly susceptible10 tumour, whereas p5l h..erozygous mice (with
one normal ddt) display • lower susceptibility to cancer (Harvey et aI., 1993). The need to
UDdenl&nd the influence of mutant p53 in tumourigenesis, requires the study of WI p53 in
normal tells. Researt:h hu been ongoing in this study.
Normal ceUs express low levels oCpSl (Ko & Prives, 1996). Adivation oCwiId type
p53 causes two types ofevents: growth arrest and apoptosis (Lewin. 1997). PS3 wu defined
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u a call <yde <hec:kpoinl &dor wbeo IlUdies showed .hat DNA damaJinI ...... induced
biih __ of WI p53 (Lewin. 1997). p5l appean '0 act like an 'emergency brake',
inducilla eilher call <yde ...... or apopIOsis thus prooeaina the call from KCUIIIlIIa'ina exceu
..._(1(0'" Prives, 1996).
.. 1 Armt DE Apoptp,lI
The decision ofwhetherpSJ will induce apoptosis or growth arrest in various ceilshas
been ofinterest to many researchers. Celllype seems to be one factor in how the choice is
made. Current experiments have shown that it is possible to manipulate cells to undergo either
responIC (Ko & Prives, 1996). Rodent primary cells that generalJy undergo Gt IITest in
response to lrradiation undergo apoptosis when these cells express the adenovirus antigen
EtA (Debbas &; White. 1995). Similarly, haemopoietic cells which ue arrested in the 01
phase in response to irradiation, undergo apoptosis upon removal of the growth factor, D-J
(Canman et 01., 1995). B<lIamy (1997) 5U811esls thaI p5l simul.aneously signal.Il'OWIharresa
and lPOPlosis wIiJe downstream events such as transcriptional function prevents one or other
outcome. He observes that suppression ofapoptotic pathways may initiate growth arrest or
vice versa. For instance, introduction ofBcI-2 transgene into myeloid leukaemic: cells causes
delay in pS3 dependeru apoptosis. with the onset ofpSJ dependent growth arrest (Guillfouf
et 01.,1995). On removol ofp21 (ap5l'llgetgenelhao inducesll'OWIharrest) fromcolorec:ul
carcinoma ..II lines .hat nonnolly engaged in p5l-dependent ll'oWlh arrest, pSl deponden.
-.mis initialed (Guilloufet 01., 1996). From.hesestudies, BelWny(I997)concludeslhat
aIthougb mechanistically different, the p53 dependent cell arrest pathway and apoptosis
38
podlway 1M)' -1Ul>s1aaIiaIIy.
4.1.1 pS3 .... ApopCoIiI
p53 ioduca opoplOIiI io ....... <dI1ypeS. VIrious rom. ofllimuJi _ p53
........ opoplOIiI tudt u odcnovirus EIA expressioll, withdrawal ofp:owth &<ton ot
DNAdImIp(Ko.t Pri.... 1994~ Evidence that p53 plays. direct role in lpOplosis _
_ the wotIc of Clark• .t Harrison (1993) and Lowe et ~. (1993). Mouse1hymo<ytea,
normal or pS3 defic:ient in one or both alleles were treated with a number of apoptotis
inducinS_. RauIu showed thatthymocytes with WI p53 entered apoptosisafter ionizins
radiaIion, wberas mulllll p53 cd1s deficient in both ~I"es did no< enter _osis. Sin>Iariy,
....... _ ofa lIUdy by I.e<.t llerstein (1993) showed that spleen and bone marrow cd1s
tom tnDIIenic: aUc::e expressina muW'll pS3 resulted in incrused resistance Co apopIosiL
Moreowr, thymoqta _ theso animals showed docrwed Ievds of _osis after
imdiaIioo. The lIUdy provided _ evidence that p53 activates _osis in_to
_ tbal ..... DNA Slnnd breakase (Lee.t Bentein, 1993).
pS3 mediated apopcosis has been shown to suppress transformation ofcells., tumour
p:owth and tumour progression (Bellamy, 1997). Th. p53 dependent pathway of_tosis
hu been important in understanding not only the development of tumours but also the
trcIImenl ofcancer (Bellamy, 1997). Studies indicate that effective pSl mediated lpopcosis
is. _ of~ <hemothenpy (Bellamy, 1997).
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pSl dependaIl_'O~' tID be inhibiled by various factors. Exposure 10 growth
&do" IlIdl u D-lllld~ tID inllibit pSl dependent apopto~. (Lin" Benchimol, I99S).
AlIO, 1ld-2 DC adenovirusEIB ate knownlO block pSl activation (Lin"!IaIdIimoI, 1m).
H.-, it ia abo thousJo that wild type pSl tID transcriptional1y repress 1ld-2 wIOIe
indu<Ula~on ofBill, one ofthe targets..... (Ko" Prives, 1996). Therefore, 10.. of
pS3 flmction by mutation would be expected to lead to an acaunulatton of &1-2 and •
clemued level oCBa. However. Krajewski et aI. ( 1997),ln astudy ofbreast cancer. reported
•sarona inverse colTelalion between immunoreactive p53 expression and immunoreactive Bcl-
2 expresaion. This poses an interesting problem in the interpretation because nuclear
immunopositive expression of p53 is generally thought to signify the presence of. sene
mutation in which the mutant protein has a relatively long half-life. Therefore. this study
woWd melle that mutant p53 is also effective in reducing BcI·2 expression. On the other
bud, this inverse relationship between immunoreactive expression of Bcl-2 and pS3 may
indK:&1e thai wt pS3 may actually be substantiaUy upregulated in breast canccrcdls. Krajewski
.. a1. (1997) found IlO relationship between pSl IIld &ax expression. A numbos of other
IIUdies in breast cancer have con6nned this inverse torrel.tion between pSJ and Bd-2
expression. Barbaresclli .. a1. (1996) .xamined 178 nod.-nesativ. breast cancers and found
Bd-2 positive tells expression were inversely associated with pS3 ovcrexpression. Lee et aI.
(1996), _do .. a1. (1996) and Haldat .. a1. (1996), found ~milu inv.rse uociations
between pSl and Bd-2 expression. The present study likewiae examines the association
between pS3 and 8c1-2 and their influence in local recurrence.
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4,U p53l1l4l'l'o1if....tioa
As discussed earlier, pS3 regulates proliferation and apoptolis by activating or
..~ other ...... required for either pro<:as (Lewin, 1997). The wild type pllgene
inbibib ptoIifenlion by inIIuellcing certain c:dI cycle regulators (Lewin, 1997). For instance,
Ibe cdk-<ydin kinue inl..bitor p21, whidl binds '0 aU edits ond anests Ibe c:dI cycle atony
pon witbin GI-S, is upreguJated by pll (l<ok Prives). As described earlier, p21.,'- <db were
incapable of arresting cell cycle progression in response to irradiation, suumina the
importance of p21 u a rqulator of cell progression and as I critical tupt for pS3 (Kg a:
Prives).lnterl<lions ofpll witb other eeIJ cycle reguJators remains unknown «1<0 k Prives).
u p!3 I,d Tt.,rilcpajJ
pS3 mutllionsoccurwith high frequency in various typesofhuman cancers. More than
2500 twnours and tumour tell lines have revealed some form afpS) mutation (Ko &: Prives.
1996). BeUamy (1997) proposes that the wide occurrence ofdefective pS3 derives ttom three
~: (I) WI pll is highly wlnerableto dysfunction caused by even a single base charge
in the codina sequence; (2) • single abnormal pS3 allele or loss of aIle&e can alter the
phenotype; (3) the participation of pS3 in multiple biologicaJ pathways makes it an Achilles
heel ofcancer suppression since a defect in its function can radically reduce cellular defence
apillsI carcinogenesis.
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u dJ t:wwiM y4 .... "rrittM
p53~ isdeI_ia 3a..5% oCprimary breast an:ioomos (Motino ..
01.,1991). FIIllhcnoor<, p53,u .. iJldependcntprolP"'sti<ftlIlI:eriabreast_, bas .....
....... ill ......... smoIIer l!Ian 3 an in sizo (Molina .. 11., 1m). In • SlUdy onOll_
IJlOCin-, p53 IlllIl&lion detec:ted ............oc:hemi<ally abo sllowed • sipificant
uaociaIion with hipande tumours. hormone recepcor negativity and poorptognotis (Porter-
l«dona: Lippman. 1994). Similarly, Elledge a: Allred (1994) observed that p531CQ1muillion
is wociated with. number ofprognostic factors such u ER negativity and high hislolosical
FIde. In another study of 304 breasa cancer cases with. 7 year follow--up, pSJ positive
tumours were IipificantIy UJOtiated with shortened diseue free survival and ovcraIJ 1UI'VivII.
_, DOCIe~ buI p53 positive eases sllowed. goo" 5 year suMvoI, """'I'Ved
to. 93% survival focp53 aepIive ....... (poner·lordona: Uppmon, 1994).S_.....
were observed iD • recent study which showed • signj6canl correlation between
overexpression of p53 and increased rate of recurrence in node negative and node positive
pIIiCllu (Molina .. 11., 1m).
4. 1w....""'kemiCJI ..gahlia oro!]
The wt pSJ protein in lbe eell nucleus is usually present in small quantities 1Nith. very
Ihon half-life. Mutations in pS3 cause various changes in its properties. Missense: nuations
_ the boIf·life and quonIity oCp53 (Greenblatt et 11., 1994). The prolonged boIf·1ife and
KaIDUIItioa of the procein, termed overexpressioa of pS3 in the nudeus, enIbaes
_ (UlC) deleetian wUh specific wibodies.ll is ICftClaIIy tboughI, buI by
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no_proven, tbIc lIJdarimmunopositivity CorpS] is an indirect indleationofa mutlUoa.
Therefore. imrn.mohiltochemica1 staining of tissue sections seems an appropriate means of
........ for p5lllUlalionai events which can affect patient proposis(Greeoblaltet II, 1994;
Sjorpn et .... 1996).
Ia VIrious lWIlOUtI, expression ofp5l measured immuooIUSlocbemically is ISIOciated
with the ........... of the proUf...."" marten, J<i.671l1d PCNA.lt i.logicoI to_1Ilal
naatation ofwt pS3, which normally restricts the movemenl ofeells through OI·S, would
result in increased proliferation. Various breast cancer studies show a positive COJTeIation
between pSJ immunopositivity and proliferative rate (Allred et a1.,l993; Gorczyca et aI.,
1995; van Siooten ...... 1996).
In this study, an wociaIion between pSJ expression and proliferative markers (Kj--67
and PCNA), apoptotK: markers (Bax. BcI-2), and the rate ofapoptosis was investigated. The




Priacipln or I..IIbontory Metbocb
5.1 ........is1odtmiatry lIRa
Since its development in the 19401, immunohistochemistry hu become • tnIjor
diqnoolic: 1001 in patholojy. The underlying principle ofall immunohistnchcmi<al.-ions
is the speci& reoopition by an antibody ora cell or tissue antigen, followed by. visualization
of Ihc ._hed antibody (Elias, 1990). The site .fthe antigen-antibody binding can be
identified either by. direct or an indirect method. In lhe direct method, the primary antibody
speci6c to the antigen is conjupted directly to an enzyme such u horsendish peroxidue or
albline phospJwue which uses. clu'omagen substnte for visualization ofstaining (Bancroft
.t Stevens 1996). Enzymes, the most commonly used labels in combination with a chromagcn,
yield altlblc eoIoured reaction easily visible under the ~ght microscope.
The indirect method, involves applicalion of an unconjugaeed primary antibody,
followed by • labelled antibody directed against the primary antibody (Bancroft 4\ Stevens
1996). In the present study an indirect method, caUed the labelled avidin-biotin technique wu
used to identify the expression of apoptotic and proliferative markers in formalin fixed breast
tissues cdedded in paraffin wax.
5.1.1 TIle Avldill Blolill Techalque
The Avidin BiotUl method utilizes three reagents: primary antibody, biotinylated
JCC:OIldIry ,,,'-body, and Streptavidin conjugaled with hor=adish peroxidase (Canon, 1997).
The unIabeUed primary antibody (raised in a goat or a rabbit) specific: for the antisen, is
..
lpIlIiod .. the ...... To dctecl1he prinwy 1IIIibody, biotinyIalcd secoDdIry 1Illibody, mode
_ aoecood __ opecific: for the prinwy IIIIibody derived from 1he lint species, binds
to the primary antibody (Canon. 1997). When streptavidin conjugated with the ITIIIker
enzyme horseradish peroxidase is applied, it binds 10 the biotinylated secondary antibody.
HonendiJh peroxidase interaots with the ebromagm Diaminobenzidene (DAB), yielding a
dirk. brown reaction mel product visible in the microscope (Elias., 1990).
This method relies on the affinity of a 67 leD glycoprotein avidin for biotin, • low
molecular weight vitamin. Avidin, found in egg whites. is composed offoor subunits which
form • tertiary structure possessing four biotin·binding hydrophobic pockets (Bancroft &:
St~ 1996). The oligosaccharide residues found in the egg white with its charged
propatia have some affinity to the tissue components which can result in non-specific
bindina. Large amounts ofbioiin found in liver, also contribute to further badqvound!llinins
(Banc:roft k Stevens, 1996). To avoid non specific: binding. use of. similar molecule
streptavidin, wlUch lacks olisosaccharide residues and contains neutral isoclectric points wu
applied to the tissues instead ofavidin.
Biotin is easily conjugated to antibodies and enzyme markers. Approximately 150
biotin~ can be attached to • single antibody molecule. The ability ofa large number
ofbiotin molecules to bind to a single antibody enables numerous streptavidin molecules 10
bind 10 the biotinylated secondary antibody and results in an increased sensitivity to the
anligelHllli>odybinding(llancroft& Steve.... t996). Consequently, the labelledavidin-biotin
method bas been found to be I moll efficient technique, capable ofdelecling minimal levels
4S
of'lIIIipl expreuioo (Gorino, 1984).
5.1 Dc TllNIL Mcd!"
The ........deoxylUCleotidyl tnnsferase(TdT)- mediated deoxyuridinettiphosphole
(dUTP)-biotinniclt-<llll1abdlins (TUNEL) method hasbeenutilized '0 identilY lJlOPl0tiec:ells
in fOtlllllin fixed, pIlIIIin embedded tiuue sections. The enzyme TdT catalyses the insenioo
of'diaoJliaeNn 1lbeiied dUTP molecules onto the 3'-oH end of fragmented DNA in c:eIIs
underJoin& apoptosis. The dtrrP molecules require no template for nucleotide elongation .
The incorporated laldcotides fonn I heleropolymer in a ratio specific for anti-digoxigenin
antibody binding. Digoxigenin is derived from the digitalis plant. In animals.
invnunochemically-similar ligands for binding to the anti-digoxigenin antibody are rare, tim
ensurin& low background staining. The Fe portion of the polyc:lonal sheep antibody to
diaoxigenin wu proceolitically cleaved, allowing a<1% chance ofcross-reactivity. The 1liii-
disoxipnin antibody fragment carries the enzyme peroxidase which reacts with DAB to
produce an intense. coloured signal. The above information was supplied by the ONCOR
Apop Till MlnuI1.
There areconmnsthat the TUNEL method does not sufficientJy discriminate between
necrotic cell. and true lJlOPlotic c:eIIs Kraupp and Nedecky (1995) showed that hepatocyte!
dyina by both apoptosis and necrosis gave asimilar positive result in the TUNEL usay. N
• result ofthe study, lpOptotic celJs were assessed with particular care by the author and the
pashoIogisu (see section 7.3).
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Chapter 6
IttHarcIl R)'potllesa aad Objectivel
Relatively few studies have concentraIed on the inter·relation orwell known apoptotic
1llIlkers(lld-2, BIX), proliferative marlton (Ki-67, PCNA) and cfinicopatbologi<al r.......
(tumour score, tumour size, and lymph node status) and their potential role as predictors of
Ioc:II rec;urrenc;c in brtut ClD(:cr. Therefore. this study was undenaken to investigate the
interrelltion ofthese facton and their clinical prognostic potential.
6.0 RauB" Uyp..""
Since tumour growth is determined by the rate ofcell proliferation and apoptosis. it
wu hypothesized that local recurrence ofbreast cancer would be predicted in either oCtile two
situations: (I) low expression of&I·2 in association with a high rate of proliferation and.
high 1'I1C ofapoplosi.; and (2) expression ofmutant pS3 was increased in association with I
hish l'IIe ofproliferation and a low rate ofapoptosis.
6.1 BntmhObimiYp
By immmohistochemistry on breast carcinoma, we wished to:
determine the rate ofapoptosis by the TUNEL method and to examine its relation
to the expres.sion. ofthe apoptotic regulators, Bcl·2. Sax and p53.
c:xanUe the interrelation ofttle pnrapoptotic factors, Bax and pSJ. and the anti-
apopIotK factor 1k1·2 .
examine the interrelation ofproliferation factors. Ki-67 and PCNA, and the
_otic reguWotS, BcI-2, and p53
.7
......... if or more ofllle foUowins fi<ton determine IIle incidence oflOCllly
.....,.. carcinoma within. Syear period foDowins initiol diqDoJis 01
invasive breast CU'cinoma:




» Expression ofmutant pS3




This reuospective SlUdy examined 145 female Newfoundland br.... eancer pili.....
The pUients were aUocued buo two groups: those with aloc:al recurrence oftumour It the
lime 1IlI)ic:al site within the S year period ronawing initial surgery or those without local
recurrence durinal1U period. Local rec:utl'cnc:e wu defined u the growth oftumour II the
orisinU site of surgery or in the axillary lymph nodes. The two groups were funhcr divided
iMo those with metasWic tumour in the axillary lymph nodes at presentlcion and those
without lymph node metastatit tumour at presentation.
Locall Recurrent Non--Recurrent
LYI1IOh Node DOWve 46 27
LYI1IOh Node neutive 45 27
7.1 blallu:I
Patientnamesand relevant clinical datiwere retrieved from theNewfoundland Cancer
CenIre. Micro.scopic slides and paraffin blocks were retrieved from various centres in
Newfoundland: SlJohn'~ SI. Anthony, ComerOroolc, GrandF~I~ andGandCf. Initially. 165
breast cancer patients with local recurrence within a5 year period were chosen for the study.
T_ of the patiaIU wue eliminated from the SlUdy due IacIc of rdevant clinical dala,
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llliuiaIllidaor lllOUIdy ponftinb_ 1be followinB diniCll cilia retrieved from palienls'
chortI ..... stored on I!le Mic:rosoft _ Duabue:
Tumour Size
Lymph node status
Presence or absence orIocaI recurnnc:e
Tumour Grade
Patient treatment (surgery, chemotherapy, radiation)
In IddiUon aU cues were re-examined microscopically by one pathologist and histoiogiclDy
gnded aecording to the Nottingham Modification of the Bloom and Richardson system
(GIIca .. II., 1992). 1be Hematoxylin" Eosin (H&E) slides were 1110 examined and
evaJuated in terms oca "non-fatty" constitution and presence oftumour cells in at ast one
ueaofdletissue. The paraffin embedded tumour tissue corresponding to the panieular RAE
slide wu then adopted for this study and analysed for the presence ofthe biological markers
~ in this INdy. The selected patients and their paraffin embedded tumour specimens
if'seIccted were represented by. number from 1-145 to observe patient confidentiality and
to prevent biu during slide examination of the apoptotic and proliferative facton. All
proc:eWr>l-. retrieval, and evaluations ofslides ond blocks were perfonned by I!le
author and the two pathologist (see chart 1 for contributions by individuals during the
pro.... oftbis study).
Chart 1: Contributions ofindividuals
involved in the progress of this study
Patients' Names (R.G.)
~
Retrieval ofPatient Clinical Infonnation
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work (A & D.R)
~
Tumor Sections cut
by (technologist and A)
~
IHC and TUNEL by (A)
Measurement ofBcI-2, Bax, p53, Ki-67
and PCNA Expression (D.R. & A)
Spss data-base & Statistics (A)
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7.1 .......... "SIIda
The 1Iideo(75 aZ5;IMdvinFreod Brud)IG be UJed were placed for Zmin in ISO
m111istosriP (Zymcd) diluted I:SOin__.Theslideswerewuhecl inthreelllininlldishes
ofdistilJed WIler(IOdipsach~ IIld placed in. SS'C 0""" fortwo houn. rwe micron thic:l<
tissue sections were cut on I microtome and mounted on the slides trated with Hiltosrip.
The a- sections were Iheo UJed for In IiI1l Terminal Deoxynucleolidy1 Transf.....
Medialed Nic:l< End LabeIIin& (TUNEL) IIld ImmullOhiSlochemiSlly (IHC).
1.3 Tcrajgl Dctm.dntidyl Tn....Mediated Nkk EM LtlMlli" mINIM
The .... ofopop!OSi. wu determined by I!le TUNEL method usins I!le Apop Til
Plu. Kit (ONCOR). Reqcnts from I!le Apop Til Plus Kit inc:luded Equilibriation Ilutrer,
_ ButI'er, TdT Enzyme, StoplWuh Butrer, IIld AnIi·Digoxipnin·P<roxidase.
PanlIin wu _ from I!le tissue sections by p10cina I!le specimens in 100 mI of
xylene, twice, for five minutes ach. The depanJIinized tissue wu Iheo plaoed in 100 mI of
absolut. ethanol, twice, for five minutes. eodl. The specimen wu plaoed in 100 mI of95%
etIlanoI foDoW<d by 100 mI of70% _I for I miJutes each. The tissue wu I!len plaoed
in tIIllllinl tap WIler,'" tinIIIy riMed with 10-15 mI of pIlospllll. bulfmd saline (pBS, pH
7.4)(6.8995WL ofSOmM sodium PhoJpbaIe IIld 11:688WL oUOOmM NaCQ.
To expo.. the Iiee l'OH ",,"p in DNA SlraIIds, the _ions were diaated in •
solution of SO ~I of proleinaoe K (Si_ ZO~Bi mI in PBS) for thirty minutes in •
humidifyins chamber It room temperature. SufIicietIl proteinaoe K solution wu added to
cover the entire area of the tissue section. with the use ofI coverslip. Initial tests lndiClled
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thirty ....... u tile opeimoI period fi>r dipIliooof_....... Followioa tile 30 minule
............ the enzyme wu removed _ deiocized water to preveol deteriorIlion of the
tissue.
The ....... were treated _ 10 mI of3%!Iydtollto peroxide (Haith Care Stores)
for five ninutes It room temperature to eliminate eudoaenouJ peroxidase activity. Sections
w«e rinIed in PBS and then pIIced in 1l)..15ml of PBS for S minutes to remove hydrogen
peroxidue. This procedw'e was repelled orK:e. Seventy-6ve mic:rolitres orthe Equilibration
Buffer (supplied in the kit) was added 10 the specimen for 30 seconds at room temperature.
A covenlip wu plM:ed on the tissue to spread the reagent evenly and to avoid evaporation.
_ buffer wu drIined offwithout rillsi11a by placing the ilide on In indine.
A mixIure ofRaction IIutfer (1lIppIiod in the kit ond conuinins diBoxipnin IobeIIed
nucleotides). ond TdT enzyme IOIution IIso IlIppIiod in tile kit (30 01 ofRaction butl'er ond
16 ~l ofenzyme IOlution), was apptied to .uleC:tions. The sectionJ were covers1ipped and
incubated in I 37·C 0YIll for 1 hour.
Coverslip' were removed ond tile tissuea were placed in I coplin jar conlIininB 100
mI ofstoplwah buffer for 10 ....... II room temperature. The stop/wah buffer (1 mI of
the stock concentrItad buffer diIu1ed in 34 mI of distilled water) stopped tile enzymatic
rea<tioa by removinB any remaininB enzyme. The specimens were rinsed ond placed in 1SmI
ofPBS for 3 minJtes. This procedure wu repelled two more times. Fifty-live microlitm of
tile In.i-diBoxiaenin peroxidue antibody (provided in the kit) wu added to each of the
specimens which were covenIipped ond _ed for I!Iirty minutes II room temperaturO.
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The opec;- ..... rillIed IIId pIocod ill 15 mI ofPBS for 5 ......... Thi._
wuperfonnedtwo 0ne_of30%hydropnperollide(SilJl1l)wuodded
to 2 mI diunino benzidine (DAB; SipIa) solulion prepared by diIulillS 10m! ofDAB Sloclt
soluUon(IO ""DAB_for 10 mI PBS) witb 15m1PBS. T1vet1O fOUTdropsofDABwu
added to adl s6de for 2-3 minutes It room temperllUre.
The opec;- were washed in WIler three times for I minute each. ne tissues were
COW1lenIIined ill 10 mI ofmethyl ..... solution (1.5m1 of 1% metI1yl ..... (SilJl1l) ill 0.1
M sodium acetate pH 4.0), for 10 mirutes at room tempenture,
The specimens ..... wuIled by difIIlin8 the slides !eVen limes _ ill two Sllinins
dishes~ 200 mI ofWlter. The sIidos were then plscccl in ...aiIli.. disIl CClIItIiIlins
200 mI ofWlter for 30 SO< without ........ Thi. _ wu repealed ..... 200 mI of
100'11 bulanoI (Si....). FlIlIiIy, the opec;- ..... conse<utively p1sccc1 for two 10 three
miJaIIes _ ill two SlIinins dishes COlllIinin8 200 mI ofxyl.... (Health Care Store'),1IId
.hen mounted ill pen1IOIIlO (Slephens Scientifie) IIId covenlipped.
Slides were examined under the microscope by the author IIId two pathoIosi.... The
rile of apopIosis wu maawed by countios the lIWllber of Slained apoplOti< cell. ill 4-5
adjacenI hi8h power fields _ consistins of.. least 1000 ceUs. The lllWl rile ofapope'"
(toralllWllberofapopcotic ceOs per lIWllber ofadjacent power fieIds[4OxIUJed ill the tissue)
wu calculated.
7." .MU.""'tIta
This metbocI _ tine _: primary anIibady specific: foe the ..tiSen,
se<ondory Ill1ibodyc:anjupted tobioliIl, and pcroxidue labelled !lreplaYiclin. This procedure
wu ",plied to the detection of the _otic &<:ton: Bd-2 (..ti·_otic sene), IIax
(ljlOptotic sene1 pl3 (tumour _ poe), Ki-67 (prolifentive muker), and PCNA
(prolifenlias IlIICIar antigen- • proIifcntive marker).
Puaflin wu teltlOved &om the ti..... -">us by placinS.he!pOCimens in 300 mI of
xyl.... twice, for five ........ each. The _ were dipped in three staining di.....
-.nos•seriea ofedlanoI~:10 dips in 300 mIlbsolutellc:ollol, 10 dips in
95% alcohol, lOcI 10 dips in 70% alcohol. The specimens were rehydrated in runninB water
for one to two minutes.
r...... 1ICIions _ethen pII<ed in. staining dWI COIlUIinins 300 mI of3% hydrosen
pero>licle (Gibco)for_ ....... to bIodc endoscnous peroxidue. FoIIowina the twenty
minute treatment, the sections were pIIced in nmning tap water for one 10 two minutes.
For antigen reuiml tWue IICIions were initially placed in • beaker comainins loo
mI ofboiJins 6M <:ilnte buft'er (Sitptll) for eight to ........t.. and then allowed to cool for
.en .......by,.",.... the beaker _ the hot pIoIe. The s1ida were temOved and pII<ed
for 2-4"" in. staining dWI c:onlIinins 300 mI oftap water. This pr<><edure wu curled
out for III ontisau _ PCNA
The tisIues were placed in the IuticIifIiIls<homber and rinsed with PBS (8S sodium
c:bIoride; Si8J1ll, 1.3Sdisodium p/aphole; Si8J1ll, 4.08 monosodium phosphate; Sitptllin IL
IS
WIler). The......PBS_dniDod,lIldlbollidesweredriodwith.delnpuze.To_
IIOIl-tpOCifiobodqround IIIiniD& "">10 Ihnedropsof 5% goat ...... (Dimensions; diluted
1:20 with_)_ oppIied 10 all1bo_1Ild iocuboled for 20 minutes. The goat ......
_ aentJy tapped off Ibo IIide IIld Ibo prinlIIy antibody _lidded.
7.U AppIka.... ofPrilur7 A._
Monodonll ....... lIlIibody forp53 (CedarIIne; Pal> 18(1) and BcI-2 (Colbiochem)
_diluted 1:401Ild 1:2.SrespecIivdy in l%bovine ...... oIbumin(8SAj(Sigma;'8BSA
in 100 mI oCPBS). The monoclonal mouse antibodies for the two proliferuivemarkers. Ki-67
(Oncotlene; M1B) IIld PCNA (Oncopne; PCIO) -. diluted 1:80 in 1% BSA TISSUe
sections SlIinins with primuy IIllibodies for p53, BcI-2, and Ki-67 -. incubated for
twenty-four hours in • IaunidifYinl chamber. TISSUe seaions staining for PCNA were
incubated for I hr. Polyclonol _ ...ibody for8ll«CoIbioc:hem; Ab-I) was diluted 1:25
in 1% BSA and sections stained with this InIibody were incubated for twenty four hours.
Two or Ihne drops ofdiluted Intibody soIu1ioo was oppIied to eacll section10 ....... thot tile
sections-.compIeIdy_. FoIIowinsinc:ubation, tile slides-.rinsed twicewilh 10-
15 mI PBS IIld Ialcr driod wilh puze.
7.4.2 Applicl ar_ Labdft Secuduy A.'ibody
Goal 1lIli antibody (1n1ennedico) 1:2000 (.5 ~, in I mI of dilutins buffer
(500m! 0.5M PBS•.258 TbimerisoI, I ml Tritoll X-lOG. 1:25 mI Tw_ 58 Cuein; Sip)
wu opplied to ....... stained for p53. BcI-2. Ki-67, and PCNA Goallllli-rabbit ......
(Intcrmcdi<o) diluted 1:2000 was oppIied to lCClions stained for BIX. Secondary antibody
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_ wuCllried out fur Ilol(.. hour II room,_.
Excea IOCCNldIty IIllibody__wilh two rinses oflo-IS mI PBS. The slides
were opin wiped dry wilh I gauze. Two to tIvee drops of the lOllIlion of Streptlvidin
~pIed wilh peroxidue (Illlermeclico) (O.SuI per I mI distilled WIler) wu applied and
inc:ubIIed fur Ilol(.. hour.
Followins _ in _vidin, the ....... were rinsed with Io-IS mI PBS.
Excess PBS wu removed by wipins the slides uound the tissue. Two to Ihreedrops orDAS
(IOma DAB table< in IS mI PBS (S~), plus 2~130%hydro ... peroxide) wu appUed '0
the sections: 4 minutes for tissues stained with anti-pS3, 3 minutes for tissues stained with
IIIli-BIX, IIlli·PCNA and 1Illi- Ki-67.
The ....... were placed in Iltlinina dish COlllIinina 300 mI ofhaematoxylin (24 a
haenlIIoxylin, 360& 1IMlOllium ...............phal.. 1S0 m19S% CIhanoI in 2400 mI Wlter)
for three minutes. The tissues were rinsed in nanning tap waler for one minute and then
dipped once in Iltlinina dish COlllIinin& 300 mI of 1% acid ak:ohollOllIlion (10 mlI2 M
HeL, IL of70'A alcohol). The _iOlll were rinsed in Wlter and then placed in a stainina
dish =tainina 300 mI of Scon's Tap WIler (7 a sodium bicarbonate (Gib<o), 40 a
........... luIpNre(Gi1K:o~I Utre water) for one minu'e. ThiswufoUowedbylfinalwash
in WIler. The sections weredippecilO timeselCh in a series ofstaining dishes comainina 300
mIs of 70%, 9S% and linaIIy absolute alcohol. FlJlIiIy, the specimens were _tivdy
placed fur two to tIvee minutes eodI in two ItIinina dishes containina 200 mI ofxylene, and
then mounted in permount (S'ep/Iens Sc:ienlific:) and covenlipped.
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7.U_I"""....~
ANipn expreaion wu quIIIlified with the oid of a pIIholosist in 'erma of.he
""- of positive __ or cyIopIumic: IlIinina ina given microsc:opic lidd. The
&cqueocywuKOtedu 0- ............ 1-lcssthanI0%0fcellswereIllined,2·1Q-
50%ofcellswereSlliJledIJld 3 =SO%or_ofcellswere SlIiJled. The ...... ofthe
IlIlnOlIr IpOcimcna were wiped by the IIdhor IJId the pathologist.
7.S StttiMiqI ApaInP
Analysisofthe -nlationof fa<:tors werecakulateelusing the SPSS (1.5 IlItisticai
packase) Chi.square <X'). Thia .... is the moll appropriate.o measure the woc:iations
between the VIriIbIes becluseofthe eatesoric:al natureoflhe data. Howe'o'er the X1test could
not be performed becawe the raw data malee1 tha. the sample population in ..... of the 4
immunohistochemica1 CIlqOries wu too JlIIIil for _ cakulation. Tbu~ the scora of
the immunohistochemica1ll1inina were _ (1- <10'10 ofcall. SlIiJled IJId 2 '>10%
ofcells SlIiJled), thereby inl:reuin& the sample population '0 cakulate the X' .
The.- rate ofapop<osi. (TUNEL -.) fOr _ tissue sample ( number of
apoplotic cell. per IUIIlber ofldj..... power fields used in the tissue) wu initially recorded
u • nominal value. To pIKe the nJNEL KOla into two CIIegorics so that they could be
entered inIothe IllIIyais, the .-lIlIllbcrofapoplotic cell. for 011145 tissue samples (sum
total oC the meIR apoptotic: ceUs per tissue O't'a' the total number of tissues) wu first
caIc:uIoscd «'6). The.--.wu then~ee1 CIlCBorically for...,h tissue sample
byaOor I;O=lcssthanthe.-lIlIllbcrofapopcoticcell.( <<6), while I' greater than
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the.-_oflpOJllAlliec:eII.( • >6).
WIiIe the X' coIcuIales the IIIOCiIliooI between variables, it does not indic:Ile the
direc:lion of the _po 11>11, the Phi Statisli<, which oneuuteS the _n of
UJOC:iIlion (u nepIive or positive) between _ wu olso obtained UJing SPSS. The Phi
S_wu c:okuIIIed only ifa sipifi<anl woclaIion between OWo f&<ton were ob.......
in.be X' ana/y1iJ.Due to the Iarp _ oft.... performed, a triti<al p-Vllu. of« = 0.01
wu implemented to control for the overaU probability of Type I error. Furthermore. for
sample sizes \csa!bon 25, rober'......... wu calc:ulated. Associations belWeen any IWO
fa<ton involvinB opoptoti<. proIiferaIive ondIor clinical parameters were '""ed for





LO CchIar........ "Iu.M2.eP rcNApdKH7
InlnaInoIlistoc IlIinina of 1110 ............. idenli6ed 1110 proliferative and
_Cllic_ T..... I.O _1IIo_ofcuesidentifiedforeachoflllomuken
in 1110 4 IfOUPS(O· noaprasion, I-lessthon 10% of<dls stained, 2 =10-50% of<dls
stained and 3 • _er thon 50% of<dis stained) priorto recodinl. Table 1.0 also indi<lles
1110 number ofumpIes ..... could not be stained for each oflllo mukers. These ....ples could
not be aaeued bec:IuJe ofthe fitty constitution ofthe tissue, resuhing in the tissue fiDinS oft'
1110 lIidc or beina folded, dills maI<in& QUIIIlitalion impossible even when the stIinin&
proc:edum were ...,..nd for I!Iose samples.
As_earlier, tumouredlswererococleduO« 10'10) or I (>IO%)dependinl
on 1110 <ytOpIumic; (Bd-2 or Ilu; see Fi.... 1.11 and 1.lb) or ",dear &equenc:y (pS3,
PCNA, and Ki~7; see Fi.... 1.10, l.1d and I.le) ofedls stained. However, in one of the
ana1yJes (section 1.4.2), 1110 usoc:iation _ lW110r grad. and Ihe pr_ (>S%) or
abseoce (0'10) ofpS3 wu examined raIher thon 1110 &equency ofilS nudear distribution «
lOlA or >10%).
The .... oflpOplOOis wu sc:orecI u 0 (1eJa thon the mean number oflpoptotic ceI1s;
ii < 6 ) or I (grater than or equal to the mean number ofapoptotic cellS; x ~6; see figure
1.lffor an example ofao apoprotic cell idenli6ed by the TUNEL method). The TUNEL
method wu..ccessfill in stIinins 142 of the 14S cues. The samples ..... could not be
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IlIinod in the TUNEL _ coincided widt tho.. tIw could not be IlIinod IIIina tile
--_.
Raults orUIOCiaIions between the _Olio, prolifenlive Illd cIini<Il &cion ...
_ individuolly in Appendix. The .......... orsunpIes assessed in ach ortlle II1IIyJa
varies due to the nature or the x! 1tItistic:. The SPSS calculates Xl with equal number of
subjeas ineach oCthe wepies. It eliminIteIlSUbject ifonc: ofthc values is Ibscnt. Results
ortlle significant _0IlS ... 1UllUllIrized in Tillie 2. (see Scotion 8.6).
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T..... Le: The,.,..., UId the total number or cues used 10 identify lhe opoptolic Illd
proliferativemuken.
hr
I·N. I J 3 T.... MiNia.
Mullen~ <10% 11·- >50% Cues Cues T....
Bu 47 30 4 63 144 I 145
IId-J 72 4 4 63 143 2 145
P53 106 17 7 14 144 I 145
KH7 22 93 20 10 145 0 145
PCNA 42 51 17 35 145 0 145
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FigureS.": EIpression ofBd-2 in Brust Carcinoma. Moderate to Strong Cytoplasmic
Staining (:l': 10%) present in Cells.
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Figure a.lb:Elpreuion of Dn in Breast Cardnoma. Moderate to Strong (~lO~.)
Cytoplasmic Staining praent in Cells.
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Figure S.h:: E:a:pression of Mutant p53 in Breast Cardnoma. Moderate to Strong
(~lO%) Expression of Nudear S"ining Present in Cells.
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Figure S.ld: Expression or peNA in Breast Carcinoma. Moderate to Strong (~IO%)
E:a:pussion or Nuclear Staining Present in Cells.
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Figure 8.le: Expression of Ki-67 in Breut Carcinoma. Mode...te 10 Strong (2: 10%)
Nuclear Staining Present in CeUs.
Figure 8.1f: A Cell undergoing Apoptotis as detected by the TUNEL Method.
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Ll 'd'site ..............1Icttn......Pl91k '.G.... IPM"tic DIe
1.1.1 Jld.l
There WU110""- UIOCiaIioa betwoen Jld.2 cytopWmic expression Illd Ihe
rlleoC~U_bylheTUNELmethod Cp> .01; ... Tobie 10.1 ;"Appendix).
Bd·2 cytopIanie expreuion wu pooitiveIy UIOCiaIed with Sax cytOplumi<: expression (X'
-7.017. elf-I, p' .01, phi-O.222; ......,..,.I.I.IIlldTIble 10.2 ;"Appendix). TheX'
.est did llOtshow oninYeneUlOCialioabetwoenBd·21lld p51 expression p> .01; ... Toble
10.1;" Appendixl).
LI.1 au
AMlysis of data showed no significant association bctwccn &x cytoplasmic
expression Illd p51 expresoion or Ihe rlleofopoplOJisCp > .01; ... TIble 10.41lld Tobie
10.5 rapectively;" Appendix).
1.I.3pS3
Analysis ofdata did not show I significant association between the rate ofapoplosis
Illd p51 expression;,,1he _Ieus Cp > .01; ... Tobie 10.6 ;" Appendix).
L:J ........... grpIIcntiyc ........tic tacton
Data analysis indicated apositive usociation between the two proliferative factors,
Ki-67 Illd PCNA (x' = 9.512, e1f= I, p' .01, phi = .257; ... Tobie 10.7 inAppondix). There








Figme 8.1.1: Association aCthe number ofpatients who exhibit low and
medium-high cytoplasmic expression of Bcl-2 with number of patients who
exhibit low and medium-high cytoplasmic expression ofBax (p ~ .(08).
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The 1'- did _. sipifi__between BeI-2 eoq>raJioo and PCNA (X';
7.077, de- I, P <.01, phi - .222; _ Table 10.9 in Appendix). In _ eoq>raJioo of
_p13 _.posilive _witIlexprasionofboch proIifenlive marken, Ki-
67 (X' = 25.145, de= I, P < .01, phi = .418;_TabIe 10. 10 in Appendix) and PCNA(X'-
9.949, de-3, p < .01, phi =.263; _ Table 10.11 in Appelldix).
... Apppttdc lid pnUtmtiu Ildm ..... It tpllOp[ U"gIocigI 'ublm lid
IggInnmwc
L4.1 Jkl.2
Therewuno significant associationbetween local recurrence and expressionofBcl~2
(_Table 10. 12 in Appendix). Howcver, there wu asignificanlwociation between medium
to high eoq>raJionofBcI-2 and low tumour"" (X' :23.284. de: 2. p < .01; _ Figure
1.4.I .... Table 10.13 in Appendix). The datadid not !bow. significant_between
Bd-2 expression and tumour siz< (p > .01; _ Table 10.14 in Appelldix).
LUpSJ
The x',nt _ no significant wociation betweenlooal recunen<e and increased
expressiooofpS3 (p > .01; Table 10.15 in Appendix). TheanalysiJ _ no wociation
between eoq>raJion ofpSJ and tumour siz< (p > .01; Table 10.16 in Appendix). There wu
• significant posilivewociationbetweenpS3 expression and high tumour....(X' = 12.967.




















Figure 8.4.1: Association between the number of patients who exhibit low and
medium-high cytoplasmic expression of Bcl·2 with number of patients who
exhibit low, medium or high tumour grade (classified according to the Bloom-











Figure 8.4.2: Association between the nwnber of patients who exhibit low and
mediwn-high expression of nuclear p53 with mnnber ofpatients who exhibit low,
mediwn or high twnour grade (classified according to the Bloom-Richardson
Method) (p ~ .002) .
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LU Kl-67 .... reNA
AllIlytiIofdltaohowedno ofbreutcarcinoma ond
expressiolI oC PCNA or Ki-67 (p > .01; ... Tobles 10.18 ond 10.19 respectively in
Appendix). The expressiolI oCKi-<l7 wu usociIIed with tumoIIr gnode (X' =16.102, df= 2.
P < .01. phi- .344) but nol tumoIIroia(p>.OI; ... TobIes 10.20ond 10.21 respectively in
Appendix). DIIa indi<lleel. potitive uoociation _ the ""'"""'" of PCNA IIld
tumour oia <x' =1.814. e1f= I. p <.01. phi-.204; ...Toble 10.22 in Appendix). Therewu
no uaociation _ PCNA IIld tumoIIr gnode (p >.01; Tobl. 10.23 in Appendix).
PCNA expresoion wu usociIIed with _ oflymph node (X' = 1.180, e1f=
I, P < .01. phi = .196; ... Toble 10.24 in Appendix).
rmiIIIII
Tumour oia ohowed. positive _on with Iooal rec:umncc: IX' =6.610, dFI,
p < .01; ... Figure 8.5 IIld Tobie IUS in Appendix) There wu no ~gnificant _on
_ tumoIIr gnode IIld Iooal-. or lymph node ...... ondIooal_ (p >
.01; ... Tobles 10.2611ld 10.27 in Appendix).






Figure 8.5: Association between local recurrence of breast carcinoma and
tumour size in patients with tumors greater than 2 em (p = .013).
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T_ U: _...,. ofoipll\cul__..........p.ptode, proIiI...tlv. ud
dio~lIct....
r_ro t Sil PIli
8<1-2 cytopIumi<: ........... Box eytoplumic expression 7.017 .008 .222
PCNA.......... ·1O-67 .......... 9.582 .002 .257
1l<:~2 cytoplumic expresoion • PCNA expression 7.077 .008 .222
p5l nuclear expresIion • 10-67 expraaion 25.145 .000 .418
.000t
p5llllcleor expresIion • PCNA expression 9.949 .002 .26l
.00l t
8<1-2 cytoplumic expresIion • Tumour Gnde 23.284 .000 .417
p5llllcleor IIIinin& • Tumour Gnde 12.967 .002 .llO
Ki-67 expression • Tumour Grade 16.102 .000 .344
PCNA expresIion • Tumour Size 5.814 .016 .204
PCNA expresoion • Lymph Node StIlUS 5.580 .018 .196
Tumour Size· Local Recurrence 6.160 .013 .210




Prior to cIiJ<uuiDa tho ........ obtIiDod &om this rettoope<tivc study. tho limilIIions
of tho me and tho TUNEL IIIIYI ill detcctini ..,..;fie lllIrlten ill ponlIin embedded
_ hovc__.llisimportultlonot• .-limilIIionsbdoreintetpRlins
the oftho study.
,., A.....,.pi", LahtAtt" Mew_
The qUllity of__ SlIinin& wbic:h il1tIlI..- tho outcome ofdata
IllIIysis i. _ by • oumber of factors. The factors that play • auciaI rol. ill
immunohisloc:hemiJlry indude Ihe IftiIiIy oflhe lIl.bodies for tho IIltig 1lxed in the lisloe
sarnpIe and tho~ oftho ceUuIIr antiaens (Bancroft &< SI 1996). Another
vesy importuIt factor is unpredictable efI'e<u of fixatives !lIc:h u f'onnoIin on ....
immunoractivityof IIltigens(Buaoft&< S....... 1996).
"'.1 F1u_ ••d Eoo_.
FonnoIin, • univenalfixativc, is needed 10 prevent disintegnlioo of .... _ions
duringsuining.lt providesc:onsislent and adequate morpIIological presetVlIion (Eliu, 1990).
However. fontlllin lowers or .......... c:ompIdeIy 1boIi1lles .... iIMtwtoreac:tivity of ....
tisIlIe IIltigens by f...... metbyIene bridge croa-Iinks _ radive oiIes 00 same
prolan molecule or _ adj.- prolan molecules (B-.fI &< SI 1996).
Conoeq~ ..... imermoleculor and inlnmoIecuIar cross-links may II primary and
tertiary IINCI1Ite of.... lllligens ellCJUIb to aIfeot ....binding of. specific IIIIibody (Bancroft
nA 51...-, 1996). T -...... fixative, c:onccntnlion, and the lvoiIIbiIity ofnarby
proceilIIlO be "", 1iaIted are the variables reIaled 10 the _ of........ (Bancroft A
St...-, 1996).
One awoach to ....oriq the lou oflOligenicity CIUIed by IixaIion or embedding
lllldaalChupantlinwaxilintigenmnevai by heal treatment(Cltlorettietal., 1993).l1is
tralII1etll invohes boiling _ formalin-fixed pantIin -... in O.OIM citnte buffer
(CltlOrettiet aI., 1993). Iligeationby citntebuffer lIIlIIlUb and ........ the ......noreacIi..
sites and enhances the .......antibody interaction. Over treatment can produee very severe
tissue damqe. TJaas • set boiling time may limit this damaging process (Cattoretti et aI.,
1993). The heal_t method ofantigen mneval ...... mon: reliable and reproducible
Ihan the alternati.. method UJing proceolytic wyme digeation (Bancroft A St...-, 1996).
l1is heal_ method abo allows greater range ofdilution of..... primary antibodies
(Cattorettiet aI.,I993).
Other Iictors, ouch u background staining caused by biJIding sites that show n0n-
specific aflinity for immunog\ollulin and endogeoous peroxidue activity, can aI.. affect the
quality ofthe stains (Eiu, 1990). These licton can be eliminated by applying reagent,lUCh
u hydrogen peroxide, which quenches the endogenous peroxidue activity, and blocking
serum (usually &om the species in which the IICOlld antibody is raised), which is effecti.. in
eliminatingthenon-specificbiJlding(Eliu, 199O).AI1houghthequalityofstainshuimproved
u I .......ofreducing the abovementiooedconfounding licton, theR remain certain inIlerent
licton that restrict the use ofthe immunohistocbemical method.
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9.0.1 LIooIta_oIIUmc_
TIler.."' 1imitatioas oflhe IIIC method. F 1he sper:ili<ity ofan anlibody
bindi"I to Ihe anti is diJBcuh 10 prove mlllC. The only tholan anti... has been
re<XJlPUat with IIIC is iflhe ....... i. iJWbited when 1 hisJdy purified form oflhe
IIlIigen of i....... is added 10 1 workinIlOlution of Ihe lpeCifi< amibody (EIiu, 1990).
80_. iIbontoria peofi:InNns Ihe IIIC IIUdies seldom have Ihe purified antigenlvaiJable
10 perform preliminary ...... A second IimitIlion is thal wessing Ihe expression ofc:eruin
marken like Bax, BeI·2 and pSl does no< -Uymean lhallhe specific antis... marker
i.bioIop:allyfimctional(Eliu, 1990). TbinlIy.lheexaminalionofo.. ti.... oIicIepertumour
may 1101 be represenwivebecauleoflhebioIop heteroseneitY oflhetumollr(Eliu, 1990).
The latter problem wu partly c:ir<umvenled in thi.11lIdy _Ihe paIhoIosist review<d
all Ihe IIides and cbote Ihe most repmenwive (I .eaion in which all Ihe hislolosical
chuaderiltics of the tumour were evident) oCtile tumour samples. However. some oCthe
.....,... collected &om Ihe varicus hoopital. had llimited lUmber oftumour Iiidcs, and .....
were either missins or required for IiIture use by Ihe hoopillls. I!en<e, Ihe palholosist had to
chooI< &om 1 limited pool oflllllpla.
The collection of tissue &om various hospitals in NewfoundJand wu • fourth
limiwion since variations in qualiIy aDd fixItion oftumow' tissue., u weD u stonse oCtile
ti.... IIlllpies may have aft'ected Ihe results of IIIC. FIllaI\y. Ihe IIIC method i. unable 10
quantify Ihe positive ...... objer:tivcIy becauI< Ihe scuMs criteris are subjc<tive and
quaIilative. This llIlUrIIIy inc:un ..... Iimitatioo on Ihe _ and reproducibility ofthe
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rauIu. A review oldie _ on _cancer thai uted die me ......... iDdic:ale various
1COrina_for dledqreeollllinins· For example, VIII derKooyd a1. (1996)
I<Ofed dirk nudar of more than 10% of tumour cells u positive for pSl
ovemepraoion, wbilecells IIained_1·10%wen:_u noptive pSl srainins.
In die _IlUdy, III overexpraoion wu defined u more than IO'~ of cells positively
stained for pS3 wNIe ,tow or IbIent expression confounded to 0-10% ofpositive celJs. In
IIIOlher 1IUdy, Sjogren d 01. (1996) cluaified the tumour cells in terms of frequency whefe
1r_ed las than one third oldie cells srainins po~tiv .. 2 ~gnified between one third
ond two lhinb of positive ceIIt, ond l wu _or than two lhinb of po~tive ceU,. The
_ in die scorinll ofdledilferenl pIlIIMers in the studies may have yielded different
results ond c:oncIusions. Ifdlecriteria for scorinllwen: simiJar IIIlOIIi studies the result, might
be more consistent.
SimiIIr 10 Sjosren" d 01. (1996) study, .he pr..... IIUdy initiolly c1usified die
positive tumour cells in • tissue into JfOUPS based on their frequency of expression. This
SfOUIJiaI metbod limits the inftueoce of individual values tJw could be given 10 I spec:ific
lIIIlpIe ond restricts die type ofststistical anaIysi,.
'.o.J no TUNEL M......
Theterninoldeoxylucleotidyl_(TdT}-mediateddeoxyuridineUipIlosphoIe
(dUTPH>iotin ni<l:-endlabellins (TUNEL) ......... has been utilized to iden~ opoptoti<
",II,. The labelled dUTP molecules ... odded in "'1_ II the J'.<lH end offllsmented
DNA through the tI<tion of the enzyme TdT. Assessing the IpOpeoti. c:eII, by the TUNEL
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methodholCllllOda_of__lheldvaltoflhetbldybyKnupp.t Nedecky,
(1995) 1IUdy. They __ ..... lhe TIJNEL method did not diJtinauisb between
hopaIocytOI dyins ofopoplOsis IlId hopaIooytes dyinaof_. III Ihe presenlllUdy. Ihe
apopl<llie ceIIIwm _ 0llIy;r1he two pathologist IlId Ihe IlIthor wmilI_..
110_, «TOn IIaISl ineviIIbIy We u Ihe morpholosi<al detection of _osis is
inher<otIy 1lIbjective. ,..wilhlhe IIIC method, quantification oflhe lIImberof_otic: cell.
wu problematic since the rate ofapoptosis may have • helerosenous distribution thJ'Oushout
Ihe_ thereby makin& precise qUUllilicalion diffi<uIt. A review oftile lllIdies,hat used
Ihe TIJNEL method indicale prIlblems of IIIbjcctivity IlId vorillion in Ihe ICOring simiior 10
thole ill tile IIIC method. The dcveIopmenI ofa consist... method ofobjectively quanlifyina
Ihe for both Ihe IIIC IlId Ihe TIJNEL method couJd in<reue Ihe validity IlId reliability
oflhe .
U 1iolI__ ....Apopl.lIe .... AJlIi-Apoplolie Faeton
U.lllcl-hadBu
II hoi been propooed ..... lhe relative sensitivity of cell. 10 apopeoti< stimuli i.
80- by Ihe inverse noIio of Box:1lcl-2 (Reed, 1995). The noIio of Box to B<I-2
expresaion hoi I profllWld cJinicaI sipificance ill determinintl'he sensitivity of cells to
radiation, or chemodtenpy «(Reed, 1995). Apoptosis, necessory for I good thenpeutic
_'0c:hemoIherIpy or_n couJd be directly inlIueIlc:ed by lhe reduction ofpro-
_otic: Box relative to ..... of anti-apoptolle Bcl·2 expression, therefore providins I
selective odwnIap for ItIItIOUr survival (Reed, 1995).
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In 1Ile ..-1bIdy. IllIlysis of!lax .... Bcl·21lqllOS1ion in invui.. c:on:inoma
IIlowed 1 poIilive IIIOCiItion rolher thon 1Ile expec:t<d invene IIIOCiItion (oee TIIJIe 10.2of
Appendix; ........ 9.2.11). The f<IUIts &om thiJ SlUdy coincide with 1Ile ~1S oflimillr
JlUdiesby KnjewtId ...1. (1995 a: 1997) on1Ile immunohi_ detection olBd.2 ....
!lax expreaion in _ cucinomo. The poIilive _00 between1lle two IpOptotic
taeton ........ thot the expreuioo ofBox .... Bd·2 moy be """lPI1oted, thus providing •
pocentiII expIoNIion for 1Ile fi<l thot both Bd·2 .... Box expn"';on tend 10 decline dutina
propaioo of__ (KrajewJki It .... 1997). Although undetermined, corquIation
of BIX .... Bd-2 level. could be controlled by lronoaipliooal .... posnrweriplinnal
_ (KrajewJki It ... , 1997). Support for 1 possible post-lrIns<:riptional mccbani...
ofcorepIotioo is proWled by 1 SlUdy thot _eel thot Bd·2 CIIl prolong 1Ile haIf-lif.
of 1Ile !lax protein in some cell lines, probobIy _ .. of 1Ile obility of Bd·2 to
heterodimerize wilh BIX (Krojewslci It .... 1991). The role of """gen IS • <:onunoo
_ oflrlns<:ripliooa reguIotion ofBd·2 oM Box has been <:onsidered in light ofthe
fi<l thot _ upreguilta Bd-2 expreuioo in MeF1 b..... CIll<Ir c:elliines (Teixeria It
.... 1995). However,_doeInot rquIole Box cxpressioo in MCF1 ceII.indicltinglllll
_ is not 1Ile__for 1Ile co-reguIotion of!lax"" BcI·2 (Toixerio It
.... 1995).
The _ of c:onguIIlion _IS the fi<l thot 1Ile most criti<Il fi<lor
deIennining 1Ile sensitivity of tumour ceI1s to _~. moy b. 1Ile ICIUI1 ratio of pro-
-.octo antiopopIotic fi<lon of1lle Bd·2limily (Rend, 1995). The Db......... of 1Ile
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VIriousIludiel,illc:ludill&tbe_~theexpreuionofB",ondBd-2_thII
it may be inIufIlcient to examine the exp_ ofBcl-2 ond Box in isoIaIion without the
knowledge ofother memben in the Bd-211mi1ySllChu Me~1 ond Bcl-X..{not meuured
in this 1IlIdy) ond their inftuen<e in _otis (\l«d, 1995).
__te<hniques are semi-qUllltiutive ond may theref.... not be
IlIited Cor the p<e<ise ......,.,..,. or the expreuion or li<ton ne<etSIl)' to unravel the
complex inlarelationship of the various pro-apoptotic and anti-apoptotic factors, their
relation to tumourprlllRSlion, ond theirinftuen<e OIl the pro<eISorapopeosis. One_h
to the problem ofmeuurement ofapoptocic f'Ktors would be the use ofsemi.quanntaUve or
quantitative RT-PeR. This technique boIdI pronUe for retrospettive studies ROW that lood
quality RNA <III be -.DyiIoIated flom panfIin embedded ti..... (Robb, 1999).
9.1.1 Bd-2 .... Apoptoti< Role
SeveroIIlUcIies have <onfirmed thII Bcl-2 expression inhibits the proeeuofopoptotis
(Craig, 1995; 8uJ.... 1995;Selvllannann,1994). Must.......I. (1997)Jbnwed .. inverse
relationship between the exten' or opoptosis, measured by the TUNEL usay, ond 8<1-2
expreuion in _ -. SimiJIIIy, VIII Slooten et 01. (1998), found thII hip
expreuion ofBcl-2 in iavuive breast carcinoma wu associated with alow rate ofapoptosis.
In contrut to the invcne associations fouud in the above mentioned studies, analysis ofthe
data flom the _1IlIdy (see Tobie 10.1 in Appendix) Jbnwed no sianili<ant usociation
betweenB~2 expreuion ond the proportion ofopoptotie <ells in breast wcinoma. Baudo
.. 01., (1998) olso found no siptiti<lm usoc:iation between Bcl-2 ond the proponion or
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___in_CIlll:«.
The _1lUdy. u wdI u the IlUdies by Mustonen .. II. (1997), ... Siooten et II.
(1998) ond 8erIrdo .. II. (1998), the prcponion of_otic: _ by the TUNEL
_ Mustonen et II. (1997) the opoptotic: index (1UIIl of_otic: cell. in a
given area)by eslimaIilla the raunberof_ cell. in 10hiaJt po_tield. ond counting the
..... _ or c ...... in these fields. Thepeteell1lgeofopoptotic _ ..... then
obtained by dividing .he raunber ofopoplOtic _ by the eslinuued number of_cell•.
Van SIooten et aI. (1998) used lirid &arne to measure the rate ofapoptosis. Within eKh
random _ orthegrid (wllich consisted of1000 tumour cell.) ,he pou,;ve _otic cell.
werescoredondexpresoed u a_ofthe '0,11__.8erIrdoetll'•.(1998)
study wed I grid subdivided into lOxI0 units each containing It least 100 tumour cdIs. The
opopIOtic cell...... COlIIlled in each _ ond expreued u apetCetlIage ofthe '0.11. In the
_ SlUdy, ,he _otic cell. were caIc:uII1ed within 4·5 fields (40X) with each field
eontainins It least 1000 tumour cells. The apoptotic rate in each cue was defined u the mean
lIImber ofapopeotic cells for all 145 tissue samples (sum 10tal afttlc mean apoptoti<: cells
",,_oYet the ,oW numberoftissues)wulirstcalcuJated(i =6). The ..- .....
then divided inlo two categoriea: 0 = leas ..... the ,oW ovenll..- for all ti ana1y!ed,
and I =equal to or grater than the mean score. These differences in the scoring systems
could 1CCOUlI' for the YIriabiIity in the resuhs obtained in dift"erent studies.
Reproducibility could be achieved if the "",ring systetn ..... more stringent ond
1IIIifixm. Thegrid method ...... more reIiaI>Ie ..... simply ........ting aCet1lin numberof_
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Illd COlIllIins the ...-ofapoplOIic: cells wi1Iin euh field. ill lIddilion, I scorinl meIhod
could be made mort _ ifthert ..... I _ for cIiJtinguiJbing whether or noll cell is
~ apoptoais or -.olis. ill one Iludy, semi-q_ve end-1IbdIinB of DNA
&qmems reveaJed I~ invene uaociaIion with the expresaion ofBd·2 (Diu-Cano
...1., 1997). ill this -ood, DNA wu_eel by the pIlenoIIchIotofonn meIhod Illd lUll
on Ul ......pl. Specimens dist>IaYinlll marlced IadderinB pan...were considered '0 have
llIldefBone apoplolis. Though leu lUbje<tive, this method of using end-labellins of DNA
&qments to detec:t apoptosis ls not applicable to formaJin..fixed tissue.
"'03 Bd-2 .... p53
Studies to date indicate that Wi p53 can transcriptionally repress BcI-2 expression
whileillducing__ ofBax. ilIpll1lllod<....ttnns...,;cmice, _of",pll wu
wociated with inc:rtued expression ofBd-2 and deer...... expression ofBax (Myuhita et
01., 1994). Sevenllludi.. have _ this inverse usociation between Bc:1·21lld
IIlUWII pll u detected immunohistochemic:ally (Krajewslci et 01.,1997; Silvenaini .. 01.,
1994; Ioensuu .. 01.,1994; HoIdat .. 01.,1994; Gorczyca .. 01.,1991; La et 01.,1996;
IIaIbuesdli et 01.,1996; Illd Berardo .. 01., 1998). Analysis ofthe present data 0150 indi<ateel
I _ invene trend between pllllld Bd-2. However, the wociation wu not ~piliaM
(see Tobie 10.l in Appendix).
There have been conc:ems reprding the id••tifi<ation of pll mutations by
imn>InnhillOdlemislry. Ddetions 1lld ........ 1lld fnmeshift mutations _ synthesis
of the pll protein (Gn:enbIan .. 01.,1994; Ko '" Prives,1996; Gananpadhy et 01., 1997).
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,__"""""*Y (GReobIolI ......I994)._.the
..,.~lypcolpll-is.__ 1hal aIten ..... _ acid
in the pll proleio (GreoobIatt .. 1I.•1994).1IU tlIbiIila theproC<in, tbenby iacreuinI the
half-life.,1IIIt it _ be detected _ochemit:aIIy (GReobIolI .. 11.•1994). Thil
pIIenomeooa is lloquenlIy refemd '0 in the Iit_ u 'pll ~on' or 'pll
_'.Sjosren .. II. (1991), studyina breast carcinoma, 1'aund.1ade of_
_ pll ........,n by imoNInoIIillOC:hemisUy and IIlIIIlIion detected by eDNA based
---.. SewnI tumoun diIt>layiJla pll invnunopotitivity!wl neplive DNA sequeo<:e
dara and vic:< ...... In addition, Sjosren _thai patieIlU with nepIive DNA oequenoc
dara but imnunopositive rauIls !wi better JlflltIl'OSis relative to those wilh positive <DNA
oequenocdara aod .... _ ......... OtberIlUcfies, _. indic:ate
eondaIioos_pll innuoopoIilivitand plllllUlOtiool obterved by DNAsequenc:io&
(HIrris.t IIoIbIciIl, 1991; Marehetti .. 11.• 1991).
To-.thedelec:tionOCpllllllllllions~ .....eondusive
methodI web u imIta&nobIol1in and Siatl\e SIrInd ConfOl11lllion PoIymorp\Qm (SSCP)
eouId be performed COlltUlTtl1lIy. Eveo thoup the presenlltUdy did noc IIJt either method
to ....ect plllIlUlIlioIII, 0Iher_ have eonlirmed the inverse usoeiation _ pll
...1IIiooaI ...... and Jld.2~_eel by imnauIohistoehemillIy (Lee .. 11.•1996;




hence is_1IY _ bywl pS3 (lCnjewoki .. 11., I99S). A5preYiout1ycliJc:uued,
mice _ ill wl pS3 ""eI1ed • reduc:tioo ill an _hiJlocllemical Bax expreuicn,
conIirmina the importance of wild type pS3 u. rquialor ofBax (Ko.t Pri..., 1996).
Theref.... ill the comext ofour tIUdy,loaa ofpS3 fiInc:lion (u indicated by immunopositivity)
sIlouId rauItiIl_Baxexpreuion. Analysis oCthe present dill showed noasaocialion
_ pS3 accumuialion IIld reduced Bax expression (ICe Table 10.4 ill Appendix). This
lindi"ll is similar to tIw oCKnjewski ellI. (l99S.t 1997) who demonstrated tIw in breast
cancer, immunohistochem detection of mutant pS3 by itself is insufficient to ClUJe
diminiIhed Bax expraaion.
The -"" reoults &om this IlUdy _ the _ oC other apop«>Iic
rquialors tIw could in&ence the expression oCBax IIld tIw pS3 may not be the dominant
rquIItor of8lx expression in breast Cll'cinoma. However. it is important to note that studies
have indicated • p53 depaldent ....... ill Bax expression ill_toDNA damage by
cIletnothenpeutdtup orbyradialion(lCnjewokielll., 1997). Apin, uillthe<UeoCBd-
2, the true reIaIionabip _ pS311ld Bax expression may only be darified by the UK oC
& combiDItion ofmolecular and immunohistochemcal techniques.
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U.5 ....... A__ Ra..
8Ix is a primary ............ involved in a pl3 rquIatecI pathway for inductioa of
apoplOIi. (Ko a: Priva, 1996). T1III, immunopositive IlIiniJl& of8Ix wu expected to be
politively uaociated with the !lie of_osi. u measured by the TUNEL medIod. DIll
liom the CUlTeIllllUdy did not indi_a lipifi<anl uao<iation(... TableIO.1 in Appendix
I). This lade. ofUIOCiation sugestJ that SIx may not be the dominant activator of lpOpCosis
and 1hal otbet important pro-apopIOtic ..... within the Bd·2 family may playa sublllntial
role in dis process. Another ....... for the lack ofuao<iation coWd be tJw _oIi. may
have_independeIlIlyofthepl3 pathway. Other pathways, lIIcltuceramide-medialed
apoptosis or capue regulated lpOptosis. may contribute to the apoptotic response in the
<ells.
Review ofthe Iitenturc shows very lilde research reprdins; the inftuence ofBax on
the rile oCapoptosis in breast carcinoma. However, there have been studies which indieale
• positive wociation between Bu and TUNEL score in other types ofcancer. One study,
by BrambiIIa" II. (1996), revealed thal8lx down-rqulation wu usocialed with low fIleS
of_oli. measured by the TUNEL medIod in luna cancer. Astudy 1hal did examine thia
wociation in breut cancer found a positive relationship between Bax and the nte of
lpOIltosis in breast cancer ceI1lines or tissues in the presence ofchemotherapeutic drugs and
any external stimulus which damag<s the genomic DNA (Han" aI., 1998). AI1Ilough dis
result, on the c:hemotherIpeutic induction ofapoptosis is important because it supports the
idea that Bax is a pro-apoptotic sene. it does not strictly apply to this study, since the
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purpose wu to eumine the rile of apoptosis in the context of tumow growth and
prolifenlion__to_.
_ of. tipific:ant uaoc:iation betweenlhe expreuion ofB", and the rile of
_Olio c:oincides with Ihe lack ofuaocialion between Bc!·211ld rile ofopoptOtis. n...,
in _ c:an:inoma, Ihe prooess01'-'"u dele<ted by the TUNEL me1hod seems to be
an ..... independent of Ihe -"aniSlft wheRby Box IIld 1lcI-2 expression oppear to be
coresuJated. However. u disawed earlier. de1e<tion of opoptotit _ by Ihe TUNEL
method may not be ~eIy reliable. Knupp IIld Nedetky (1991) showed that
hepIlocyr... dyins by both _0Ii01lld 1lCCfOSi~ pve • similor positive result in lhe
TUNEL usay. Thus. the TIJNEL usay did not differentilte~ the two processes.
SII/IeIin .. 11. (1991) have propoaed that false positive stainillll in Ihe TUNEL usay may be
due to the release ofendogenous endonu<:Ieues following proteinase treatment. The faJse
positive stainiIlll in Ihe TUNEL usay can be IboIished by prior _ oftissue _ions
with diethy\carbollal(SII/IeIin .. 11.• 1991). These SlUdies "88e.IlJw filnIIer investigations
into Ihe reliability oflhe TUNEL me1hod need to be conducted.
9.1.6 pS3 ud Apoptatlc Ra.e
W~d type pl3 ~ known 10 promote _Otis (1(0.1: Prives, 1996). Therefore. loss
ofpl3li1llt:lion whicltcooesponds to immunoI1istothemitallttUmuIIlioo ofpl3 sbouId be
uaociated with low riles ofopoplOlio (Greenblatt, 1994). Anolysi. ofSlUdy in Ihe present
data did not revel! an usociation between-"' rIlIlIld pl3 _ (see Table 10.6
in Appendix). Our findiop _ that Ihe rill ofopoplosis u d..ermined by Ihe TUNEL
8'J
uayis......--aCpS)_._-.ppanedbyllodiaet ... (l996).Ia_
Shell et II. (1997) found thal die differia&"" aC apoplOIiaill_ aod iafilIraIiIlI
cartOloalacouid be rapIaIed by aIland pS) expmaion. SiIIIiIarIy, Shell et Ii.(1998)"-
.posiIivocomlalioo_iammopotiliwpS)cellaUld ....or_.... u......-.!
by die TUNEL method, in inlraducllII Uld invuive ductal_ carcinoma. The abteIlcc or
an uaociation between pS3 and nte ofapopcosis may alto reflect the existence ofahemative
pathways independettt ofdle ac:tivaIion ofspecific wgets- by pSl.
Once opin, it.,.. be amphuized 1hal die -,,"...wt could be I methodoloai<al
probletn with die TUNEL Illel!Iod Ot with_hist_ anaIysiI aCpS)~on.
It i, aIsn impon... to recall dill pSl iJmamopositive c:eIIs _ just one fonn or
naltaIion, oameIy-.~ die pruponion oflpOlllOtic cella in relation to this type
or llllIlIlion could be _ thaD in <XlIllpIrioon to other types of IIllIWion. AIthousb an
wocialion _ pS) Uld ",eof_otiswu'" observed, die outcome does_
the ........ ofthepmioua ........_ iodicaled llacl<ofusoc:ialion_ Baxand pSl
Ot _ Bax Uld the TUNEL JCOre. Since WI pSl ICIiYll.. au for the incb:tion or
_osi~and no wocialionwu lOw1d_thetwo paramet~ it is pr_1hal,hete
would be noalOcillion between Sax and the TUNEL S(:Ore or between pS3 and tIM: TUNEL
JCOre. The ........ ofdle _ daIa confirmed thi, rationale.
Ia cotdIoion, ..Jysis ofthe reIalions _the various _otic ficlon!lUdicd
_ dill in__ apoplOIia isl distinct ..... iDdepcndenl ofBax, Bd-2 Uld
...... pSl expmaion. Thenfore, our liIldinp _the need fOt fiIrdler SlUdiesto_
90
if _ opoptocie facton such u Bel-x... Md-I IDd Bad play I sipiflcam role in the
apoptOlie _ oe_ can:inoma. We are cognizant ofthe fact ..... our reoults may
be inIIuenced by inhemIl errors IDd limillliona: (\) the semi-quantiwive IlIlIlre of the
imnamohi_ D*hod; (2) &be posi1ive reoults orisins in the TUNEL~ IDd (3)
errors in imnullohiJlocll idenlifiCllioll orisins from the wiIcI-type p53 with proIooaed
haif-lifelllimiclWl&u_pS3.
9.1 BNIjM JIcIp. PmlM'cratiu ""' AR9plotic fu,on
9.2.1 PCNA ..d KH7
DaIa from I!Ie praent study showed I positive correlalion between the two
proliferorivemukenPCNAIDdKi-67(seeTIhIe 10.7 in Appendix). Dawsonet II. (1990)
IDd IIaIIA 1.cYinton. (1990) II.. found I positive usociation between PCNA IDd Ki-67
immunopositivity in hreut c:artinoma. IIowever, in IllOtI1er study, Leooardi et II. (\992)
found no usociation betwun the two pmmeters. Leonardi sugated that Dawson obtlined
I positive rauJt be<auJe his study wu performed with I dift"erem PCNA antibody, 19A2.
However, the varilrion in the results may not be due to difl'crenc:es in the lIIIibodies.
Leonudi', study, u well uthe praent study, used I!Ie .mibody PeIOto idcl1li1Y the PCNA,
yet our study, in c:ontrut to that ofLeonudi, showed I clear positive correlation between the
two proliferation facton. Dervan et II. (1992) round I positive uaocialion between PCNA
IDd Ki-67, thouaIt Ki-67 wu identified in _ tiasue while PCNA wu _ in formalin
fixed panfIin-embedde tissue of the ..... tumour. on- findings not only confirm the
raulu ofthe praent study hut I!JO indicate the rdiabilily orusins the immunohistochemical
9.
melIlocI in thetwo proIiferIli.. mul:en.
'~2 _2 reNA, Ki-67
AIlrOllll invcnecomIaIionbetweenBcl-2 and proIiCerati..lClivityhisbeen reponeel
inallllllberoflllldies. Tbiailproblblyrelated tothefi<:t thatBcl-2 illaIownto promote the
relelllionofc:dlaintheGOIGI phueofthecellcycle(Reed, 1995). VanS_etll. (1998;
19961 SiIvenIini .. aI. (1994;'996) and Gon:za .. aI. (1995) found a stron8 invone
comIaIionbetweenBd-2expreaionandproliferationuidentifiedbyPCNAo<Ki-67. These
IIUdies .._ that highly proliferative tumoun are uoociaIed with an upregulation of
-"'mechaniJm reouItina from adeaeue in anti-apoptoticBd-2 .......00. Data from
this study, did not show an inverse usociation (see Table 10.8 &: 10.9 respeaivefy in
Appendix I). However rauha fiO<n this study indicaIeeI that Bcl-2 expression wu positively
usociaIeeI with PCNA expression (see Table 10.9 in Appendix). An possible explanation fo<
this ...tcome, couIcI be that hip expression oCBcl-2 in b..... c:on<ef c:dIa is usociaIeeI with
loss ofnormal WI p5l IClivity whidl ralri<:ts entry ofc:dIa in the 5-phue of the cell cycle.
The vIriaIion in the resuIl between Bcl-2 and the proliferati.. muI:.., Ki-67, wu not due
to the scoring system. In c:ornparison to our Karina method •van Siooten found • significant
invwse auociation between 1Ci-67 and Bcl·2 despite usina' more stringent (OYa'eXpmSion
IS puter than 20'10 of Ki-67 immunopositiw c:dIa while in the present study, Ki-67
immunopositivity of 10% 0< great.. represenleel an over.......,;on) S<OrinS system.
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,.u ,sJ_lCNA,~7
The tumour_,._ pll oppc:an to inhibit cell prolifenlion by reslrictins
entry ofcells imo die 5-pbueofdlecellcyde(Ko& Priv... 1996; BeIIamy,I997). Thus, loss
ofpll _lads to on increue in ceI1uIIr proIifenlion (Ko & Prives, 1996, KnjewsIri,
1996). As expected, die pre.- lindinp of this IIUdy ,"gesl t1lIl lCCUIlIlI1ation of
imnunopooitivepll ceIIs(__lossofpll function)was ........ee1 withinaaled
prolifenlion u detecteel by PCNA and Ki-67 (ree Table 10.10 and 10.11 respec:tiveiy in
Appendix Q. Other studies by Allred .. 11., (199l), Hoersiev & Jacobsen, (l99l) ond von
Sioocen .. 11., (1996) have also shown t1lIl expression ofmulllll pll protein was ........ee1
with hip prolifenlion.
The usociaIion between loss of pll limction and incroued proIifenlion ......
reliable in baht of die fict tha' pll overexpression was not ........ee1 with the rate of
apoptosis. Studies have <:onfirmed the dual utioR of lhe tumour suppressor aene: death or
growth arres1 (Ko & Prives, 1996). Perhaps in this sroup of tubj..... the mechanism of
srowth arrest wu favoured over cell death. N a result, loss of wt pS3 function wu
........ee1 withincraJed pro_andnot cell dealh u meuuredby the TUNEL meIhod.
Von 51001.... 11. (1991)found"'" overexpression ofBc:I·2 tends to ICQlmulale cells
in die GOIGI phue. Thus, ifdie mechanism of growth IJTeSl was favoured in this 1IUdy,
incraJed proliferation sIlouId.- with mutationole-. in pll and reduction in Bd-2
expression. The dIIa &om die preoentllUdy did no, indi<ote this invene usociaIion between
Bd-2 and proIifcralion, tugeslins t1lIl die tumour eels.. not dependent on Bd-2 for Iheit
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_ This ...".,.n;c. is coofinDed by Ibe li<t 1hIt Ibe ... _ 110 UIOCiIIioo
_1Id-2expR11ioo__of poIIibiIiIyCOOlldbelbe_
of_1Id-2 fimiIy""""'" iD Ibe proIilinIioa prO«ll._, dis posoibiJity .........
of_~ _ proIif«1UYe 0lIIbn io order 10 determine the cIiDi<al tiInifi<:ance
ofthe iDdMduII markers u predidon ofioc:ll rec:umn<e in ...... cancer.
,.3 A.ptgtk u. PrgHImtiyt '1d9n BeIlIn Tq aliqp'thplnjql
Clynctajrtig 'id Loc" Rcqtrntsc
9.1.1 lId-l
Sludies .......... 1be proposlie VIIue of the 8"·2 expression io""" c:ucinoma
ha... yielded -..._. SiIQ Bcl-2 n:IIrds cell powth by inducioItI relellIion ofcells
intheGGlGI pbueoflbecd<yclc(lleed, 1995). iI mi"be~dlIllowexpression
ofBcl-2 would be IipificIady uaociIled wilJl incRued frequency of ioc:II rec:umn<e of
dccreued expression of Bcl-2 _ ioc:II recurrence (see Tobie 10.12 iD Appendix I). This
6nc1in1_with the studyofl_.. II. (1994) which Ihowed till! Bc:l-2 expression in
breast carcinomI wu not an independent proposlie indieator ofeither dise:ue free survival
or o....u ..!Vi'" io 174 _. In --. HeIInwI .. II',. (1995) study found.
proposlie value ofBcl·2 expression in predic:tins di......&-co lUrvivaI or.....u lUrvivaI in
1ympl node positM pobeaIa._. Bcl-2 did ... prediet _&-co lUrvivaI or .......
lUrvivaI in lymph node -"'< paIieaU. In one of Ibe Iarpst IIUdies by IIenrdo .. II.
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(1998~ tile-"' in8uence ofBd-2 in primary _ IumOur opecimens Iiom alarie
_ oC9791ymp1l node pooitM poIienb wu examined. Berardo', reaoh showed IIlI1 hip
Bd-2--"'" led 10 IoDpr survival. Thi, _ ofBd-2 10 proIona_lioe survival
may be uaoc:ialed with its Ibility 10 hold cells in tile GOIG1 phase, reduc:e prolif....ion ond
promote tisIue _ Similar mulu were indicated by Kobayashi et II. (1997) ond
van SIooIen et II. (1996).
AJthouah the Ibove studies showed &1.2 to be. valuable prognostic indicator, in.
I1llIitivuiat. analyses BcI-2 failed '0 maintain an independen. prognostic: role in relapse-free
orovenllsurvival(Silventinietll., 1994; loensuu et II., 1994; van SIoo... et II., 1996). In
tile study by Benrdo et II. (1998), however, • multivarill. analysis did show IIlI1 hip Bd-2
expreaion is IIIOciIted with better survival. The varied nature o(d~ raults ofthese studies
"'uatllll1 Bd-2 does lIOl satisfy tile criteria ofan independent proIJlOS!i. 1001, for Bd·2
cannot consisteatly disc:riminlte independently between groups of patients with better or
worse prognosis.
Ahhouah Bcl·2 appears not to fimction u an independent proposeie indicator, iu
--"'"hasbeen found'o _ withotber.liri<opotbolosi<al features sueh u tumour
...... ER ...... ond IumOur .... DaIa liom the pr..... IIUdy showed IIlI1 in<reued
expression ofBd·2 wu UIOciIled with low tumour score, which is repreIClIttativ ofagood
prOSJlOSis, for tumours with hip ""'" are clwa<teristieally unditTerentilled ond probsbly
independcat ofBd-2l'oc survival (leO TaI>I.IO.13 in Appendix). Other studies ha.. reported
~milar<omIations(vanSIoot ..etll.,I998;Leeetal.,I996;H_etll., 1995;Benrdo
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et .... 1991; KobIyuIIi et .... 1997). indicIIinIa correlation betweeo BcI·2 expreuion and
IIllIII t1IIlIOIIr'" and IIle praence orER positivity.
The lindinp liom the _ IllIdy did not exhibit 1ft USO<ialion betweeo Bcl·2
expreuion and 1IllIII_... (1Oe Table 10.14 in AppauIix). Similarly, Leeltet ... (1994)
and Silverllini et ... (1995) round Iinle _on betweeo BcI·2 and tumour ....
AsIociIUonsbetween &&.2 and Ell stIlUS were not analysed in this retrospcc;tive study sinc.e
IIle charts orllle paIients W<re~ thtoushout Newfoundland. Moreover much orllle
infonnltion on the ER IWUS ofpatients wu incomplete or lost.
The lindinp &om IIle preoenllllldy, and othen, "'88"" that ahhough 1Icl-2 CUV10l
predict diJeuc.free or ovenIl survival. it can still function u • marker for better proposis
with repnb to _ dilI'erentiaiton.
U,2pS3
Anumbctorlludieshmexaminedllle rdalionship betweeo nudar_or
IOllWll p53 protein, u det...ed by imINIIlohillocllemilll')'. and various pIlholosiai racton
and proposis. In breast carcinoma some of the studies have indicated that mutant pS3
expreuion is an independent marker oCpoor proposis. In I group 0£700 patients, I1iscue
tree IUtVivaI II 5 yan wu 80% for p53 neplive lUmoun, 72% ror low positive to
inIermediale positive _ and 58% for p53 llroaaJy positiv,tumours(EUedge I< Allred,
1994). Similallindinll' by Thor I< Yanddl (1993) and Allred et ... (1993) veritY IIle role or
p53 Ulft indepeodent pr"""'"tool.ln~1I, lindinp &om IIle present IllIdydid not
indiwea"snm-USO<ialionbetweeop53 expreuionandlo<al rec:umnc:e(...TabI'10.15
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in Appendix). SimiIIr ............ been obIIined by 0s1r0w1ki .. 01. (1991) ond_.t
_ (1995) who found no eorteIaIioD between mutIIll p53 exprasionond diJease.1iee
JUrVivol. A reuoo ror _ vuyiq ....... could be related 10 _ in the
immunohistochem IC<lIinll _ Tbere ue lOme IimiIIrilies between the IC<lIinll
mcdlod oflilenlev .. 01. (1996) IIld the preoemllUdy. Imnwmopooiti.. cells in 1!IenIev',
IIUdy were cIwified inlo 5 poups incIic:IIini the &equen<y to whicll immunopositi.e cells
were IlIined; 1=1ess thin I%, :z..1·10%, 3 = 11·25o/~ 4z26-lO% IIld 5- _erthln 50%.
In the present study, the expression ofnutant pS3 wu also rated to indicate the extent of
staining. However, wtonly divided into two groups: 1'" less than 10% ofteUs. 2 =greater
thin 10%. Silventini .. 01. (1994) IIld Liponnen .. 01. (1994) who both found p53 mutlnt
expression in__asiptk:ant PfOBIIO'Iic factor, simply classified immunoposilivily
u either positive or negative. However we still found no significant auociation of pSJ
expression in reIItion to local recurrenee when our dill wu re-analysed using the
SiJventini·s and Liponnen's method where pS3 expression wu dassified u positive or
negative. This sugests that the scoring system wu not responsible for the different
outcomes.
Another possibility for t1le dilFerina findings cou\d be !dated 10 cross-cuJturol
ditJ'crences in the type ofpS3 mutations found in the breast cancer patients. Sommer et aI.
(1992) found that the pIIlem of pS3 mutation in breast cancer in 53 white Midwestern
women differed &om pdems observed in women ofother <:oUntries. Missense mutations
(responsible for p53 _ression) were lower (44%) in _ ....... of the 53 U.S.
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ofcues may .............. by immunohiItochem. This fiIrIher emphuizes the need to
.....................(•.•. SSCPandcDNAoequencina)inaUtlUdiesexaminillatheetfect
ofp5J on clinical outcome.
A«umuIatioo of pS3 prolIin his .... been woeiIIed with • number ofotIler poor
Jl'OIPlO'Iio _ incWiaa ER neptivity (Thor" Yandell, 1991~ PRneplivity (Allred II
aI., 1993) hiP IOIIoIo&icaIpade (ElIedae" Allred, 1994;!IIenIeY" Iacobsen, I99S~ and
hiP proifenIioo .... (SiMnIioi et aI., 1993). In the _ ltUdy ICaImlIIalioa of pSl
procein__with proifenIioo ....(_TIbIe 10.10" 10.11 in Appendix)and hiP
biIloIotlioI1padeof_(_ Table 10.17 in Appendix). This 6ndinaiI_with
hiP I1IIllOlIrproifenIioo ........ _ Iouofwild type pS3 fiuldion Iadioato_
enIty ofl1llllOllr ceIJs into the S-Phue ofthe cell <ytle. Then: was no Jisnificant woeiIIion
between pS3 ICaImlIIalioa and tumour size (_ Tabl. 10.16 in Appendix) . This outcome
__with the.......ofHaenlev" lacobsen (1994), Ellead." Allred (1994) and
MoIinIetal.,(I99I).
The liJldqsoflheae SlUdiesstrooafy_ dIoI pS3, especiaIIywben combined with
the ...... Jl'OIPlO'Iio fKlon, may be • ....- predidiYe _ of_ ...come. The
pS3 procein _ to be.lIlOlI_ Jl'OIPlO'Iio tool than the Bd-2 protein since pS3 can
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indqlendendy predi<:t the """"""'" of diteue &eo survMI 0< ovenJI survMI in a
nalltivariale anaIyU. 1Ioweva, in order lO UDeqIliYO<llly de1ine the role of pS3 u an
independent _iii< _or, more IlUdies are requimI win& moIec:uIar tc:reelliJlI,
defined anlibodies, and allandardized ...... sy1Iem.
U.J lCNA .... KH7
A> with the apoptotic markers, neither of the proliferative markers in thiI ltUdy
predicted Io<aI recurrenc:e ofl,,_ c:artinoma (... Tables 10.18" 10.19 in Appendix). A
number of IlUdies have, however, shown woc:iation. between e:enain dinicopatholosi<al
panmeten and expmoion of proliferative markers. Sheen-Chen II 11. (1997) found that
presence ofPCNA positive eeII. ofbraR c:an<erwu closely related lO hiSlological anode and
lW1lOlIt size. Usina nalltivariate analysi~ Sheen-Chen'. study showed PCNA expression u
an indepelldent prCJ8llOstic indicator. Similarly, .....111 from the present ltUdy showed a
~gnific:ant usoc:iaIion between PCNA expmoion and tumour size (... Table 10.22 in
Appeodix)PCNAexpmoionandlympb node ......(...Table 10.24 in Appeodix). However,
there wu no sianificant association between PCNA and tumour score (see Table 10.23 in
Appeodix). lJl_T..... II 11. (1993) found no correlation between PCNA expression
and tumour size, and Iympb node invoivanent. Howevor,ltUdy by T..... II 11. (1993) did
_a~pificontdifferenceintheovenJlsurvivalbetw ...highandIowPCNAexpression
JlI'OUPS; the high PCNA arouP indicated poer overall survival compared with the low PCNA
8'OUp. Similar lindinp were obcained by Horiguchi's II 11. (1997) ltUdy Olpported with
T.....'s lindinp.
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IJI Iho cumnl 1lUdy, Ki-67, the ...,oad proIifenlive motker, showed • positive
wociation to tumour ICOI'e but not to tumour size, recurrence or lymph node SWUS (see
Tabla 10.19-1Q.21 in Appeodix). There are however, certain studies Ihat do incIi<ate an
usociaIion between Ki-67 immwlopositivity and clini<al prosnos1ic parameten such u
........ and lymph node ....... Pierp at aI. (1996) showed that high Ki-67 expression
wu sipificantly _eel with lymph node involvement and tumour ..... but in •
univariate anatysis, Ki~7 wu not III independenI: prognostic:: indicator. In contrul, Weikel
at aI. (1991) found no _ion between Ki-67 and tumour • or lymph node .....~ but
there wu. sipificant c:ondItion between Ki-67 and tumour grade.
IJI studies whete both marken were examined, PCNA and Ki-67 expression revea1ed
ditf..... rauIu. Lecnatdi at aI. (1991) showed that PCNA did not_el..e with Ki-67
expression or lIlY oIhor clinical prosnollic parameter. However, Ki-67 wu _eel with
high ....... grade (though no'wiIh ........or lymph nodeltllU5). lJlcontrut,HaenIev
at aI. (1996) found Ihat high Ki-67 score wu_eel with PCNA over-expression. Both
prolifentive markers correlated with dinicaI parameters such u tarse tumour size and hiab
histo&ogicallflde. However. in a multivariate analysis, neither of the marken attained
independenI: prognostic significance. IJI Iho present study • sipificant positive correlation
between expressionofKi-67 ond PCNA wu obtained (...Table 10.7 in Appeodix). Result.
showed a positive wociation between PCNA and tumour size; there wu no association
betweenKi-67 and........(...Tabla 10.22" 10.20 in Appeodix). However, therewu




"""","",oCpn>IifonIioalllIIk<nlliPlillh< the poceobII pn>bIaos .............0....,...
.-.....otber-.... Ooe pouibIt ...... for the divono _ could be the
dilf..... -...mcdlodsllledby_.HaenIev.. II.(I996)definedowrexpreaion
of KMi7 u _er ..... 1% immunopositivit of the '011I cell populalion while PCNA
overexpression was~ecl u graIer.han 25% immunopositivity. Pierp" II. (1996),
cluIifiod immunopositivity areater than 8% u an overexprasion of 10.-67 score while
S-.cben" II. (1997) defined I9PCNAelIpRSIion u l5% ew.....er. Tbeoe_
in the -... systems may typically rauIt in dilf..... tincIinp. As in .be other
imnuloIliJIoche ..... procedures, there is ...... _ '0 _ -...
mcdlods few the purpote of_cIinic:opIIhoIo comIIUon.
To _ the -... method could be. CIlIX few the_ ol>oeNed
in this tIUdy tIIII of 1IIenkv', 1ft IdditionaI IllIIysis was perfonnecl .. whidl
immunopositiveKMi7I11in1gra1er..... I%.....consicIerecluowrexpreaion...1IlIlyoecl
with the clinicopatholoaic:al variables. The 1% cut--oft' vahle wu chosen to usimilate
1IMnIeV... II. (1996) tIUdy. However. the rauIt.liom the ....islicallllllysi.did no' exhibit
• sip&onl dilfennce _ the iDitiaI 1lIIIysi, .hereby~8 IIw, lib the pll




_---.--. .... Iyp< olllllilody. or ....... ol.... ponlIin bIocbor_
proc:edlns.
,..........."" re:. %H eI'arawtmlltlyPIRcgurng
Tocllle, _ c:oc6med ............. fourcliaicolponmaen .... inlIueoce
projplClIis in ...... <IIl<:<r. _ gnde, tumour tize, ER ..... ond lymph node
~. n-puometenClft reIiaI>Iy ond independenllypreclict _ he or ovenU
IlItVMI (Greenfield .t MuIIhoIlond, 1997). A potential prolJlO"ic ponme1e< for b.....
c:arci..... is _ by its ability to: (I) independently predict _ he or overall
IlItVMI (2) show correIoIioa to""known independenI prtlIllOStic tieton ..c:Il u lUmOUr
tize, lymph node ..... ood lUmOUr ..... IIacnIcv .tll.• (1996) found .... wNIe PCNA
ond 1G-67 &iIecI to be orilldependeal~ siPficance, histllpllholop:olponmel'"
..... u _sizeood _ .... wereobietoprodict .... lUMvaI or.... lllbjccts. 0Iber
__found _helUMvalwuprodictedbylW1lOllrsizeondlymphnode
....... ond 001 by ol-'" or p53 or Bc\·2 expmsioo cu- et 01.• 1994;
1IacnIcv.t 1"""'- 1995; _ et .... 1995).
The presenllludy found ..... Jld.2 wu invenely woc:iIted with _ ....while
increued expression ofmulant pS3 wu positively associated with tumour pade. Ahhoup
woc:iIIions _ .... two biolosicaIlllIIl<en ond l1ImOUr ""'" were determined, lUnher
IIlIIysis oftlllllllUr ""'" ond 10cII rec:urmlCe indicated no sianm- woc:iItion _
.-twocliaic:lll_ T_size wu positively wociIIed with proIiCauioo ....
udeteaedbyPCNAexpmsioo(... TobIe 10.22 inAppenoix).1n1ddition, tumours IorJer
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..... 2an waelipific:lndy uooc:ialed wiIh IIocaIIOClltIIllCO (Me Table 10.25 in Appendix).
RubiAaI:F_ (1994)l'oundthalwomenwithnoaxillltylymphnodeinvolvemelll
had I 5 _ ............ or 8O'A wilen """'JlORd to thole wiIh potitive lymph node
involvemenl whote survival rite fell to 21% in the presence of 4 or morc affected lymph
nodes. Mc:Guite (1987) reported I JItOIlg inv«se ",rrdation between .... probability or
diseue free survival and the~ of positive nodes. In the current study, there wu no
wociation _lymph nod....... and loc:aI recu.....,. (Me Table 10.27 in Appendix).
Caner It II. (1989) in I study or 24,740 breast cancer -. round that lymph node
invoMnent along with tumour size were independent yet additive prosnostic indicators of
breast carcioomu. With repnls to IUIIlOUr size, Clner It II. (1989) aIao reported thai
survivall'lteS varied from 4S.'Y. for tumoun larBer than Sem with positive nodes, to 96.3"'.
lOrtumoun Iesa ..... 2an wilhno lymph nodes involved. The study indicated that eli free
survival dec:reased U .... lUIIlOUr size inmued, regardIeu orthe lymph node Also,
U lymph node involvemelll inmued, cIi!CISI free survival dec:reased regardIeu ortumour
size. In this study there wu no usociaIion_local recurTefI<C and combined sc:ore
ortumour size and lymph node ....... However, Caner p....seleded 24,740 cues from
I pool or63,316 cues usintI tumour size oreither 2an or San and abseo<e or _ (if
I mininum or eiaht nodes wae involved) or lymph nod. involvment. In _ in ....
presa study there wu no selectionofcues with regards to specific tumour size and number
ofpositive lymph nodes. This could be one reason for the lack. ofassociation.
In 0WIIIIIIry, only tumour size, I clinic0pathoiogical parameter, seemed _ in
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predictiDa the cIinicIlllUlCOllle. Jhouah wociIliolls _ some ofthe_ode: onul<en
Illd clinicaI_........oblelVed, neither ofthe onul<en ..... capable ofpredidirw the
1o<aI rec:umn<e or_c:u<er.
Ooounexpectedfindina in the..-Sludywu that, ohhouah lipifk:ant usociations
_ tumour hiJloIotIi<aI Illd Bd-2, pl3 Illd 10-67 obIelVed, there wu no
ISIOciItion _ tumour 1lld local rec:umn<e. AnoIher iciplled findina from
the present ...eIy wu that, with the exception of PCNA, there wu • lac:k of wociation
between tumour size and the other biolosical marken. Although studies have consistently
obterved theJl'08llOslicvalueoftumour"'in independefIlly pr<dictiJladiseue-freelUtVivai
(Caner et at. 1989), it wu surprising that there wu no inteNell1ion between the apoptotie
marken and size of the tumour. One reason could be dw the nwken examined had •
nesJi8ibIe effect on the progress oftumour srowth and that other markers not examined in
thi, IlUdy play • Iartier role in reauJIlinB the sroWlh of the tumours. Aside from lhi,
sugpstion, it seems that tumour size is • reliable parameter for predicting IotaI recurrence.
However in should be noted that in prattic:e. the accurate measurement of tumour size is
_.
The divene scorins S)'IIemJ, u wtU as the inability to objectively quantitate the
expression of immJnopositivity. remains • significant concern in detennininS the predictive





Propolli<: lidorstIlII CIII prodid the c:Iillic:aJ OUlCOllle ofpatieJIts with breast c:onc:er
lie dfecti.. in three 1ituItions. Fonl1y, \bey lie helpful in identifyina patieJIts with good
propoois following surgery, thereby di!peosing with the possible need for expensiveodjuVlnt
tberIpy. 5econdly, \bey CIII be _ to identify palial1. with poor prognosis who require
more ......... odjuv... tberIpy. ThitdIy, \bey _Ie the identitkation ofpatient. who lie
more likely to benefit from~ types of tbenpy (CIarl<, 1994). To dale, extensi..
investigations have been performed on the use of parameters relarinS 10 tumour
differenliltion, tumour IfOWlh. and tumour qgrcssivencss u proposcic flttors. However,
• number ofconfIj.... 1indings ha.. been obcIined reflecting the ditIk:uItiea encountered in
developing laboratory method. capable ofpreci.. q_i'"ive ......_ ofpar.....",
in complex bioIogi<al ti......
The ....... retroope<ti.. study examined the inter-relation between ,he proUferllive
and -.uc morlcen and their role in the progression of tumour growth and dini<II
outcome (see Figure 10.1). This study confirms the dual fiInction of the tumour suppressor
Sene. pS3. Expression ofpS3 IppeII'S 10 o<:alpy I distinct central role In the control of
proIiferaIion. Loa of pl3 liulction, u eviden<:ed by nuclear politivity, leads to incrased
proliferation (see Tables 10.10.1: 10.11 in Appendix) which, in IUm, is usociaIed with
increue in tumour size and tumour grade (see Tables 10.21 ot 10.22 in Appendix).
Local
Recurrence
Figure 10.1: Inter-relation of Apoptotic and Proliferative Factors
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Incnued 1lIlllOUr ...~ 10 list of I0<oI re<UmII<C. Thus, it Ippan tlw IIrse
1lIlllOUr'" is the _ ..... in I _ orbiolotli<al cbona... _ by _tiona!
...... in pll, which ...m- 10 I0<oI re<UmII<C. AIthouBh UIOciatiolls were round
betweenplloverexpreuionondpn>lif'entionllleondllOlbetweenpllondlo<olrecumnce,
it is """ likely tlw the Ialler woc:ialicm c:ouId be reveoIed by the use or Il10R sophistiClled
Iabolllory techniques. Overexpreuion or pll is correloled with high IUmOUr hiSloiogicai
grade consistent with Ill. induced state of high proliferation. Expression of &1·2 is
rec:iprocaIIy usoc:ialed with 1lIlllOUr hiSloJoaical grade, ..pponingthe view thatlkl-2 is 1ft
effective ... in promoting tumour differentiation and better prognosis. Tumour grade,
however. wu not associated with tumour size, or kx:aI recumnee. A surprisins findin& wu
the positive association between Bd-2 and Bu. expression, indicatina some sort of co-
regulation orthese &ctors ond the possibility tlw the rstio orJlax to Bd-2 expression, IlOl
the absolute values, is • critical factor in reauJating apoptosis. No association wu found in
this study between apoptDtic rate and expression of Sax, Bcl·2 or pS3, or to any other
parameter examined. It is possible tlw the prooess oflpoplosis opelSt..by Itoully difl"ereoI
_ or is delermined by _otic &ctors other than BeI·2 or Jlax. This speculation
can only be clarified by I detailed scudy of apoptosis in relation to the expression of the
various known Ipoplotic &ctors _ u Mel-I, Bel-X, Bad ond Bilt using qllllllitativo
IabolllOry ltdmiques.
Many orthe bioJoaical markers used in this study still need to be examined in I large
...... ~ve, c:oofirmatory trial with node neptivo patients who havo the highest
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IikeIihoocI of_liee ...m.I. If tudt _!up IllIdy were to be performed, ...... ofthe
methocIoIogicaI problems need to be IddmIedIlld resolved in order to vaIidaIe the results.
Most ofthellllldies examineopecificpro~ lictorsbymeansofIHC staining with
oc:<UionaI ... of molecular te<hniques. The IHC method, thou&h easy Illd _-efficient,
contains certain draw-baclts t!lat hinder _ reliable Illd reproducible resuk. Studies that
examine _putalive lict... by the IHC method should let _ sIandard cutpoint selection Oow
values VI. hi&h VI1ues or positive vs. neptive outcome) where the number ofimmunopositive
c:eII. "e placed in specific Il'OUPS. However, because of the inkerent keteroseneity of the
tumours. settin.1 riaid cutpoint may craie I prob~. A problem of miscalc:ulltion may
OCQD' when counting the number ofcells in several fields. Therefore, the use ofagrid which
can ponition _ sroup of 1000 cells per section may aid the process of COlIIIting the cell.
objectively.
Another problem to 0Vert0me is the currenl use of. variety ofantibodies and me
methods in ideIItifying cellular antigenic: expresaion. The diJf<fellCeS in these _ods may
produce divergent results. Also, placing immunopositive cells in sroups 1imitJ the ofthe
non-caIeJClrica swillicalanalyses, IhoushtheX' analysis is _reliable non-parametric 1lld
can be applied wheo the datJ analyzed is ranked or dassilied (IlonieI, 1995). A review ofthe
lit........ t!lat examined thepro~ value ofspccilic: licton reveal the many methods of
analyzing the datJ Currendy, few compantive studies have been perfurmed 10 determine
wbick _medlods might be optimoI in dilfercnl circumstances.
1118
To dote, .... _ ia onaoin8 for. propostic tool dlIllidfils .... three criteria ...
by Caner..... (1994). Future...,.,... ioclelerminini sucll _iii<: ti<Iors would n:quVe
lorge data. _ with '1oIli ..... follow-up 1IIlI. reIiabIelllllhod ofquIIIIilYins out""""
so dlIl it ia reproGocibie. Abo. to determine .... optimaIllIIlysi. for 1llIIlIininI value of
.... prognolli<: li<ton, various IlIliJtic:aI melhods mull be applied to ......... data. These
IlIIIdards need to be Il1Iioed 10 help identifY reliable IIIlI valid prognolli<: iodicaton.
Thi.studyprovides liutberinsighl obout .... inter-relations_ .....poptotic: Illd
prolifentive fidors. We have railed to coafinn the role of pSJ and &1·2 u lnde:pendent
prognostic: ti<Iors. Future prospe<1S enWI.1IlIdy of.... IpOptOlic: Illd prolifenlive markers
usins flow cytometry and moIeculIr ledu1iques to ensure reliable clinical wrrelalion. From
sucll. study we predict dlIl.combinationofpl31os&0flilllction, low Bcl-2 expression Illd
hilhproliferationidenlifiespatiemsllriskforloc:alrecurrenc:eofbreulc:ancer.
109
AaIt..-, S.,~ P., Eskelinell, M., KOSIlI, VM., Marl, S., AIhavo, E., SYIi....... K.,
(1992).IIiJloloP:aI_ ofprosnotli< ti<:lon in femIIe breut CIIar.
Oncology 49: 1-8
AImdII, S.,_,0, 1orpIuea, 0., EIiwen, G.,1WIJIu, 0, PihI, A, (1984). Estrosen
rec:epton Inc! 1ont!4enn proposis in breut _. CIIll:el'. 13:2121·2129
Aldenon, M., IIamIin, I., StIlIllton, M.,(I97I). The_sipifi<:an<eofprollJ1Osticlicton
in breut c:arc:inomI. Britioh Journal ofCan<:er. 21:646-611
Allred, C., CIul<, G.M., £DecI&<, R,F_ S.W., Brown, RW., (1993). AssociIIionofpl3
protein expression with tumour cell protifenrion rate and clinical outcome in node negative
breut _. Journal ofthe National CIIll:el'lnstiMe. 81:200-206
Anwi, B., Littlewood, T., Evan, G., Lond, H., (1994). Thee-Myc prolein ind_<eIl
cycle progression Inc! opoptolis Ihroup dimerUalion willi Max. EMBO lounW. 12:1083·
1087
Arends, M., Wylie, A, (1991). Apoptotis: Mechanisms & Roles ofPllholoBY.
International Review ofExperimental pol!IoIoBY. 32: 223·214.
AxcIsson, K., Ljuna, B., Moore, D., Thor, A, Chew, K., Ed....on, S., Smilh, H., Mayall,
B., (1995).T~ U I propostic usay for invasive ductal breast
carcilIoma. lournal ofthe Nllionol CIIll:el'lnstiMe. 87:997·1008
BaIdin, V., Kulw, I., Man:ote, M.J., hpno, M., 0rIetta, G., (1993). Cydin DI is.
nuc:1eIr protein required for <ell cyde progression in GI. Genes Inc! llevdopmenl.
7:1:812·821
Bancroft, I.D., St A, (1996). T1leo'Y Inc! Practice ofllistologi<al TechIliques.
Bancroft, I.D., St A eels. CIwn:hilll.Mnptone, Rollett Slevenson House.
8altenby, S., Anderson, T., (1990). CorreIIIions ofproJifentive IClivity in breut ti....
...... PCNAicydin.1Iwnan hIhoIosY. 21::7:781
Ilarboreschi, M, Onzio, C., Veronese, S., Leek, RD., F"IJII, D., Foll, S.,1lonzanini, M.,
GirIIndo, S., MordIi, L., EtcIler, L., PezdIa, F., Doglioni. C., DaIIa·PaIma, P.,1Wris, A,
(1996). 1IcI-2 Inc! pl3 Expression in node-neplive Breast Cucinoma.1Iwnan PIlhoioBY.
110
27:11:1149-1155
IIIrJou, R., IlanieI, P., MIpIn, M., Bommen, K., W........, C., KaIIinicIl, B., \toyc<, R.,
DorIc... B., (1995). Expreaioo of.... 1ld-2 sene FIIlliIy in normal and l1lIIi__
tiaue: low bax... expnuion in tumouR:eIIs toneIaIes with resistance towards apopeosis.
60:854-859
Bar-. R., Muood, S.,_, E., Ro...."d, A, Cogin, D., Crowell, T., Kin& C.,
Porter-Jordon, K., W....... E., Liot1a, L., (1991). Low nm23 protein expression in
infiItrIIin& du<lII_ <IRinomu comIIles with reduced poIi<nt IlIlVivol. American
JoumoJ ofPllhology. \39:245-250
Bar-. D., Dublin, E., Fisher, C., Lcvioon, D., Millis, R., (1993). Imnunohistocbemical
detection ofpS3 protein in mammary CU'einoma. An important new independent indiCltOl'
ofplOlJlOsis? HumIn PIIhoIosY. 24:<169->176
Battifora, R., GafI'<y, M., M..... P., Bailey, A, Faucett, C., N'dand, J., (1991).
JmmunohiJlo<hemicol usay of....,.-2........,. prodw:t in pu.mn embedded ti......
in earlybreua canc:er.lletrospectiveFoDow-upof24S mae land n cases. modem
pathology. 4:%6-'174
Ilazzoni, F.,_, B., (1996). The ..1IlOUf1ICCfOsis focto< ligand and recepto< IimiIies.
New EnaJand JoumoJofMedicine. 334:26:1717-1725
Bellamy, C., (1996). p53 and lpoptosis. British medical BuUetin. 53:3:522-538
Bendo, M.D., Elledge, R.M., Moo<, C., Clarlc, G.M., Osborne, C.k., Allred, CA,
(1998). Bd-2 and Apopcosis in lymph node Po~tive B..... Carcinoma. American Cancer
society. 82:7:1296-\302
BerJl, J., Robbins, G.,Faeton inftuenc:ins sIlon and Ions·term IlIlVivol ofbreast c:an«I'
patients. SuraicaJ~andObaletri<s. 122:1311-1316
Bharp... Y., KdI, DL., Rijin, M., Warnke, R.A, (1994). Bd·21mmunoreactivity in
B..... Carcinoma comIIles with Hormone Rca:pco< Po~tivity. American JoumoJ of
PIIhoIogy. 145:3:535·540
Bialeriidd, S., NoI\, I., NoD, E., Wobhmann, D., (1995). Blocking A: MilOtic Frequency
u. prosDOstic factor in breast cancer. Human Pathology. 26:47-52
Bodis, S., Siziopikou, p., SdlIlitt, S., IIarrit, J., FIsIter, D., (1996)., £xIensive Ipoplosis in
III
....... CIRino.. iaIiluOCthe"'--CIllCel'.77:9:1831·I83S
1louzubIr, N., Walker, K., 0rifIiIhI, K., Ellis, I., EIslon, C., Roberuon, I., BIamey, ll,
N~ ll, (1919). Ki-67 imlnunoslaininI in primuy breast ..-:pIlhological clinieol
uroc:iIIionI. BriliIh_ ofCIllCel'.l9:943.947
8rImbiIII, E., N_ A., Gazzeri, 5., Lamuejoul, 5., Moro, D., BrombiIla, C., Con,I.,
(1996). ApopI_ fi<:Ion pS3, Bd·2111l1 Bax in _ kina 1UmOn.
Americ:on loumoI oCPIlholotlY. 149:6:1941·19l2
Bravo,ll, MacDonIId-Bravo, H., (1917). Existeoce of two popu1aIions of
cyeJ;.vprolifenlinB cell nudeIr OIlliaen durins the cell cycle: usociation with DNA
ropIicaIion sitos. JoumoI ofColi BioIollY. 10l:Il49-1l54
Brown, D.C., C.... D., Ganor, K.C., M..... D., (1988). Corcinoma ofthe <erVix utori:on
.......- oftumourprolifontion using the monoclol1llontibody Ki-67. BritiJII Jourl1ll of
Con<or.l7:178-181
Brown, D.C., Gatter, K.C., (1990). Monoclol1ll Antibody Ki-67:its ... in histopllho1ogy.
1Iist~. 17:489-503
Brown, ll, Tho Jld..2 Funi1y ofProteins, (1997). British Modieol Bulletin. l3:3:466-477
Bronner, M., Cutin, C., Rood, J.C., Furth, E.E. (l99l). Bd·2 proto-onc:ogonolllll the
pstrOinlestilII epithelial twnourprogrossi model. Amoricanloumol ofPathology.
146:20-26.
But1or,/., BretJIty, 5., Menendez, B., Kinne, D., (198l). Estrogen receptor protein of
breast tucer u a predictor ofrecumnce. Caneer. 55:117"1181
CaoodionC_Statistic. (1997). NIIionII Cancer Institute ofC....... 10th AnniVOBUy
Ed.
C_ incideo<e in the provin<eofNewfcwulIaod 1IIlI1.abrIdo, (I99S). NF C_
T,_IIIlI_ FOUJIdItion. Dr. H. Bliss Murphy Comer.
C....... C.E., Gihw, T., CoulIs, 5., (I99S). Growth t'a<tor modulation ofpS3-modiated
growth arrest _ opoptosis. Genes IIIlI Devdopment. 9:600-611
Cairns, P., Polascik, T., Ehy, Y., ToIciDo, K., CIliIino, J., Merlo, A., Moo, L.,1Iearth, J.,




c.ner, c" Allen, c" Hen-. D" (1989), Rdalion 10 IUJIX>Uniu, lymph node ....... 1Od
IUlYivolin24,74O__-.C_.63:181-187
Cllloret1i, G" PiIeri, S" PuraYicini, C" _, M" Poui, S" Bifulco, C" Key, G.,
D'Amllo, L" SabIllini, E" FeudaIe, E" (1993), Anligen WIIlIIIkina on CormaIin-6xed,
poralIin-embedd IWue _os. loumII oCPIlhoIogy. 171 :2:83-98
ChIn& I., Kim, D" Lee, K., Choi, Y., (1995). TflJlSl<tivllion ability oCp53
u-rip<ionalllCliVllion domain is ditedly RIated to the bindins afIininty 10 TATA
bindina protein, loumal oCBioJosicll Chemistry. 270:25014-25019
CbIIldruoma, P" ToyIor, C,R., (1995). Concise Pathology, lohn Dolan ed, Appleton.!:
Lanp, Conne.c:"t
Cho, Y., Pavleti<:b, N" P.vletic:h, I" (1994), CI)'StI1 stru<ture oCp53 tumounuppreuor-
DNA c:ompIex: uncIentandins tulllOrigenic: ...,....., Sc:ien<:e, 265:346-355
Clemente, c" -hi, P" Andreola, S" Del Ve<:<hio, M" Veronesi, P" RiIke, F.,
(1992), Perlimonllympbalic: invuion in patiatu with node-neplive II1III1IIlIt)' dw:t
wcinoma, e-, 69:1396-1403
Colbert, A, Y...... D" (1986), Ghu:o<:ortic:oid-indu<:ed _ ribonudei<: Kid. in
rat thymi<: Iympho<:ytes: rapid primary etre<:ts specific: COl' g1u<:o<oni<oicl, Endo<:rinology,
119:2598-2605
COllIn, R.S., Kumar, V" Robbins, SL" (1994), Psthologi< Basis oCIlisase. W.B.
Sanden, ed, Har<:oun Braulovanoviclt, Philadelphia
Clark, G., (1994). Do \YO rally need JllO&IlOstic: ti<ton Cor breast <:an<er? Breast C_
lOd T_, 30:117-126
Clarke, A, Harrison, D., (1993). Thymo<:yte apop,osi. indu<:ed by p53-depeodenl and
independent palhways, NaIure, 362:849-852
CfIi&, R.W., (1995). The 1Id-2 Gene Family, Seminars in C_ BioIoIY' 6: 35-43
CWMinp, M.C., FumivII, C.M.,1'InoaI, P.G., TOWllJ<lld, E., (1993). PCNA
immunc>IlIiIIir in B.... Cancer. AuJlrIIion and New zaIand Journal oCSurpry.
63:630-636
D...... W., (1995).B_: ,foundllion for IIlIIysiJ in the haIth scienca. Newyorit
Wdey.
0...-, p.,F_D., KmiJoo, T., (1982) The paIhoIotPcollindinpof_ CIII<eJ
in poIieals uvi... 25 yan aft.flldicll mulec:tomy. Cancer. 50:2131·2138
0...-, A, Nonoa, J., WeinberB. D., (1990). ComplBlive ........... ofp<oliferatioo
and DNA ....... in by imqer IIlIIysiJ and l10w cytometry. American
Journal ofPatholotlY. 136:1115·1124
DdIbu, M., W1lile, E., (1993). Wdd-type p53 medial.. _tOli. by EIA, whim i.
inIIibited by EIB. Genes IJId Devdopment. 546-554
Demers, G.W.,~ C., GIIloway, D., (1994). Elev,ted wild type proeein level. in
human epithelial cell lines immonIIizecI by human papUomaYiN. type 16 E71l....
VuoIojy. 198:169-174
DervIn, P., Mape, R., Buddey, C., CIIlleY, D., (1992). ProIifOlllinj cell nucIeIr sntisen
counts in fOfmltin..fixed panffin-embedde tissue correlate with Ki-67 in fresh tissue.
American Journal ofPSIho1ojy. 97:121·128
Di..-CIIIO, S., Garcio-Moliner, M., CIIlleY, W., Wolfe, R.I., (1997). Bcl·2 Expression
and DNA Frqmenwion in B.... Can:inoma, PllholOjie and Steroid Hormone
Recepton CooeIIl... Diqnostic Molecular PIlholojY. 6:4:199-208
Dietricll, D.R., (1993). ToxieolOjieal and Pllholojieal Applications ofProliferalinj Cell
Nucleu AIllisen (PeNA), A novel EIlCIopnous Marker for Cell Proliferation. Critiel!
Review. in ToxieolojY. 23: I:77·109
1liLeonanIo, A, Linke, K., Clarkin, K., Wahl, G.M., (1994). DNA darnqe triBll"l'
proIoojed pSJ-dependent G1 uresI and Ions...... indudion o«:ipl in normal human
_. Genes and Devdopmetll. 8:24SQ.2SS1
DojIioni, C., Dei Tos, A, Loutino, L., ChiIteIIi, C., Bsrbaresehi, M., VI&Ie, G., (1994).
The prevaIenc:e ofBel·w imnunoIeIcIMty in and its clinicopIIholojieal
eorrdIles with paniao\Ir ref....... to oestrojen receptor SUIUS. Vilhows An:hives.
424:47·52
114
_, L., (1994). T_Genep53I11dApoploti•. Thee-
BuIJetin. 46:2:161.166
Dou, Q.,1.eYin, A, Zhoo, 5., Pwdee, A, (1993) Cydin E IIld cycIin A u cIIIdi...... (0'
the-.oonpoimptoteill. e--.Jl. 53:1493-1497
DuIic, V., KIufinIn, 5.1.,W~ Thty, T., Lees, I., (1994). p53 dependeot inhibition o(
eydin-<IependeD kinue I<livitiel in _ fibroblul. durina rodialion-induced GI .......
c.u 76:1013·1023
Dupont, W., pori. F.,1larlman, W., Brinton, L., Winfield, A, Worrdl, I., Schuyler, P.,
PIwnmer, W., (1993). _ CIIlCCl' riJk wocialcd with proJi(erative _ di..... 1Ild
IIypic:aIIIyperp\Ia e-. 71:1258·1265
EIiu, MJ., (1990). lmmunohillopalholosy. A pnctical spproodl to Iliagnosi. American
Society o(Clinical Patholosilt. Preu.
EIlcdse.Il, AIIted, CD., (1994). The p53 IWIIOUt1Uppreuor sene in _ cancer. B.....
C_-.JlllldT_. 32:39-47
EIIiI, E.Il, Horritz, H., (1986). Genetic conuol o(proBJllMlcd cd1 death in the ......od.
, ........ Cell. 44:6:817-829
Elli~ G., Gown, A, (1990). New sppliwion o(monoclonal antibodies to the diaplsi.
IIId prosnosis 0(_ CIIlCCl'. PathoIOSl' Annual•. 25:2:193·235
Elston, C.,EIIiI, I., (1990). Palholop prognostic l'adon in _ CIIlCCl'. Experience
from. luge Sl1Idy with 1ons4enn t'oUow-up. Hiltopathology. 19:403-410
Evan, G., Wyllie, A, GiIbcrt, C., UttIewood, T., B,ooks, M., Penn, L., Ilan<o<k, D.,
(1992). Inductionof__ infibroblulsbye:-My, protein. ceO. 63:119
Evan, G., UttIewood, T, (1993). The role o( ,.My, in cd1ll'owlh. C\llTIIII Opinions in
Genetic D.velopm.nt 3:44-49
F'_ AI., Douglu, Y., M<Goire, W.L. (1993). PrognoItie l'adon in early b.....
CIIlCCl'. The Americanlouma\o(lheMedicalS<:ien<a. 305:176-181
F'mIay, C.,1IiIIds, P., Levine, A, (1989). The p53 ptOlo-o"",sene <an '"u. SlIpt1S1O'
lIS
of_ CAl. 57:1013-1093
F_, B.,-. N.H,~ LD., (1969).e-of,"- ... ofaeoplum ond
propoois. e-.24:1071·10I0
F_, E., GroaoriO, R.,-.C.,Ilokbr, A, F_, B., (1976).1'IIIloIoBi<=o1
Ilndiop Iiom the__ UJicoI bnut project (jXOCOCOI4). IT. 1110
Iipific-. of........ node biIloIolI)' siJIIS biJlqloois ill invasive I1lIIl1IIlIIY
'"'"*.~ IourIlII ofC1iricll PIl1loIoIY. 65:21·30
F_, E., SWIIlIidou, 5., Lee, C., Rockettc, R., Redmond, C., F_, B., (1971).
IleIec:tion and IiFificance ofoccult axiJIIry node met....... ill paIients with ill"';..
_ c:ancer. Cancer. 42: 2025·2031
F_, B., _, M.,w~ L., Redmond, C., Fitbet, E., (1913). RcIation of
...-ofpooitive axiJIIry nodes 10 the propcl!i. ofpalients with primuy bRut '"'"*.
e-. 52: 1SS1·1SS7
F",,- H., Wolber, R., aa- K., F............. D., Glft'ey, M, Willut, D., (1995)
_~ofthe~_.... theBIoom""
Itidlordsoa 1lisIoIc>P:oI .........- for iaIil1rIlilla dudal c:on:iIIOma. American
_ oCOioicIl PaI!loloPL 103:195·191
F-. P., Uu, Q., _.Eidens, D., Codnll, C.,1IanNnIIl, K., Toziajon, 5.,-'
L., Hauaen-Slrono, A, 5_1., Miki, Y.(I994). BRCAlouationsillprimuy
_sad 0YIriIn_. Science. 266:120-122
GIIea, M., BIImey, R., Ebloo, C., Ellis, L, (1992). 1110 NottiJIBhsm ProsnoSlic Index ill
primIry _ '"'"*. B.-e-~ ....T_. 22:207·219
Gsnao\>Idhysy, 5., AbrahIm, I., LiD, Y, Benchimo~ 5., (1997). Ooc:og<nes ....
TUIIlOUI'Suppason. F_ill Mo1ec:uIIr Biology. Pet.. Gordon, Km:n Vousden eels.
IRC Press, Oxford Press. 19:261·210
Guparioi, C., POZZI, F., (1993). EVIiuIIioa the polentilllUdWncu ofnew proposti<
fadon ill axiJIIry node nepIi.. _ '"'"* paIients.loums1 of the Nllioosl C_
_ 15:1206-1219
Gerdes, I., SdIwIb, U., Lemke, H., SIcio, H., (1913)., Production of. MouseMoaodooaI AIIli>ody _ with.__Adiaa> _cd with Cd
__ OFe-.31:1l·20
116
Gna. J., Lemke, 8., IIIiI<:h, 8., WICker, H., _, U., Stein, 8., (1984). Cell Cyde
AnIIy1iI of,CeIl_-...~Nudar AoIipn Defined by the
MoaoclonaI AllIibody KMi7. The Journal otlmmunol"lll'. 133:4:710-711
Gna. I., Li, L., ScIIIucter, C.,IlucIlrow, M., W-.. C., Gerlach, C., Stahmer, I.,
KIolh, S., Brandt, E., F1od, 8., (I99I).lmn>mobiochemicalllld MoIccuIar Biologic
Chan<lerization orthe Cell ProIiferaIion-uaocialed Nuclear Antigen TboI is Defined by
MonodoNl Antibody KMi7. A-':an lournal orPalhoJosy. 138:4:867-873
Gilliland, M., But... R., Copeland, E., III. (1983). The impIic:aIion orlocal rec:umnc:e or
_ c:anter u the lint Jil. of therapeutic: 1iiIute. AMaI.orsuraerY. 197:3:284-287
GiIIeIt, C., Smilh, P., GreaorY, W., RidlUds, M., MiUi~ R., POlen, G.,1lames, D.,
(1996). Cyclin DI and proanosi. in human breast """"'. Int....tional Journal orCancer.
69:92·99
Goray<a. W., MarkiewJlci, M., Ktsm, A,Tuziak, T., Domagala, W., (1991).
Immunohislo<hemical analysis orBd·2 and pl3 expression in breast cancer: their
coneIation with Ki-67 powth llaction. VIlChows ArdUves. 426:229-233
Gorino, R., (1984), A comparillClll orrwo Immunoperoxidue ltainina Methods Bued on
the Avidin-Biotin Interadion. Disanollic ImmulIology. 2: 161·166
~ D.R., BiIIonnelt.. R.P., Colter, T.G., (1994). Imponant odvances in Cancer.
Lippincon Company, PhiIideIphia, PA
GreenbIalt, M.S., B_ Wl'., HoDstein, M., Ilarri~ C.C.,
(1994). Mu1aIions in the pl3 TlIlIlOIIrSuppresaor Gene: Clues to Cancer Etiology and
MoIccuIar PaIboaenisis. Cancer Resaroh. 14:4811-4878
GreenficId, LJ., MuIIhoUand, M., (1997). SUIIOlY: Scientific Principles IIId PrIClice. J.L.
Greenfield ed. Lippincott·Ra.... PuI>Iishen. Phillddphi,.
Groul, DJ, Rajah, F.,IIoWJ<oi~ S., (1989). Cyclic: AMP-depcndent p'..ein killue
moduIaIion orthe aJue;ocorticoid-induc<d cytolytic response in nwrine T-Iymphoma celIs.
Molecular Endoc:rinoIogy. 3:2119·2127
GuiIIou( C, SeIvakwnuao, X., De Luca, A, Giodano, A, Houman, B., Liberman, D.,
(1991). Dissectionotthe seneIic Jl'OIlRIIlI orpl3 mediated GI srowth arrest and
opoplOtis:blodcins p13-induc<d apoptosis unmask> GI arrest. BIoocI. 81:2691·2698
117
_,T.,locabIen, G., (1995). An immooIiJloch.mic.lJtudy ofp53 willi correloUons
to biIIopoIhoIop:o _ o-erb-2, proIiferIIinaceIl_ll\Ii.... 1IlCI propotis.
IiumIn JlIlhoIoay. 26:3:295-301
_, T.,locabIen, G.,ZecIeIer, K., (1996). Com1Itionofll'owth ftodionby Ki-67
IIlCI proIiferoIiIIaceIl_ ....... (PeNA) immunohiJlocheaUlry willi
hiIlopllholosicol poromeIen IIlCI propotis ill primory lxeut cotcinolllll. B..... CIIlCer
_T_.37:101-113
HoIdor, 5., ClUIopoIIi, I., Croce, C.M., (1996). TlllOlinduceo BcI-2 phosphorylotion IIlCI
cIeoIhofprotlll.CIIlCercell•. CIIlCer_.56: 1253-1255.
HoIdor, 5., NeariJli, M., Moone, M., Sobbioni, 5., Croce, CM., (1994). Down-rquIolion
ofBcI-2 by p53 ill B..... CIIlCer Cells. CIIlCer Reseuch. 54:2095·2097
HoI\, P.,Levinson, D., (1990). Review:............ ofcell pr_on ill histologicol
motaiolloumol ofCIillicoI PolhoIOBY. 43:184-192
Hon, E., Atber, N., YIlIIIlIIOlO, H., Lim, I., DeIohery, T., PIlllUkeu, R., PiozD, G., Xill&
W., Weinsleill, B., (1998). Efrecuof_1IlCI it._liteson growth lIlCIopoptosi.
ill humin lIIIlIIlIIIl)' epilheIioJ IIlCI breut cotcinomo cell lines. B..... CIIlCer Reseuch IIlCI
T_.48:3:195·203
HIIlIdo, M., Aime-Sempe. C., Soto, T.,.t Reed (1995). Suucture-filnction 1IlIIysi. of
BcI·2 protein:1_of-.d domoins importonl for _ with
BcI-211lC1 heterodimerizlI willi box.loumoI ofBiologico1 Chemistry. 270:11962-11969
IIorrinston. E.,-.M., Fonidicl, A., EYIft, G., (1994)., c-Myc-induced opoplosi. in
6brob1uts is inhibited by~ eytokines. EMBO loumol. 13:3286-95
!IIrTis, C.C.,1IoIIstein, M., (1993). CIillicoI itnplicotions of the tumo"llIJlIlf<SIOr g....
NewEngllllClloumolofMedicille.329:13I8-1327
"-'c}',I., (1964). An unicIentitlecI virus which ....1eI the ropid production oftumon ill
mice. Nu.•. 204:1104
"-'c}', M., McArtINr, M., Montgomery, C., (1993). Spoll!ll1eOUS IIlCI CItcinog....
induced IUlIIOrigenesis illp53_ mice. N..... Genetics. 5:225·229




IIeinu, R, LetIie, K.,~ L.,1Ioword, P., (1990). AmpIilICIIion ofthe~
onc:o_and _lit of...... ldenocIn:inoma. Arcllinva ofPIIhoIosY 1.IbonloIy.
114:160-163
HeIimonI, P., VIII Dam, P.A, WeyIer,l. Oollerom, AT., (1995). PrOSJlOllie VUllO of
Bcl-2 0lljlRSIi00 in invuive Breut cancer. BritiJIl loumtl OfCancer. 72:35>1-360
1!eftpIlIw, M.,1Iorviu, H., (1994). C.•1ops lWVivalgene c:ed-9 enc:odes I fiInc:liontl
homc>Ioau< of the I1IIIIlIllIIiIn proto-onc:ogene Bc~2. Cd!. 78:665-676
HenIwt, P., (1996). ICE limily pro......: Mcdilton ofall_otic ",D delth7
Immunity. 4:3:195·201
Herr, C./., (1993). MImmIIiIll GI <ydins. CdI73:1059-1065
HewisII, D., BllJiOyne, L., (1973). The calcium dependent endonu<l.... lOlivity OfilOllled
nuclear preparations. Relationship between its oc:currence and the occurrenc:e ofother
<iuIa ofenzymes found in nu<icIr pRpIIIlions. Biodlemi<aI Biophysi<I1 Raeu<h
COlllIlIlIl1i<IIions. 52:475-481
IIiII; R., FeIdoIein, M., GibIon, S., Cllrip, M., (1980). The relllivo imp<nInceof
estroaen receptor analysis U I prognostic fidor or response chemotherapy in women with
...... cancer. Concer. 45:1993·2000
Hinds, P., FinlIy, C., Levine, A, (1989). (1989). Mull.ion i. required.o ldivilethe p53
_ for oooperIlion with lUo_and tnnsformllion.loumtl ofV1tOIogy. 63:739-
746
HoUllein, M., Rice, K., 0.-' T., Soussi, R., Fucks, T., (1994). DI!IbIse ofp53_
IOlllIli< muwiollS in humin lIlOlorSand c:eU lines. Nucleic Acids Raeuch. 22:3551·3555
Hoovtr, R., Gray, L., Cole, P., MocMohon, B., (1976)., mcnopllllll Esuogensand br....
ancer. New EngIIIld loumtl ofMedicine. 295:401-405
IIoriaudU. I., Iino, Y., TI1cei, H., MIemurI, M., Tokeyoshi, I., Yak.., T., OhWldl, S.,
0yIIl1I, T., Nlkljiml, T., MorisbiII, Y., (1997). Long.."," prognostic VI1ue ofPCNA
libeling index in prinwy operobIe ...... cancer. Oncology Repons. 5:3:641-644
119
IIorikoIIIi, N., U A. Chon, 1.• 1.eWle, A, (1995). Two domains .fp53 inIenct wiIh
.... TAU bindintl IdenoYiruII3EIA procein diJrupls .... UIOCiation.
reIieYioBP53_~"""""'M_CdIuIIrBioIosY.15:227-233
_.T.• Pines, I.• (1994). Cydins .... CIllcer II: cydin D .... CDK inhibit... «>me.f
.... Cell. 79:573-512
_.1.1.. Bond, B.L., PonIow, T,G. (1996). Functional_n .f.... 8<1-2 protein:
Sequcoco roquiremenU for inhibition .f_si•. MoIe<uIlJ CoIIuIar BiolotlY. 16:3:177-
113
Hunler.1.1., hnIow, T.G. (1996). A pepIide sequeoce Iiom IlIx that converts Bd-2 into
1ft IdiVllor .f..,.pCo..... IOW1III.fBioIogicaJ Chemistry. 271:15:1521-8524
Hurlimonn, I., (1993). Proposlio VI1ue .fp53 protein expression in breast carcinoma.
PIIhoIogy ResardI .... _ 119:996-1003
Huller. R.V.P. (1980). TheinlluenceofpolhologiCllflClorsonbreulc:ancer_.
Concer.46:96I-976
Huvos, A. Huner. R.V~.• IlerB.I. W.• (1971). Signific:anc:e ofaxillary maao...........
.... _ in IllIIllIllIry cancer. AMual Surgery. 173:44-46
Juku1Jki, D.• Gani, C.• Travali. 5.• CaIabmta, B., Baserp. R.. (1911). Replalion oflbe
pre>liferatin& ceB nudar IIllipn cydin .... thymidine kinase mRNA level. by srowth
lKtors.IOW1III ofBioIo...... ChemiJIry. 263:21: 10175-10179
Ienninp, R.. Reimer. K.• (1981). LdhaI myo<I1dia1 iscllemi< injury. American loumol.f
PIIhoIogy. 102:241-255
1_H.• PyIkkonen. L.• ToiIdconen, 5.• (1994).1k~2 protein Exprusion .... Luna-
Term Survival in Breul Concer. American 10W1III ofPllhoIogy.l45:5:1191-1198
Kamel, 0 .• FronkIin, W.• Rift&us, I.• Meyers, I.• (1989). Thymidine labeIIins _ .... 1067
IlJOwth _ in lesions of.... breast. Americanloumol .fPolhology. 134:107-113
KuIan. M.• 00yeItw<re. 0 .• Sidrwlty, D., Vosdstein, B., Croi& R.W., (1991).
PorticipItion.fp53 in .... cellularrespooseto DNA damage. CIllcerResardl. 51:6304-
6311
KcIsey.I.• Gammon, M.• (1991) The q>idcmiolotlY .fb..... cancer. Concer 10W1III for
CIinic:iIns.41:146-165
Kerr.1.F.R.. Wylie, A.M.• Currie, AR., (1m). Apopt.sis: Abuic biolo...... phenomenon
120
with wide ....... impIieoIioaa ia tisIue-.British I""" ofCulcer. 26:239-2l7
~ CM., T..... K., TourtdIone, W., Brown, G., Koruneyer, 5., (l99l).IlIx-
_ mice with 1ymphoid hypcrpluia and IllIIe aerm cell daIh. SCience. 270:96-99
Ko, L., Prives, C., (1996). pl3: puzzle and pIlIdiam. Ga1es and Ilevdopment. 10:1054-
1072
KobayuIIi, 5., Iwue, Ii, YuWhi, I., Y.......... Ii, (1997). C1iaicol Sipific:anc:e oCbd-2gene""""'" ia humin bnut concerliuues.1IrastCanc«_ and Treatmeol.
42:173-111
KrajewsId, 5., TIIIIIca, 5., T.......ya, 5., SdlibIer, M.I., F...on, W., Reed, I., (1993)
lnvaliplioos oflhe IUbceIIuIIr dillribulion oCIhe Bd-2 oa<oprolaon: Residence in Ihe
nudear envdope, endoplumic: mi<:ulum, and ou'er mi.odIondriol membranes. Canc:er
_.l3:19:4701-4714
KtajewJld, 5., Thor, A., Edprton, S., Moore, D., Krajewski, M., Reed, I.C., (1997).
AnaIy1is oCIlax and Bd-2 ........... in pl3 inur<mopositi", bnut canc:er. Clinical Culcer
Reseatdl.3:199-201
Knoupp, B.G., llut1by-Nededty, R, Koudellca, R., Bukowulca, K., 8undI, W., SdwI'e-
R....... R, (l99l).ln Iitu derectioo oChjmenled DNA (TUNEL AJsay) fiil. '0
__apoptosis, nec:rosi~ and lUlolysis. Cell Death: A cautionary 110'0.
lIepoIoiosY.21:l:l46l-I467
Kraemer, G., (1997). The protC>-Olll:OgetlO Bd-2 and lis Role in ResuIatina Apoplosis.
Nature Medicine. 3:6:173-111
Kujari, R., CoIiIIl, Y., AlItin, N., (1994). Use oCIhe milotie eounts for Ihe ",osnow and
aradia8 ofbnut concer. PaIho1oIY _ and Praaice. 19O:l93-l99
~ G.,~ G., (1997). The eeIl eyde in breast canc:er. AMPIS. IOl:l7l-l19
Lane, D., Crawford, L., (1979). T anti..,. ~ bound '0 a host protein in SV4Q-lIIIIsConned
eeIls NIIUte. 271:261-263
I.azebIIick Y., Kaufinan, S., Desooyen, S., Poirer, G., Earnshaw, W., (1994). CIea"'ll" oC
poIy(ADP-ribose) poIymerue by a proteinue with p<Opertiesliko ICE. Nature. 371 :346-
347
Lee, A.,1leI.eIlis, R, Silverman, M., Wolfe, R., (1916) Lympllatic and blood vessel
invasion in bnut carcinoma. AusefiIl prognostic factor?!IumIn PaIho1olY. 17:914-917
121
Lee, 1.,1IemIlein, A, (1993). pS3 ......... incnue raiIlanc:e 10 ionizioa rodiIIion.
Proceodioa of1he NalioaIl AA:Idemy ofSCience. 9O:S742-S746
Lee, Y., rIO, Y., T_ C., (1996). Reciprocal expmoion ofBd-2 and pS3 in _ duCll1
W<:inomI. _ -. 16:3007-3012
Leek, Il, iWdImIniI, L., PazeIIo, F., GIlt«, K., HanU, A, (1994). Bcl-2 in IlOrmalbumon _ and corcinoma, _ widl_ receptor-potitive, epicIermol
growth _ receptor--",< 1UlllOn .... in situ cancer. British lournal ofCancer.
69:1:l3S-139
LeonIrdi, E., OitIIno, S., Secio, F., Mauri, F., Perrone, G., S<ampini, S., DIIIa Palma, P.,
BIlbIrachi, M., (1992)., PCNA and Ki-67 expression in br_ carcinoma: correlalioos
with cIinicIl and bioIogicII _ ... lournaI ofClini<al Pathology. 4S:416-419
Lewin, B., (1997). Genes V. Oxford University Pr.... Wlllon Street, Oxford.
Lin, y., 8eD<himoI, S., (I99S). Cytolcines inhibit pS3-media.ed _otis bu.llOI pS3
mediated GI ....... Molec:ullrCdlBiolosY. IS:160S·16S4
Linzer, D., Levine, A, ChIn<:leriDlion ofa S4K dalton cellular SV40 tumouruUiJl'll
........ in SV40 _ormod _ and uoinfo<Ied emb<yonol carcinoma _. Cell. 17:43·S2
Lipponen, P., AoItoIllll, S., K...... V.M., SYli K. (1994). Apoplotis in Breast C""'"
IS Related 10 Hislopllololi<ol C1lIncteriJlics Pr08JlOSiL Europesn lournal ofClll«<.
30:14A: 2068-2073
Love, S., Pork«, B., (1996). _ Guiddines for B..... C"""'. The cancer lournal
From Scienlitic: Amcri<u. 2:1A:7·21
Lowe, S., Schmitt, E., SInith, S., Otbome, B.A,lacla, T., (1993). pSI is required for
rodiIIion induced _ ..... in mou.. t1tymo<yIes NIlUre. 362:847-849
Lyons, S.Il, CIuke, All, (1997). Apoptosis and Carcinogenesi•. Brilish Medial Bulletin.
S2:3:SS4-S69
Mack, D., Vutibr,I., Pipu, I., Laimins, L.S., (1993). Specific repression ofTATA-
mediated but llOl _-mediated 1rIllCripcion by wiJd-type pS3. NIlUre. 363:281-283
MoIkin, D., Li, F.P., SlfOIlB, L.C., Frowneni, I.F., Ndson, C.E., Kim, D., IWsd, I.,
Bischoft; F., TainsI<y, M., (1990). Genn-lille pS31lU111ions in I familial syndromaof_
cancer, san:omas other neoplasms. SCience. 2S0: 1233-1281
Marcheui, A, Buni F., PeIIepini, S., (1993). pSlllUlllions and hiscological type of
122
MIuri, F., GirIIado, 5., DoIIa PoImI, P., BuII'o, G., Perrone, G., DogtiOlli, C., Knipe, H.,
BarboracIli, M., (1994). Ki-6711lliboc1ies (Ki-Sl, MIll-I,IIld Kkl7) in _ carcinomu.
Abrief~ Applied _stochemiJtry. 2:171-176
McConkey, D., ,N_ P.,-.P., Wyl1ie, A, Orreniu, 5., (1989).,
~ ..._.ouicide_inthymooyt"lhroush .. _of<ytosolic
Ca2+__ Archiva ofBiocIlemiSlry.t Biophysics. 269:361-370
McConkey, D.,-.P., 10IIdaI, M., 0neaiuI, 5., (1989)., lIlhibition ofDNA
liqmcnlalion in thymooytes IIld iaoIated thymooytellllClei by ...... thal stimuJale protein
kinase C. lournal oflliolotlical Chemistry. 264:13399-13402
McGuire, W.L., (1987). Propostic tiel... for recurrence IIld lUMvaI in human br....
cancer research lreatment. Breast Cancer Ilescarch and Treatment. 10:5-9
Mquire, W.L., AtuI, K.T., Alfred, D.G., (1990). How 10 use propostic tid... in Axil1ary
Lymph node _ c:arcinoma pili"",, lournal ofthe Notional CIllIdian Institute. 82: 1006-
lOll
MichaIides, Ro, Hapman, P., VIIl1....... H., HOIIben, I., W.....jens, E., K1ornpmarlter, Ro,
P_l., (1996). AclinidpatholoBi<al study on overexpreuionofcyclin DIIIld ofpI]
in. series of248 patients with openble breast cancer. British Journal ofCancer. 73:728-
734
MOO, Y., 5_1., Shattuck-Eidens, D., Fulrea1, P., IlanIvnan, K., Ta.,igian, 5., Liu,
Q., Cochran, C., 8erInett, L., Jling, W., (1994). A ....ng candIdale for the_1Ild
ovarian susceptibiIily .... BRCAI. Science. 266:66-71
Miller, C.w., Aslo, A, Tay, C., SIlmon., D., Tosuchida, Y., (1990). frequency IIld
suucture ofp53 reamnaements in human osteosarcomas. Cancer Research. so:7950-7954
Miyachi, K., frilzler, M., Tan, E., (1978). Autollllibody to anuclear antigen in proliferating
cells. lournal of1mmwlolosY. 121:2228-2234
Molina, Ro, Sepi, M.A., C1imen~ M.A., AIbaneIli, M.,fernandez, M., FilldIa, x., 10, I.,
Gimenez, N., Isiaiu. E., MiraIIes, M, Alonso, C., Peiro, G., Perez, P., BaIIesta, A, (1998).
pS3 oncoprotein u. propostic indicator in patients with breast canter. Anticanc:er
ReaeardI. 18:507-112
Moore D.H., Moore, D.H., Moore, C.T., (1983). Breast Carcinoma ....ological tid....
AdVlllCes in C...., Research. 40:18-21
123
-.5" _,M., Lian& K, Meadows, R., Fesik, 5" (1996), X-ny IIId NMR
_ of....... Bd-.... III inhibilor ofprosnmmed cel1 cIalh, N 311:335·341
Mwlonen, M., RIUIlio, K, Pukko, P., Saini, Y., (1997). T1Ie ofapoptosi. is
ilMneIy _eel with bd-2 explaIioo in pnmaJigJllllllIId IIlIiigJlllll _lesion•.
Ilislopolboloay. 3\ :4:347.354
MyuIlita, T., Krojew1ti, 5., \Crajew1ki, M., WIIIlIo H.G., Lin, KK., Hollinlll, B.,
Liebennon, D., Reed, I.e, (1994). Tumc>ur..ppraso p53 i. a replator ofBd-2111d 8Ix in
aeneexplalioo in vittollld in vivo. Oncopne. 9:1799·1105.
NIIIIIYlh. K., (1996). At the heart ofthe buddinayast cel1 cycle. Trends in Genetics.
12:405-412
N~ N., Emdin, 5., CIjander, I., Landber& G., (1997).lleregulationofcyclin EII1d 01
in breuI c:aneer in associated with inKtivation oCthe retinoblastoma prOIein. Oncopne.
14:295-304
Nime, F., Ro.... P., Thaler, H., Ashikari, R., Urbon, I., (1977). ProSJlOsUc sipificance of
tumouremboli in intnmammuy Iympbatics in patients with mammary carcinoma. Ameriun
lournal of Sursical PathoIosY. 1:25.30
Nopoclli, M., 0hIa, N., koyuaki, N., TIniya, T., Miyazaki, I., Mizukanni, Y., ReappraisIl
or internal mammary node mctutues u • prognostic factor in patients with breast cancer.
Cancer. 61:1911·1925
O'K..... I.C" Ok... E. (1990). Anti-esuadiol immunoperoxidase Ilbelin& ofllllClei, not
cytoplasm, in parafIin se<tions, determines _en rc<eptor llllUJ of_ cancer.
Americ:an lournal ofSoqicaI PathoIosY. 14:2,:121·127
ONCOR: ApopT.. P1us in siN Apoptosis D<t<etion. S7101. GaithenbIIrg, MD 201n
Oren, M., (1994). R<laIionship of pS3 10 the control oCapoptotic call death. Seminus in
CancerllioloaY. 5:221·227
OIIrowski, L., Sawan, A,Henry, L., Wriahl, C., Hemy, A, Henessey, C., Lennotd, I.,
An&us. B., Home, H., (1991). pSJ explaIioo in ....... breast cancer rdaIed to lIiMvallIId
pro l'acton: an imnamoIIiIIochemicaI study.lournal ofPllhoiosy. 164:75-11
p D., (1916). Cancer Risk ........... in benip br.... biopsies. Human PathoIosY.
17:171-174
PIle. D., Ilupont, W., (1992). Breast ....... angioaenesi1 Through. narrow window.
lNCl.l4: 11lO-iISl
124
Pida<n, I., (1961). Sipific:once ofoc:cull ........... AS1Udy ofbreul_. C-.
14:1266-1273
Pierp, I., Leroyer, A, V...... P., Moueri, V., CbeviIIard, S.,~ H., (1996). Lona
..... pn>tplOIIic ...... otpowth liIction deIermiJwion by~7 imnaInoll&ininl in primuy
~breul_.B_C--=andT_.37:57-64
Poner-InrdIn, It.,~ EM., (1997). Overview ofbio1oliCl1 nwken ofbreul_.
Bri"" loumal ofC-. 75:1295-1301
Reed, I.C. (1995). Bd-2: _ of_olil u, _ ofdru8 resiJwlce.
IUcmarDIotlY 0nc01osY Clinics nfNorth~ 9:451-474
Reed, I.C., Zha, H., Aime-Sempe, C., (1996). Mec:hanisms ofLymp/locyI. A<:1ivuion and
_RquIalion VI. Gupta and Cohen ods. Plenum Press, NewYorlc.
Ro.... P., Lesser, M., Arroyo, C., C....."., M., Bo'lleD, P., Nonon, L., (1995). p53 in nod..
neplive breut carcinomL An immunohiSlO<hemiCl1 S1Udy ofepidemiolosiCl1 risk "",ors,
hiJlolop features, and ptOIDOtis. loumal ofCIiniCl1 OncoIoIY. 13:821-830
Roten, p., Sai80, P., B_ D., WOIlhers, E., F-m., A, Kinne, D., (1981). AxiIuy
miao- and macrometutues in bre:ut cancer. Prognostic significance oftumoursize. AMJal
Sufsery. 196:585-591
Rolli, I., (1996). Ad<ermon's SlIlJicaI PathololY. Lynne Grey ed. Mosby-Year-Book Inc.
Missouri
Rou, R., Papnini-HiI1, A, Gerkins, V., Mad<, T., Pfeffer, R., Arthur, M., Henderson, B.,
(1980). A _ study ofmenopousol estro8en .henpy and breut _. lAMA
243:1635-1639
Ro.wki, B., Benchimol, S., (1988). _onofrat embfyo 6brobluuby 'eh
_ p53 0_. Oncogene. 2:445-452
Rubin, E., Fuber, I.L., (1994). PaIhoIogy. Richotd Wll1Ien ed. I.B. Lippinc:on Co.,
Philadelphia.
Russo, I., Fredri<k, I., Ownby, H, F.... G., Hussain, M., Kin:ksloin, H., Robbins, T.,
Rosenberg, B., (1987). PredicIorsof_and survivol o(patients with breul <an<er.
88:123-131
Ryan, I., DInish, R., GouIieb, C.A, CIIrke, M.F., (1993). Cell cyde IIlIIysiso(p53-
induced oeII daIb in IlllIrioe erythroleukemia oeIIs. Mnlecular Cell BiolosY. 13:711-719
12$
Saboaioi, P., Lin, 1.,l.eWle, A., While, E., (1995). EueoIiII role ofp53-medi1led
trIIIICripcioIl in EIA-induc:ed lIpOpCOIiI. Geoa IJId Devdo_. 9:2114-2192
SINn, A., 110, I., Ro., Y., BIid<, M., "'N_, A., 0nI.-, N., Fritshce, H., Smith, T.,
IIo<1obIIYi. G., AyoIa, A., (1991). Ki-67 ............... in llOde-nepliw .... VB bRut
corcinomo. Si",- comiIIion with prGIllOIiI. Cancer. 68:549-557
SliSO, P.,Roten, P., (1!11O). Propoolic: &don in invuive IllIIllIllIIY carcinomu I.Oan or
leaindilmeler(_). _1_ofClinicll PIIhoIosY. 73:303-304
SuIId, K., MurIkami, T.,lCawuIId, M., ToIcahuhi, M., (1987). The cell cyde wociated
c1lanp ofllle Ki-67 ractive nuclear IIIliaen expression.lournaI ofCell physiology.
133:579-584
SilO, T.,lIInada, M.,IlodNs. S.,1rie, S.,I_ N., Boi.., L.H., Thomp_ C.B.,
GoIemis, E., Fong, L., WillS. H.G., Reed, I.C. (1994).lmerldions _ members ollhe
bd-2 protein family IIlIIyud with I yast two-hybrid system. Pro<eedinp ofllle NlIionai
A<ademyofScience.91:9238-9242
Selvakumann, M., Lin, H.K., Miyuhitl, T., (994)., Immediate early up regulation ofB..
expreuion by p53 bul not TGF belli: I paradilP" for disliDc:t _lie: pathways.
Oncoaene. 9: 1791-1798
Sdlon, A.F., Ape\, I., NlIlleZ, G., NlIlleZ, M., (1995).1I<~XL protects<ancer cells &om
p53-medi1led IpOpIOJiI, Oneogene. 11:13119-1394
Schluter, C.,lluchrow, M., WoIlIenberg, C.,lIecker, M., Key, G., FlId, H., Gerdes, I.,
(1993). The Cell Protiferllion-usoc:illed IIlIigen of lIUibody ki-<;7: A very lara.. ubiquitous
nuclear proeein with IUlllerOUS repelled e1emenlJ, representiDs I new kind ofcell cycle-
mainlainina proleina. The lournal ofCell Biology. 123:3:S1l-522
SchWWl/Ullllll, R.A., CidIow1ki,IA, (1993). Apoptosis: The Biochemistry IJId Moiecular
Biology ofProgrammde Cell Death. EodocriDe Reviews. 14:2:133-151
Scott, R.,IIaII, P.,HaIdane,I., Price, Y., VlIlNoorden, S.,lIIle, D., Wright, A., (1990). A
compariaon of immullohistochemi... markers ofcell protiferllion with experimentally
determined JIlOWIh _.lournaI ofPllhoiogy. 165:2:173-178
ShIhIm, S., EDi, R.,IIoMtz, H., (1996). Caenorhabditis eIegans neurons may contain cell
deIIh protective IJId killer ldivities. Geoa IJId DeveIopmem. 10:578-591
ShauliIIl, E., Hlviv,1., Shaul, Y., Oren, M., (1995). Trans<riptional repression by the ...
tennillll dollllin ofp53. Oncoaene. 10:671-680
126
~S.,~8.,Cbou,F.,C!Ien,W., (1997). The propollicIipiliconcool
proIil'enlina eel IUC1eor IIIIipa ill pIIielU with Iympll node-pooilive bRut aoeer.
ArdlivaolSurpry.132:264-267
Shen, L.,1!Im, 8.,110, L., Yo, C., Chiu, S., Lee. W., (1998). The ...... olproliferolive
IIId _otic ICIivity ill iOlnductIIlIId invuive duc:talbRut can:inomu delecled by Ki67
IaI>dinB IIId tenninoI deoxymJdelidyltrllUferue.medilled dipdgenein-II-dUI1' nick end
1obcIioa·82:12:2373-2381
Sherr, C., Roberts, I.M., (1995). Iohibiton oflllllllllian GI c:ydin-dependen KUwes.
Gelles IIId Ilevdopment. 9:1149-1163
Sierra, A LLoveru, B., Xavier, Cutel1Jque, X., (1995). &1-2 Exprasion is Asoocilted
with Lymph Node MelUIUi. In I!umIn llucbI Breast Corcinomo. lnIematiOlll1 loumol of
C.-.60:~
S~veslrini,I., Veneroni, S., Daidone, Ilellioi, E.• Bo....hi. P., Mezzetti, M.• (1994). The
Bcl-2 pro.ein: a proIJIOstic iIldicatoc IIronsJy related to p53 protein in lymph node-negative
breast cancer patients. Journal ofttle National Cancer Institute. 86:499·504
S~vesIIilli, R..1lellioi, E.• Veneroni, S.• Daidone. M.• Tomasic, G.• Squicciarini, P.•
Salvadori, B., (1996). p53 IIId Bcl-2 expreuion c:omal1es with clinical 0Ul<0llle ill a series
olnode-positive bRut aoeer patient. loumol ofClinical Oncology. 14:5:1604-1610
Sjoar<o, S., In_ M., Nor1>erB. T., Lind.... A, Nord.... H.• Holmber.. L.• Bergh, I.•
(1996)., The p53 _ ill Braa Cancer: prognostic Value ofComplementary DNA
sequencinj Venus InununomIochemisrty. Journal ofthe National C.-Institule. 88:3-
4:173-182
Smith, M.W.• CoIlan, Y.• KahnJ, M.W., Trump. B., (1980). Chanses ill mitochondrial lipids
of... kidney durina iIclIemia. Bioc:bcmical Biopllysic:s Ac1a. 618:192-201
Sommer. S.• CllIIIIinshatn. I.• McGov.... I., SoilOh, S., Schroeder, I., Wold. L.• Kovach,
I., (1992). loumol ofthe NItional..- Ins1i1ute. 84:4:246-252
Sondik. E.• (1994). lncidellce, monaIity.1Ild suMvoi. Cancer. 74:995-999
Stahelin, B.• Mor1i, U.• SoIioz, M., Zimmermann, H., Reichen, I.• (1998). False Positive
Stlinina ill the TUNEL _10 dc<CC1IjlOp101i. ill liver IIId illtestine is caused by
0JICI0sen0uJ nucIeues IIId inhibited by diethylpyrocarbonate. loumol ofClinical Pathology:
Molecular pathology. 51:204-208
T...... I., SchuI1z, S.• Bartelt, I.• "'8& E., (1994). Cell cycle analysis ofthe activity.
sub<:eIluIar localization, IIId IUbunit compooition nofhuman CAK(CDK......vatills ki....).
127
IcumoI oCCelIIIioIotIY. 117:467~71
ToilIa, 5., N....... D.,1lidI'eabIcll, A, Y-.b, L., (1993)., PredictionoCarly relapse
.... _ ourvivII in poIieou with breast CIJIc:er by proliCenlion cell nucIar IIlIipn
J<Onl. e-. 71 :3SSS1·3SSS9
Thor, A, YIIldeII, D., (1993). Propootic Iisnificanc< of pS3 overexpresUon in node-
.....ve breast cucinom: prdirniMry _ IlIpport cautious optimism. I...... ofthe
NIIionII Cancer lnItitute. 8S:3:176-177
Thut, C., Chen, J.L., Klemm, R., Tijlll, R., (I99S). pS3 Trwcriplionalldivltion mediated
byc:ollClivatonTAfll40 .... TAfll60. Scienu.167:1OQ.104
TllIjimoco, Y., Croce, CM (1986). Analysis ofthe IUU<1Ure,lrIIIS<ripU, .... """em
producu ofbcl, the .... involved in IoIman foUi<uIar lymph nodes. Proceedinp ofthe
Nalional Aademy ofScience. 83:S114-S1I8
Umemun, •., YuudI, M., Osomun, R., KaWltlda, Y., SusiYlIllO, T., TllItlllllli, Y., (1996).
EnhoDcement oCTtIt-medialed dUTP-biotin Dick end·labeIIin& (TIlNEL) method usin&
Il1lIIl8 belli nucleue, 1 ......_ DNA diBation enzyme. I...... oflliltoc:hemiltry
.... Cyloc:hemiltry.44:1:11l-1l1
Unaer, T., Nou, M., SepI, 5., Minna, D., (1991). pS3: I trWdominant~or of
tnnICription whose fi.mctioll is ablIted by mutations occurring in human cancer. EMBO
I....... 1I:13B3-1l90
van derRooy, R., Rookus, M., P....... H., Leeuwen, F., (1996). p53 """em
Overexpression in J.eIaIion to Risk Factors for Breast Cancer. AmericaJ Journal of
EpidemioIoay. 144:10:914-933
van S1oolell, H.3., CIahsen, P.C., vanllierel1donck, I.H., (1996). Expression ofBcl-1 in
node nepIive breast CIJIc:er is uaoc:ialed with various prognoslie Ii<:tOlJ, but does not
predict reapo... to one c:oune ofperioperative chemotherapy. 8ritilll I...... ofC.......
74:78-8S
van Slnoten, H.3., Vijver, M.V., VeIde, C.l.H., Dierendonck, I.H., (1998). Lossofbcl-1 in
invuive breast CIJIc:er is_ed with hip rotes ofcell death, but allO with increued
proliferative activity. 8ritilll I...... ofCancer. 77:5:789·796
Vedleijen, R., Kuijpen, H., van Oriel, R., (1989). Ki-67 detects I nucIar lllIlrix-associated
prolifention -<datedllllipn expression D.LocaIization in mitotic cell..... association with
chromotomes. I...... ofCell Science. 91:531·540
Veroni, 5., CollI, A, MotU, R., Giardini, R.,IiIke, F., SiIentini, R., (1988). Comparitive
128
IIlIlyIiIai'lldl,-....... iIldex IIld -.xlaNl1IOibody 1067 ia ooo-IIocIIkin"
~ I-.qyOacoIoIY, 6:21-21
V_, D., Wykes, S.,1Cubu. I., en-, I., (1992). ComporiJon aiPCNAIcydia
__,.,........;crywilb8owcylOllldrics-pllueliocliooia!nul....,..._e-
_IOIIT__ 22:III-111
v......... B., Kinzl«,IC., (1991). The Geaolic: Buis ofllumu <IIlCCt. V......... B.,
Kinzl«,K."'" MoOnw IliI e-,Inc.
W_, N., (1993). _or...... oppIicalions ialllmOUrprlllllOltieoli. Seminusia
DiqnoIIic 1'IIboIoI)'. 10:302-313
W_, N., FoIIanIn, I., p..... F., Bevilocqua, P., Allred, E., Moore, D., Mell, 5.,
Guporini, G., (1992). A new,;pific:am and independ.nt propollic indicItor in early -.....
breastc:arc:inoma. Iomolofthe NationII eo-Inllitute. 84:117l-1187
Weikel, W.,1leck, T., Mila, M., Knopacia, P., (1991). _hiIIoc:hemicII evo1uIIionof
arowdt _ .._!nul cancers ...... -.xlaNllIIIllJody Ki67. _ eo-
_T_.ll:14~114
WcinberJ, R.A, (1995). The _ .... protein and cell <)'de COlIlJOI. Cell. II :323-330
WNte, E., (1996). Lire, deoIb, and the purU of_OIis. Genes and Devdopmenl. 10:1-
Il
W_,Il, Zipfel, L, Sdutle-MooIin& I., (1991).~7 irnmunostIinill in _ breast
tumors IIld its r<Iolionship to proposis. e-. 67:421-421
WIZiI, T., ...... I., Ola, 5., SchIid, D., TIbory, R., Wold, L., Gnnt, C., Gon<horofl; N.,
1CalzmIIl, I., (1994). DNA ploidy IIld the _ ofeells in 5-pIwe u prosnoIIie
foctonfor ........ wilhlympll node nepti.. _ <IIlCCt. eo-. 74:17l2-1761
WOOIler, R., NeuhIussen, 5., MIlIIion, I., Quitk, Y., Ford, D., Collins, N., NIlIIyen, It,
Seol, 5., T.... T., Averill, D., FoeIds, P., MarWIJ, G., Nsrod, 5., L<ooir, G., ormillOll, W.,
McMInus, R., Pre. C., Lewis, C., Cannoo-Albright, L., (1994). Loc:aIizalion of. breast
<IIlCCt1UlCeplibiJity ..... BRCA2,lo_llqI2-11. Science. 26l:20111-2090
Wylie, All, (1997). ApoptoIis: III oveMew. BritUh Medi<:al Bulletin. l3:3:4ll-46l
Wylie, All, (1993). ApopIOIis. BritQh loumII ofC...... 67:2:20l-201
Wylie, All, Kerr,I.f.R., Currie, AR. (1980). Cell death: The SipificIIlceofApopIosis.
............. _ ofCytolosy. 61: 251-306
129
Y.... E., Konmeyer, SJ. (1996).__opsis: Adis<oune on IheBd-2flon>1y
IIld cell daIb. BIoocI.II:3116-401
Yon, XM., 0IlVIi, Z.N., Konmeyer, SJ. (1994). BHIIIld BH2 domains ofBd-2 ...
required for inIlibiIion oflplllMOOis IIld heterodimerizaton wilh 1Iax. N...... 369:321-323
Yonilll-1louI<h, E., Reznitzky, D., Lot.... I., (1991). WIld type p53 induces opoptosis of
myeloid IeuUcmic: cells ..... is Inhibited by inlerIeulrin-6. N...... 352:345-347
Yu,C., Woods, A.,l.eYison,D., (1991). Theusessmentofc:dlularprolifentlonby
immunohistoc:Il:. review ofcumndy .voiIIbIo methods IIld their appIicalions.
IIistociIemial lournal. 24: 121-13I
Y I., SbIhIm, 5., Ledoux, 5., Ellis, H.,1Iorvilz, K, (1993). The C. 010"'" cell deIth
S Ced-3 -.._olis limiIar to I1IIJllIIlI1iIn inlerleulcin-Ilkonvenins enzyme.
Cell. 75: 641-652
Zamzami,N., Susin, 5., Marchetti, P.,Hinch, T., Qomez-MOOlert<y, I., Kroemer, M.,
(1996). Mitoc:l1ondrial control ofnuclar _sis. Experimenul Medicine. 183:1533-1544
ZhI, H., Fisk, H., Yaffe, M, Mallljll1, N., Hennon, B., Reed, I., (1996). Strueture-fUnc:tion
compui_ oflhe pro-_otIc protein IIax in yeast IIld I1IIJllIIlI1iIn cells. Molecular
Cellular BioiOS!'. 16: 6494-6508
ZhI, H., Aime-Sernpe, C., SIlo, T., Ree, I.C. (1996). Pro-opoplobc procein BIX
heterodimerizes with Bd·2 and homodimerizes with Sax vi•• novel domain (BID) distinct
&om BHIIIldBH2. lournaIofBiolop ChemistI}'. 27\:13:7440-7444
Z11u, W., Cowie, A., Wufy, G., p..... L., Leber, B., Andrew~ D., (1996). BcI-2 mutant.
wilh restricted subcellular localization reval spatially dislillCl palhways for _osis in




Tobie 10.1: NonporuneIric IlIIIysis orlhelSlOcillion between Bd-2 <ytoplumicexpreuion





R&1eof Low 64 63 127
Apoptotis Med- II 4 IS(...142) High
TOII1 7S 67 142
StllistiCll x' =2.833 dC-I p'.092 p=.IOS'
S;pfieance
132
Tobie 10.2: NooporameIriclllllysisoflhe_on_Bd·2 cytoplumic:expfmion





Box Low 48 28 76
Cytoplumic Med· 27 39 66Expmsion Hip(IFI42)
T.... 7S 67 142









pS3 ExpreGon Low 60 62 122
(..142) Med- IS S 20
IIiib
T.... 7S 67 142
-
x'-4.S97 dC-I p-.032 pIa- •. 11O
Sipific:Ince
134
Tobie 10.4: NollJll'OlllO'ric IlIIIy1is of the auoc:ialion betw... Bax cytoplasmic ...,....;on






Low 66 57 123Expression
(0=144) Med- II 10 21
High
ToIII 77 67 144
SwUtical X'=·012 df=1 p' .914 p' \.000'
Significlllce
• p-value calculated using FISher's exatt test
135
Table 10.5:N~ anoIyJiI orthe IIIOCiIlion betweee Box eytopIumic expression





bear l.<>w 66 10 76
Apoptoti. Med- 60 5 65(1F14I) High
Totli 126 15 141
SwistiCII t-t.IOI dr-t p"'.294 p=.4IJ·
Significance
• p-voIue calculated UJins F"""'...... test
Tobie 10.6: Nooponmetric onaIysiJ ofllle urociaIion _ pSl nucIar expreaiOll





pS3 Expression Low 110 11 121
(..141) MecI- 16 4 20
IliIh
TOlII 126 IS 141
SlIIiIlicII 1'=2.149 dr-I p-.I43 p-.230·
SiPfic:Ince
• p-value cak:ulIled • F'lSher's exact test
136
137
Tobie 10.7: Nonponmetric lIlIIyoiaofthe_on_tbttwo proIiCerIlivemorlten,




Low 81 34 115
Ki-67 Med-lligh 12 18 30
ExpreNion
(11""145) TOll! 93 52 145










Ki-67 Low SI S6 114
ExpraUon Med- II II 29(1F143) Hip
Total 76 67 143
Statillical X'= 1.163 e1f=1 p=.211
Sipificlnce
139
Tobie 10.9: N__ lIIIIyJitof.... _onbctweenBc:l-2 <yIOplumic ""Jl'<'Iion




PCNA Low l6 3l 91
Expression Med· 20 32 l2(1F143) IIish
TotII 76 67 143
5_ X' -7.077 elf-I P=.008 pili =.222
Significance
140
Tobie 10.10: Nonponmetric 1III1yti. oflht UIO<iaIion between p53 nuclear exprasioo one!






106 114Expression Low 8
(...144) Mod-Hip 17 13 30
TOCII 123 21 144
SI_ 1'= 25.145 df= 1 P =.000 phi =.418
Signifieance
TlIble 10.11: NCIllpIRJIlCOri< IIIIIyaiI oflbe IIIOciation between p53 IWcIeor expreuion





PCNA Low 85 7 92
Expression Med- 38 14 52(1\"'144) High
Toul 123 21 144
SwiJIicaI x': 9.949 elf=1 p=.OO2 p= .003' p/Ii:.26J
Sipifi<an<:e
• p-value c:aladlled using Fisher's exact test
t4t
142
Tobie 10.12: Nooponmelri<lIlI1ysisoftbewoeiation _ Bcl·2 cytoplasmic










Toll! 76 67 143









Tumour Grade Low 20 36 56
(0'"134) Med 19 19 38
High 34 6 40
Total 73 61 134
Statistical X'-23.284 df=2 P =.000 phi =.417
Sipificance
Tobie 10.14: NOIlpIlII1IOIric ono\yIiJ of the UIOCiaIion between Bd-2 cytoplumic






<2cm 38 31 69(..138)
>2cm 36 33 69
Total 74 64 138




Tobie 10.15: Nonpuuneuie IIlOIyIis oCtile _Oft_ p5l nudar expresoion and





Lo<II No 49 5 54
Recumnce Rec:umnc:e
(n:I44) Rec:umnc:e 74 16 90
Tolll 123 21 144
SIali_ x' -1.966 elf-I p-.161 p-.22l·
Signifi.....
• p-value ca&culIted using FISher's exact test
146







(11"'140) <2cm 6l 8 71
>2cm l7 12 69
Total 120 20 140
SwisticaJ X'-l.072 di-I p=.lOI p=.l4I'
Sisnificance
147
Table 10.17: NonporonWic: 1IlIIyJi. oflhe _on between pll nucIar expression u
deemed by immunohistochemical sui"'" ond Tumour srade.
pll ExpresSon
(nollS)
Absence of Presence of TolII
pll pll
Exprmion Expression
TIII1lOUt Grade: (0%) (>1%)
(1I"'Ill)
Low 49 7 16
Med lO I II
IIiah 23 18 41
ToIII 102 II III
SIIIistic:aI x' = 12.967 e1f- 2 p-.OO2 pbi=.310
SigJificance
148
Tobie 10.18: NonpalIIllOIric:lIlIIyaisortheuoocialion _PCNAexpresoion udete<led





Re<:umnce No 38 16 54
(n=145) Re<:umnce
Re<:umnce 55 36 91
Total 93 52 145
Staliltical X' =1.453 dr:1 p: .228
Sipificance
149
Tobie 10.19: N__ 1llIIysis oflhe .......ti.. between Ki-6711lc1e1r expmsion u





Recurrence No 46 8 54
(.-145) Recurrence
Recurrence 69 22 91
Total 115 30 145
SlItisti<aI X'-1.810 eIf= I p= .179 p=.208'
Sipifi<ance
150
Tillie 10.20: Nooparvneuic IIlIIysis of the uoociIlion between Ki-671l11clar expression u




TumourGnde Low l4 2 l6
(0=136) Med 27 II 38
High 28 14 42
Total 109 27 136
SIIIisticaI x': 16.102 df-2 p :.000 phi:.344
Signific:anc:e
Tobie 10.21: NOIIpIlIIIlOlricwlysisoCtbe _onbetweenKHi7la1deorexprasion u






<2cm 19 12 71(1F'14O)
>2cm 12 17 69
Total III 29 140
Stllislical X'-1.271 dC-I p".219
Sisnificance
• p-value c:aJcu1II:ed using Fisher's exact test
152
Tobie 10.22: NonporIllIdric:lIlIIysisoCtbeuaocillion _PCNAnucleor expression u






52 19 71(11"'140) <2an
>2an 37 32 69
Toll! 89 51 140
SIIliJlicIl x' = 5.814 dC=1 P =.016 phi=.204
Sipificonce
Tobie 10.23: NonparameUic llIIIysisorthelSlOCialion between PCNA nucI..e>qmsion u





Tumour Gnode Low 41 IS 56
(..136) Med 18 20 38
Hi&h 29 13 42
Toul 88 48 136
SWisti<l1 x'-7.121 dt"=2 P= .028 phi = .229
Significlnce
154
TIble 10.24: NOllpIIIIlldric: IIlIlyais oftile _on between PCNA _ exprasion u






No 53 19 72SlaIus
(...145) Involvement
Involvement 40 33 73
Total 93 52 145
SlIlillicll X'-5.580 df=1 P=.018 p/Ii=.I96
Sipificance





No 34 19 53
Recumoce Recumoce
(...140) Recumoce 37 50 87
Total 71 69 140
Stili..... X'-6.160 eIf'l P-.Oll phi=.210
Sigoificlnce
156
Table 10.26: Nonpanmeuio IIIIIy1is of the UIOCillion _local recurrence ofbreut





Tumour Grade Low 31 2S S6
(1F136) Med 22 16 38
High 29 13 42
Total 82 S4 136
SIIlisIic:aI X':2·006 df'2 p·.367
Sisnifi<an<e
157







No 27 27 nStIlUS
(n=145) lnvoIvment
lnvoIvment 45 46 73
Total 91 54 145
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2.50 ; 00: 1.00 !




8.00 I 8.00 I 1.00 I
2.00 ; 8.00 I 1.00 !




97 i .00 ~ 1.00 . .00 I .00 !
102 1 oot 100 1001 100:I I , I
103 2.00 \ 1.00 I .00 ' '.00 ! 3.SO 1 5.00 ; 1.00
104 1.00 I 1.00 i 1.00 1.00 5.00 .00 I 1.00
105
.00 I 999.00 ! 1.00 ....00 1.00 9.00 i 1.00 :
106 300! 1.00 i .00 1.00 3.00 9.00 1.00
10'1 1.00 I 1.00 I 1.00 .00 2.20 8.00 1.00
108 .00 1.00 l 1.00 1.00 1.40 I 5.00 1.00
109 .00 1.001 ....00 .00 , ....001 9.00 1.00
110 .00 1.00 I .00 00\ 2.40 1 8.00 1.00
111 1.00 1.00 ! 1.00 1.00 I 1.50 1 5.00 1.00
112 1.00 ! 1.00 .00 1.00 i 2.50 ~ 4.00 i 1.00 t
113-i-- .00---,.00 ·-...--,.~-:--2:OO__-· - .00:
tscorel baxcyfl bcl2cyfl
1.00 --,-_.00-,-'__._00-,',-_
1.00 .00 : 1.00 :
93 . 1.00 ~ 1.00 . .00 : .00 I
94:-.00, -,.00"---;--,-.00--+\---.00--7-\-------...;...-----i
95 ; 2.00 1.00 1.00 . .00 '
--'-------------+'---+,--------..,..----'
96 : 3.00 I 1.00 . .00 i .00 !
















































































.1~~~_.00 '_.00_: '~J ~o:o~
.00 . .00 1.00 .00 .00
1.00 ! 1.00 2.00




.00 1.00 2.00 i
..._ .._--_ ..
.00 1.00 2.00 :
_.._----
.00 : 1.00 : 2.00 i,
1.00 I
1.00 I II
2.00 I.00 I 1.00
100 00 1001
1.00 ! 1.00 2.00 '
1.00 .00 1.00
1.00 .00 2.00
































108 .00 I 1.00!
111 .00 I 1.00 I
109 .00 I 3.00 !
107 .00 I 3.00 I
110 .00 I 3.00 i
106 .00 I 3.00 I







































lsutJ;ects bd2cyfr baxcyfrip53 b.neI,tscorejki67








134 4.00 I .00 3.00 .00 I .00 1.00 I 1.00 i
135 4.00 3.00 ! 3.00 .00 .33 I 1.00 I 1.00
136 4.00 3.00 I 1.00 .00 2.30 I 2.00 1.00
137 4.00 .00 I .00 1.00 .16 1.00 200
138 4.00 .00 .00 .00 I 1.80 1.00 1.00
139 4.00 .00 .00 .00 I 1.00 1.00 2.00
140 4.00 .00 .00 .00 I 2.30 2.00 1.00
















129 i .00 I 1.00 i 1.00 : 1.00 I
133! 1.00 i 1.00 1 1.00 i 1.00 i 2.00 1.00
13O! 1.00 I 1.00 i 1.00 I .00 i
131 I 1.00 i 1.00 ; ~oo i 1.00 i
1321 '.00 I '.00 I .::00+-----:.00::7-'-----;-::+-----:=r--:=
_121~..00 1.00 .00 .00 5.00 I 5.00 1.00 I
1221 1.00 ·_·_--2.00--1.00--~oo I 2.10 I 7.oo! 1.00 i
12~OO-,--'.00 1.00' .00 I 1.40 I 5.00 I 1.00 i
~2~.~__ ;'00~+------=-'OO=-i:---.::00c1!--:-2.00::::i1--8:-.00:::i-1---:-1.001
~~~_' .00_. 1.0~__1~~ -:-.00:::i-1--c=,----:-:::+---:-:::e
~~6 i 3.00 1.oo "_00 "00::::i1__,=-·0,,"0t-_-:c:::+__-:--i
127 i 3.00 1.00' 1.00 i 1.00 I
128 i 1.00 : 1.00 ! .00 : 1.00 I
134 2.00 I 1.00 i 1.00 I .00 1.30 7.00 1.00
135 1.00 i 1.00 i 1.00 i 1.00 1 .00 .00 1.00
136 3.00 1.00 I .00 1.00 4.00 6.00 1.00 .
137 1.00 1.00 I .00 .00 2.50 8.00 1.00
138 1.00 1.oo! .00 .00 3.00 5.00 1.00
139 I .00 I 1.00 I .00 .00 1.80 6.00 1.00
140 1.00 I '.00 I .00 .00 '.50 5.00 1.00
141 .00 1.00 ! .00 .00 2.80 8.00 1.00
1.00
~4~~~~J__1.~.c'-!----._'-;:.00:-'-1 1.::OOc1i__:-2.50::i__5::c.00::+__,;-:.00.::
143 1.00 : 1.00 .00 I .00 3.00 I 8.00 ! 1.00
-144-'--3-.00--~ 1.00 1.=-00C-----,-'.00:c:-'--2=-.2""0+.---,,00c:- '.00










porap53 i sizoftum p532 I pcna2
121 ,OOJi__'_,O~O__ .00 .00-+'__2_.00-,-__._00--1ROO i,
-122
1
.00 ! 2.00 i .OO~ .OO-+:__2_.00+__.00-1. .00 i
123 .00 I 1.00 I .00 .00 I 1.00 .00 I .00 j
124 .00 I 3.00 : .00 .00 1.00 .00 I 1.00 ~
--- ~---~---------+-----+-----i--~
.00 ~ 2.00 .00 i .00 ;
-- .----~---_._--- ~--~---J.___-----I


























3.00 1 .00 1.00
1.00 I .00 .00
2.00 ! 1.00 .00
2.00 I .00 .00
100i 001 100i













127 .00 1.00 1.00
-+------
128 : .00 I 1.00 1.00~
129 I .00 1 2.00 ! 1.00 .
130 i .00 ! 3.00 ! .00 i
____. __. -'-_l-'--_
1.00 j 1.00
139 .00 2.00 .00 .00 1.00 .00 .00 I
140 .00 1.00 .00 .00 1.00 .00 .00 I
























128 1 .00 I
~














143 i 1.00 1
__ ._______1
144 1.00
145· .00
-----




